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Abstract
Advances in dementia research have shifted attention towards earlier stages in the natural
history, such as Mild Cognitive Impairment. The current gold standard outcome measure,
the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, is not optimally
responsive to changes in pre-dementia populations. Modifications to scoring methodology
and content have improved the measurement performance of the ADAS-Cog. However,
no published modifications have addressed a second key shift in the field towards
understanding motor function as an important component of dementia and pre-dementia
syndromes. This thesis used a Pooled Index approach to combine an ADAS-Cog-Proxy
measure with assessments of gait velocity and dual-task cost. The responsiveness of the
PI to baseline discrimination between older adults with normal cognition, Subjective
Cognitive Impairment, and MCI was similar to the ADAS-Cog-Proxy. The PI
demonstrated greater responsiveness than the ADAS-Cog-Proxy to change over 6mo. and
48mo., but not 36mo. of follow-up. Overall, motor function assessments improve ADASCog responsiveness.
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Chapter 1

1

Introduction

The purpose of Chapter 1 is to provide a brief overview of this thesis. Three outcome
measurement challenges will be addressed, which are currently present in the field of
dementia research.

1.1

Epidemiology of Dementia

Dementia is a syndrome characterized by deterioration in cognitive abilities such as
memory, praxis, and language, and in the ability to perform everyday activities.1,2 The
worldwide prevalence of dementia is 47 million people, with an estimated incidence rate
of 9.9 million cases per year.1 In 2016, an estimated 564,000 people living in Canada had
dementia, costing an annual $10.4 billion.3 The prevalence of dementia in Canada is
expected to reach 912,000 cases by 2030.3 There is no known cure. Hence, much research
is aimed at trying to better understand dementia syndromes and develop effective
treatment approaches.

1.2

Outcome Measurement Challenges

The quality of any research study is influenced by the measurement tools employed to
assess constructs of interest.4,5 Because a construct is a hypothetical concept, a
fundamental challenge lies in valid and reliable measurement.6 In the context of health
research, constructs are often aspects of disease pathology or encapsulate the impacts that
pathology may have on one’s experience of life; they are dynamic yet bounded by the
current understanding of a health condition or state. In some cases, a ‘gold standard’ or
best possible outcome measure has been established. Beyond individual study quality,
gold standards help to increase consistency and comparability throughout a body of
literature, which is especially important when evaluating novel treatment approaches.
However, as a field advances the understanding of a health condition or state, including
what constitutes pathology or burden, and ultimately treatment benefit, may change. If a
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gold standard is not harmonious with these advancements, the quality and relevance of
research findings, and by extension the speed with which a field progresses, may be
limited.
The circumstance of a long-standing gold standard in a rapidly advancing field is the first
of three challenges pertaining to outcome measurement that this thesis will address. The
second is how an outcome measure may be modified for improvement if the original
version is deemed unsatisfactory for use in a particular population or context. The third is
when all necessary outcome measures for a research objective are not available in a single
database, but a preliminary test of hypotheses is desired before investing the time and
resources required to run a new study that would collect all measures together.

1.3

Outcome Measurement Challenges in Dementia

Research
These three measurement challenges will be examined in the field of dementia research,
where the gold standard for assessing the efficacy of antidementia therapies is the
Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog).7 Although the
ADAS-Cog works well for studies on dementia populations, the research field is
changing in such a way that the ADAS-Cog is now being used in contexts that it was not
originally developed for.
More specifically, two important advancements in the field of dementia research have
occurred since the adoption of the ADAS-Cog in the 1980s. First, research interest has
shifted to pre-dementia stages of disease progression, such as Mild Cognitive Impairment
(MCI), where impairment is more mild than in dementia.8-13 It is thought that intervening
to slow or stop the progression of disease will be more effective than waiting until severe
neuropathology and dysfunction have developed.8,11,14-16 Thus, many research studies,
both observational and experimental, are being conducted in pre-dementia
populations.12,15,17-21 Outcome measures that work well for studies of older adults with
dementia may not work well for studies of older adults with pre-dementia syndromes
because the impairment that occurs in pre-dementia syndromes is more mild than the
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impairment that occurs in dementia syndromes, and may differ in type. For example,
memory is often impaired at early stages while language does not become impaired until
more severe stages.22 It is important that outcome measures being used for pre-dementia
populations can reflect a person’s level of cognitive ability, as well as changes in disease
severity over time, otherwise disease progression or potential treatment benefits may be
missed. Concerns have been raised about whether the ADAS-Cog, which was originally
developed to assess dysfunction in mild to severe dementia, is able to detect important
changes at earlier stages of disease progression.9,14,23,24 These concerns relate to the first
measurement challenge introduced above, and motivated a literature review for this thesis
that explores the measurement properties and performance of the ADAS-Cog in predementia populations. In accordance with the second measurement challenge, the review
extends to document all modifications that have been made in an attempt to improve the
ADAS-Cog. This literature review is presented in Chapter 3.
The second advancement in the field of dementia research is the emergence of motor
function decline as an early pathological manifestation, in addition to cognitive decline,
of disease progression; at the time of ADAS-Cog development, cognitive and motor
function decline were understood as separate processes. A seminal study in 1997 found
older adults who stop walking while talking are at an increased risk of falls compared to
those who do not stop.25 Since then, a literature base has been growing that supports an
association of dementia and pre-dementia syndromes with both motor and cognitive
decline, whereby these declines are understood as interrelated processes.26-41 For
example, Buracchio et al. (2010) found walking speed begins to slow twelve years in
advance of MCI diagnosis,26 Montero-Odasso et al. (2014) suggest that subtypes of MCI
possess a unique “motor signature”,27 and Kueper et al. (2017) performed a systematic
review that found poor lower limb motor performance is associated with an increased risk
of incident dementia.28 Importantly, motor function and cognitive abilities together may
provide the fundamental basis for functionality, or the ability to perform activities of daily
living, the loss of which is a hallmark of disease severity.42-44 Motor function assessments
may therefore be helpful for detecting important changes in pre-dementia syndromes,
such as to evaluate whether a novel treatment approach is beneficial. However, the
literature review on the ADAS-Cog did not find any modifications that incorporate motor
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function assessments. The main question this thesis aims to address is whether adding
assessments of motor function to the ADAS-Cog improves its ability to detect changes in
pre-dementia syndromes. This research question is presented in Chapter 4 along with
three formal objectives, which include developing an outcome measure and assessing its
ability to detect two types of change in a pre-dementia sample. Chapter 5 includes a
version of a manuscript centered around these objectives.
The third measurement challenge presented above becomes relevant as this thesis relies
on secondary data analysis, and no database contains both the ADAS-Cog and motor
function assessments. A proxy ADAS-Cog was developed for use in a database that
contains motor function assessments. The framework used to build this proxy ADAS-Cog
may be followed for other, similar situations, and is covered in depth in Chapter 6 along
with other detailed methods and results pertaining to the three objectives.

1.4

Overview of Thesis

The next chapter provides an introduction to outcome measurement terms and concepts
that will be utilized throughout the remainder of the thesis, Chapter 3 presents a literature
review on the ADAS-Cog, Chapter 4 states the research question and objectives, Chapter
5 is an integrated article, Chapter 6 includes more detailed methods and results than are
presented in Chapter 5, Chapter 7 provides an extended discussion, and the Appendices
contain supplementary Tables and Figures.
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Chapter 2

2

Introduction to Outcome Measures

The purpose of Chapter 2 is to review important concepts and terminology related to the
development and use of outcome measures for health conditions involving latent traits, to
outline approaches for improving pre-existing outcome measures, and to introduce three
of the main cognitive outcome measures used today.
The overall goal of a health-related outcome measure is to score specific traits to help
determine whether a health condition is present, or to assess the relative severity of that
health condition in an individual or group. The approaches and challenges differ
depending on the nature of the outcome, specifically whether it is a manifest variable (e.g.
a physical property, such as gait speed), or a latent trait (e.g. cognitive ability). Because
manifest variables are often measured directly with instruments and devices, evaluating
measurement is primarily a technical exercise concerned with reliability, accuracy, and
precision. Latent traits are more difficult to evaluate. Section 2.1 will provide a brief
overview of what latent traits are and how they can be modelled, and then Sections 2.2
and 2.3 will describe two main measurement models used to assess measures of latent
traits, namely Classical Test Theory (CTT) and Item Response Theory (IRT).

2.1 Overview of Latent Traits
In contrast to medical abnormalities that can be physically seen or detected, such as a
broken bone, there are many health states or conditions, often with a strong psychological
component, which cannot be directly observed.1,2 Rather, they are associated with some
underlying ability that is not directly observable, such as cognition or personality, that
drives people to behave or function in certain ways.1,2 Outcome measures can quantify
these latent traits using multiple test items that capture observable manifestations of the
latent traits.3-5 The covariation between a subject’s observed test item responses is
assumed to be due to the latent trait.1-4 Latent traits can be modelled in three main ways:
1) Categorical latent traits include discrete, mutually exclusive classes, that can be
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used to separate a group of people who may appear similar based on observable
traits (Figure 1).4,6 Members within each class share the same latent trait category,
and are considered homogenous.4,6

Figure 1 Categorical latent trait.

2) Dimensional latent traits follow a single continuum spanning from low to high
magnitude of the latent trait (Figure 2).4,6 Subjects can be given a quantitative
score to indicate their placement on the continuum, and then compared to each
other (e.g. Subject A has poorer short-term memory than Subject B), but no
straightforward group classification is available.6
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Figure 2 Dimensional latent trait.

3) Factor Mixed Model latent traits include both a categorical and a dimensional
structure (Figure 3).6 Factor mixed model latent traits categorize subjects into
different latent classes (e.g. subject has Subtype A of Disease X), and within each
latent class subjects can be organized along a latent trait continuum (e.g. to
indicate within-class differences in level of disease severity).6 Characteristics of
the dimensional latent traits may differ between categorical latent classes.6

Figure 3 Factor mixed model latent trait.
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Unidimensionality refers to the situation where one dimensional latent trait is
responsible for all scores produced by an outcome measure or test (Figure 4).2-4,7 More
specifically, the probability of responding a certain way on a test item is assumed to be a
function of the underlying trait.4,6 The shape of the probability function will depend both
on the underlying trait and on the format of the test question.5 For a unidimensional
outcome measure where all items are designed to measure the same underlying trait,
scores can be used to compare subjects’ relative abilities on the underlying trait.8

Figure 4 Unidimensionality assumption.

2.2

Classical Test Theory

CTT is one of two main psychometric theories underlying outcome measurement, and is
focused on the observed scores of an outcome measure.9 A subject’s observed score on
any single measure administration is assumed to be composed of their “true score” and
some error of measurement.2,8,9,10 True scores are sometimes referred to as “trait scores”
as they are intended to relate to a subject’s latent trait ability.8 CTT maintains an
assumption of unidimensionality.2,10 Measurement errors are assumed to be random,
follow a normal distribution with mean of zero, and not correlate with the true score.2,5,9,10
Xi = Ti + Ei
Where Xi = Subject i’s observed total score on an outcome measure, Ti = Subject i’s true
score or latent ability level, Ei = error of measurement.
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Observed total scores are often obtained using an unweighted sum of all individual item
responses on an outcome measure.2 This method assumes that all items are equally
difficult and equally important, that the difference between any two response options is
the same across all test items, that all items correlate equally with the latent trait, and that
subjects have responded to all items on an outcome measure.2,10 Rarely are all
assumptions of CTT met, but the CTT model cannot be disproved because the
assumptions cannot be directly tested against an unknown latent trait.9
Another limitation of CTT is the assumption of measurement invariance.2 An outcome
measure is said to be invariant when it performs the same way regardless of what, or who,
is being measured, because the method by which results are produced is independent of
the individual object, construct, or person being assessed in any given testing
situation.11,12 For example, a scale designed to assess Attribute X should be able to
identify the same amount of Attribute X in two people who truly do have the same
amount of Attribute X, but differ by age or education. In reality, properties of outcome
measures constructed using CTT are dependent on the samples in which they were tested
and validated.10 Thus, with CTT there is a circular dependency between outcome measure
properties and subject attributes.10 While properties of the outcome measure such as
reliability and validity depend on the sample composition, especially how homogenous
the sample is, subject scores depend on the properties of the outcome measure.2,10 A final
limitation of CTT is that different outcome measure scores obtained under CTT cannot be
compared unless transformed to Z-scores, T-scores, or percentiles.10 This method of
transformation requires the raw outcome measure scores to be approximately normally
distributed.13

2.2.1

Standardization

Any random variable following a normal distribution, which is a bell-shaped probability
distribution, can be standardized by subtracting the mean and dividing by the standard
deviation so that it becomes a standard normal distribution with a mean of zero and
standard deviation of one.13 The resulting standard scores, or Z-scores, can be expressed
as percentiles and allow direct comparison of scores from outcome measures which
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initially had different scoring methods, scales, means, and standard deviations.10

2.2.2

Reliability

Reliability is the ability of an outcome measure to give the same results for the same
subjects, under different circumstances, assuming the underlying construct of interest has
remained constant.10,14 Four main subtypes of reliability include:
1) Inter-observer reliability indicates the degree to which two different people
administering the same outcome measure to the same subject at the same time,
will produce the same results.2,10,14
2) Intra-observer reliability indicates the degree to which the same person
administering the same outcome measure in two different circumstances, will
produce the same results.10
3) Test-retest reliability refers to the ability of an outcome measure to give the same
results for the same subject at two different time points, assuming the subject
remained stable for whatever the measure was designed to assess.2,10,14 If a subject
has changed with regards to the construct of interest, then an outcome measure
designed to assess change with high reliability should reflect this change in the
final score.2,15
4) The first three types of reliability apply to both single items and to scores based on
several items. Internal consistency is applicable only to composite scores, and
refers to whether all items of an outcome measure assess the same construct.2,10,14
There are several approaches that can be used to assess reliability, and an outcome
measure which shows high reliability for a certain population and context of assessment
may not demonstrate similarly high reliability for a different population or context.2,10,15
Hence, it is important to refer to reliability of test scores in specified populations and
contexts, not the reliability of an outcome measure on its own.2,10 Reliability parameters
range from zero to one, and will increase as between-subject variation increases and
decrease as measurement error decreases2,10,16:
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Reliability = σ2subject / [σ2subject + σ2error]
Where σ2subject = True variance between subjects, σ2error = Measurement error variance.

2.2.3

Precision

Precision in the context of outcome measurement refers to the reproducibility of a score
for a given subject in a given circumstance.17 Although similar to reliability, precision
does not distinguish between score variability due to true subject differences and
variability due to error.17 An outcome measure may demonstrate high precision but low
reliability.10,17 For example, if a group of subjects all obtain very similar scores on an
outcome measure there will be very little true subject variability and therefore low
reliability, but high precision.17

2.2.4

Standard Error of Measurement

The Standard Error of Measurement (SEM) provides an absolute measure of the precision
of individual subject scores, expressed in the same units as the outcome measure.10,16 As
described above, under CTT the score on any single outcome measure administration
consists of the true test score and measurement error. 2,8-10 If an infinite number of test
administrations were performed for a subject, the average of the observed test scores
would be the best single estimate of the true score for that subject.5,10,18,19 The true score
in this sense is referring to consistency, not validity.19 The standard deviation of the
sampling errors for the distribution of observed test scores from the hypothetical infinite
number of administrations is the SEM.10,19 The SEM can be calculated as10,16:
SEM = σx √1 − 𝑅 = √σ2error
Where σx = Standard deviation of the observed scores over a population, R = Reliability,
σ2error = Measurement error variance.

2.2.5

Coefficient of Variation

The coefficient of variation (CV) is a measure of intra-individual variability that accounts
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for the overall performance of study participants on an outcome measure, calculated
as20,21:
CV= σ / μ
Where σ = standard deviation, μ = mean.
The CV is dimensionless and allows comparison of score variability for the same
outcome measure administered to different samples, or comparison of variability for
different outcome measures administered to the same or different samples.21

2.2.6

Validity

In general, validity is the extent to which an outcome measure evaluates what it was
designed to measure, and is specific to both the population and context of
assessment.2,10,18 Validity can be expressed as10:
Validity = σ2construct of interest / σ2observed
Where σ2observed = σ2construct of interest + σ2systematic error + σ2random error
Validity exists on a continuum, and whether or not a measurement tool is “valid” for a
particular population and context requires a decision based on results from a series of
hypothesis tests that make up the process of validation.10,18 As knowledge of a health
condition or state increases, or the theoretical framework underpinning a construct of
interest changes, further validation will be required to determine whether a previously
developed outcome measure remains valid enough for use in the current context and
population of interest.10 If an outcome measure is designed to assess a multidimensional
construct, then validation for each of the individual dimensions must be performed using
separate hypotheses pertaining to each dimension.2,19 Three major subdomains of the
validation process include:
1) Content validation determines the extent to which an outcome measure assesses
all important components of a health condition of interest.10,15,18,22 As more
components are captured by an outcome measure, inferences about the true
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underlying health of a subject obtaining a given score can become more
comprehensive.10,15,22
Content validation differs from other types of validity in two important ways.
First, an outcome measure can have high content validity even with low
reliability.10 Content validity is improved by including items to assess all
important aspects of a health condition, but if these aspects are highly variable
across individuals internal consistency may be compromised.10 Secondly, content
validation is a non-empirical approach as it depends solely on the judgement of
experts in the field or comparison with theoretical models, rather than on
statistical tests of comparison with other measures of the health condition of
interest.10,15,18,22
2) Criterion validation assesses how well an outcome measure agrees with other
well-established measures of the same health condition.10,15,18,22 Subtypes of
criterion validation include concurrent validation, whereby the comparison
between the two measures is made at the same point in time, and predictive
validation, where the outcome measure under study is compared to some
measured criteria that occurs in the future.18,22
3) Construct validation assesses whether an outcome measure outperforms (rather
than mimics as with criterion validation) the gold standard, or criteria currently
believed to be the best possible assessment of a health condition of
interest.10,15,22,23 Unlike criterion and content validation, which can be estimated
for a particular population and context in a single appropriate study, construct
validation is a continuous process and tests the theory and outcome measure at
the same time.10 Construct validation requires both justification with explicit
reference to evidence about the relevance of the components of an outcome
measure to the health condition of interest, as well as statistical tests and
numerical comparisons with measures of the health condition or individual
components of it.22,23 As the theoretical framework of a health condition changes,
hypotheses may change and further tests need to be conducted.10,22,23
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Construct validation may be further broken down into convergent and
discriminant validation. Convergent validation tests how closely an outcome
measure relates to other variables and measures of the construct it was designed to
measure.10 Discriminant or divergent validation tests that the outcome measure
undergoing validation does not correlate with measures of constructs hypothesized
to not be part of the health condition of interest.10 An acceptable strength of
correlation between the outcome measure undergoing validation and the other preexisting measures will depend on the relative importance of what is being assessed
by the other measures for the health condition of interest.10

2.2.7

Responsiveness

Responsiveness is a type of validity, however for simplicity this thesis will review
responsiveness as a separate concept.10,19 Responsiveness is broadly defined as the ability
of an outcome measure to accurately detect change,15,24-26 and must be contextualized by
the type of change being assessed.24,26 This contextualization may occur according to the
taxonomy of responsiveness developed by Beaton et al. (2001), which includes three axes
of classification:
1) The “Who” axis differentiates between individual level and group level of
analysis and interpretation.26
2) The “Which” axis describes whether the scores being contrasted are measuring
between-person differences at one point in time, within-person changes over time,
or between-person differences of within-person change over time.26
3) The “What” axis specifies the type of change being quantified in the study, such
as minimum potentially detectable change by the instrument, observed change
measured by an instrument in a population, or observed change in a population
deemed to have improved by a clinician.26
The three conceptualizations of change most relevant for this thesis, and examples of
methods for assessing responsiveness for each, are presented below. Please note that the
group-level analysis and interpretation of change is often used for research studies, but
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outcome measures will require adequate levels of responsiveness to individual-level
change if they are intended to also be used for one-on-one assessments, such as in a
clinical setting.
Baseline Discrimination: Responsiveness to group-level between-person differences in
stage of disease progression at one point in time. The health condition of interest for this
thesis can be viewed as a continuum of severity which includes the key stages of Normal
Cognition (NC), Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment
(MCI), and dementia.27-33 At any arbitrary baseline point, subjects at the different stages
of disease progression beyond NC have already changed in terms of their underlying
disease pathology and phenotypic expressions of such. And, if the natural history of the
disease has predictable stages, then all subjects are expected to go through similar
changes in phenotypic expression as they progress from NC to severe dementia. Just
because the changes did not occur within the observation window of the study does not
mean it is not change we are measuring – it means the change has occurred
retrospectively. Therefore, the ability of a measurement tool to discriminate between
subjects with NC, SCI, MCI, dementia, or even more refined categories at one point in
time, can be interpreted as a type of responsiveness. This separation of subjects into
distinct diagnostic categories is adopting a categorical latent trait conceptualization of the
dementing process.
A simple way to assess baseline discrimination is to compare the mean scores of the
outcome measure in each of the predefined diagnostic categories. These scores may be
tested for statistically significant differences with a t-test or Analysis of Variance,
depending on the number of groups to be compared.13 Non-parametric counterparts to
these tests, Mann Whitney U and Kruskal-Wallis, are also suitable options.13
It is important to note that if the health condition of interest did not progress continuously
through stages of severity in its natural history, it would not be appropriate to refer to
baseline discrimination as a type of responsiveness. For example, if we were trying to
identify children with different allergies, a child with a peanut allergy is not expected to
have previously been in a citrus allergy category, nor are they expected to progress
towards a fish allergy category. For these types of health conditions defined with nominal
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categories, baseline discrimination is more similar to sensitivity, with the caveat that
discriminative ability is often quantified in relation to other measures while sensitivity is
compared to pre-specified criteria of presence versus absence.10 Sensitivity is further
described in Section 2.2.8.
Disease progression: Responsiveness to group-level within-person observed change
measured by an outcome measure in a given population. This may include progression
(i.e. increasing severity) within or between the above-mentioned stages of dementia
progression.26 It is not limited by those diagnostic categories, and therefore is adopting a
dimensional latent trait conceptualization of the entire dementing process.
The main statistical tests used to assess this type of responsiveness include paired t-tests,
which test the null hypothesis that there is no change in the individual outcome scores for
the same group across two time points, standardized effect sizes, which express the
magnitude of change in outcome measure scores across two time points by comparing the
average amount of within-person change to the variability of baseline scores, and the
standardized response mean (SRM; also known as the signal-to-noise ratio,
responsiveness-treatment coefficient, efficiency index, or standardized change), which
expresses the magnitude of change in the observed outcome measure scores relative to the
variability of those change scores.24 A key advantage of the SRM is that it allows direct
comparison between different outcome measures because it takes into account the fact
that different measures have different score ranges and variability in change from
baseline.34
Treatment Effect: Responsiveness to group-level between-person differences of withinperson observed change over time. Sample statistical tests that may be used to assess this
type of responsiveness are a two-way Analysis of Variance including a treatment group by
time factor, an Analysis of Covariance with terms for baseline score and treatment group,
or regression models.13 The scores from an outcome measure designed to be responsive
to a treatment effect can be used to calculate an effect size, which summarizes the
magnitude and direction of differences between two or more groups which differ on at
least one important characteristic (in this case, whether or not the group received active
treatment).35 For example, a treatment effect in a clinical trial may be that the group
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receiving active treatment improved their score on the outcome measure by 15% whereas
the group receiving placebo remained stable. Effect sizes can also include different rates
of deterioration, such as if the treatment group experienced average 5% worsening in
scores compared to the placebo group’s average 15% worsening. Regardless of statistical
significance, the clinical significance of a treatment effect size should always be
interpreted within the context of what is being assessed and how much of a reduction (or
increase) in the outcome is meaningful to patients, caregivers, or clinicians.35 Effect sizes
can be adjusted for potential confounding factors. Confounders may increase or decrease
the magnitude of effect, or change the direction of effect (qualitative confounding).35 This
is important to keep in mind when comparing effect sizes from different studies.

2.2.8

Sensitivity and Specificity

Sensitivity and specificity are characteristics of outcome measures designed to classify a
subject as having or not having a health condition.36-38 These outcome measures do not
need to be based on CTT. Sensitivity and specificity are calculated from the perspective
of a ‘gold standard’ or external criterion:
Sensitivity, or true positive probability, is the ability to detect a specific health condition,
when that health condition is truly present.10,36-38
Sensitivity = # True Positives / (# True Positives + # False Negatives)
Specificity, or true negative probability, is the ability to identify those without a specific
health condition, when that health condition is truly absent.10,36-38
Specificity = # True Negatives / (# True Negatives + # False Positives)
Where True Positive = The test provides a positive result (disease present) when the
subject really does have the health condition of interest, False Positive = The test provides
a positive result when the subject does not really have the health condition of interest,
True Negative = The test provides a negative result (disease absent) when the subject
really does not have the health condition of interest, False Negative = The test provides a
negative result when the subject really does have the health condition of interest. Overall
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accuracy can be obtained by dividing the number of correct assessments (True Positives +
True Negatives) by the total number of assessments.38
When the health condition of interest exists on a continuum of severity that can be
captured by increasing or decreasing scores on an outcome measure, cut-points can be
used to decide what score corresponds to a positive test result indicating that a subject
may have the health condition of interest.10 Choosing higher or lower cut-points will alter
the sensitivity and specificity of the test. Usually when sensitivity increases, specificity
decreases, and vice versa.10,37 The prevalence of the health condition in the population
being tested does not affect the sensitivity and specificity.10,37
Receiver Operating Characteristic (ROC) curves plot false positives (1-specificity)
against true positives (sensitivity) for all possible cut-off values.38,39 The area under the
curve (AUC) represents the probability that, given a random pair of people where one
truly has the outcome and one does not, the person who has the outcome will score higher
than the person who does not.10,39 The AUC ranges from 0.5 (random chance that the test
will correctly classify a patient) to 1.0 (test perfectly classifies all patients).37,38 ROC
curves can be used to assess responsiveness when responsiveness is described in terms of
sensitivity and specificity for detecting change and no change in an external standard. The
external standard score must be dichotomized at a cut-off for what constitutes meaningful
change.

2.3

Item Response Theory

The above definitions of reliability, validity, and responsiveness are based on CTT.10 The
second major measurement model used to assess outcome measures for latent traits is
IRT.8,10 IRT is both a measurement model and a probability model.8,9 It estimates the
probability of a subject selecting a particular test item response given their ability on a
latent trait.8,10 So, unlike CTT which focuses on the total test score, IRT focuses on
individual test items.9,10 Furthermore, IRT does not assume that all test items are
equivalent.8,10 Rather, specific item properties can be built into the IRT model to try to
obtain the best possible estimate of a subject’s level of latent trait ability.8,10
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IRT models are usually described by the number of item parameters they contain. Three
different item parameters have been defined, any number of which may be included in an
IRT model.8,10 A multi-item outcome measure may contain items which have the same or
different values for each of the item parameters.8 The three item parameters can be
described visually with item characteristic curves (ICC) or item characteristic functions in
plots of the latent trait ability against the probability of a particular response (Figure
5).8,10 ICCs can be plotted for dichotomous or polytomous items, and each item response
option may be given its own ICC on the plot.8

Figure 5 Sample item characteristic curve.
The first item parameter is an item difficulty parameter, and is situated at the point of
inflection of the ICC, or the point at which the probability of selecting a particular
response option is 0.5 (Figure 5, point A).8,10 The purpose of the item difficulty parameter
is to locate each test item on the same continuum of latent trait ability that subjects are
located on.8,10
The second is an item discrimination parameter, and is reflected by the slope of the
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ICC (Figure 5, point B).5,8,10 The item discrimination parameter relates to how much
information a test item holds about the underlying latent ability.8,10 An item with a steeper
slope is better able to discriminate between levels of latent ability, for the levels of ability
which it covers, because the probability of the response changes very quickly as one
moves along the latent trait continuum.5,8,10
The third is an item guessing parameter, identified by the lower asymptote of the ICC
(Figure 5, point C).8 The item guessing parameter models the chance probability of
responding to a test item in a certain way (e.g. how likely one is to choose a correct
response by guessing).8,10
Model-data fit analyses can be used to test whether an IRT model is a good description of
the data, whereas with CTT the model is just assumed to be true.9 IRT also does not
calculate reliability in the same was as CTT.10 IRT focuses on precision rather than
reliability, whereby higher precision indicates a higher level of “information”.8,10
Standard Error (latent trait) = 1 / √information (latent trait)
Methods for calculating level of information differ among IRT models, but in general
higher information corresponds to lower standard error of estimate for a person’s location
on the latent trait continuum, and the higher the item discrimination parameter, the higher
the item information.8,10 Item information is the cumulative sum of all information from
all of that item’s response categories.8 Test information is the cumulative sum of the
information from all test items.8 The information peak is located at the apex of an ICC,
and corresponds to the level of latent trait ability for which the item (or response option,
or test) holds the most information.8
The simplest IRT model is the Rasch model, which is a particular type of one parameter
logistic model.8,10 A one parameter logistic model provides the probability of a particular
item response given the subject’s latent ability, the item difficulty, and the item
discrimination.8,10 For a Rasch model the item discrimination parameter is set to 1, and
for the one parameter logistic model it can be any number, but that number remains
constant for all items.8,10 The two parameter logistic model builds on the one parameter
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logistic model by allowing the parameter for test item discrimination to differ between
items.8,10 The three parameter logistic model adds in the item guessing parameter.8,10 IRT
models have three main assumptions:
1) The dimensionality assumption states that test responses are due to one’s latent
trait ability level.8,10 Although most often the latent trait is assumed to be
unidimensional, modifications can be made for multidimensional cases. If
different latent traits underlie different test items (between-item
multidimensionality) then separate IRT models can be built for clusters of items
relying on the same latent trait.8 If multiple latent traits underlie responses to a
single item, then a multidimensional IRT model can be built.8 A multidimensional
IRT model can be either compensatory or non-compensatory depending on
whether one latent trait is able to compensate for deficiencies in the other latent
trait.8,10
2) The conditional or local independence assumption states that each individual
item response is independent of any other item responses given the subject’s latent
trait ability.8-10 In other words, test item responses are due completely to a specific
latent trait ability, not due to other latent traits or knowledge or priming from
other test items.8-10
3) The functional form assumption includes whether the model correctly specifies
the function that the data follow.8,10

2.4

Approaches for Modifying Outcome Measures

Two main approaches for modifying, or attempting to improve, a pre-existing outcome
measure are changing the scoring methodology and adding additional test items.40 These
approaches can be used individually or in combination.40 Regardless of the approach
taken, it is recommended that the modified measure be backwards-compatible with the
original measure. Backwards compatibility means the original measure can be recovered
from the new or modified version, which preserves the ability to compare results between
studies using the modified and original version.41 When the measure to be modified is
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considered the current gold standard, backwards compatibility will also allow researchers
to show regulators results from their study in terms of the original gold standard measure,
while results from the modified version can be used for further research purposes
including demonstration of improved measurement properties.

2.4.1

Statistical Modification of Scoring Methodology

The simplest scoring method for any outcome measure is a straight summation of points
across all test items, whereby points gained from any test item contribute equally to the
total score.2,42 This transparent method assumes that all test items are equally important
and informative for assessing disease severity.43-45 Item weights can be altered so that a
point on one test item would contribute more or less to the total score than a point on a
different test item.2 Applying a weight of zero to a test item is effectively the same as
removing the item from the scoring process, while maintaining the capacity for
backwards compatibility. Values for the re-weighting process may be derived statistically
or theoretically in accordance with the relative importance of each item for the health
condition of interest. Psychometric methods, such as IRT, can also be used to modify
scoring for any given outcome measure.43,45

2.4.2

Adding Additional Item Content

The second approach to improve a pre-existing outcome measure is to administer the
original outcome measure along with additional test items.34,40,46 Often items are added
because theoretical advancements in a field identified an important component of a health
condition that is not effectively being assessed by the original outcome measure.
Statistical approaches to adding test items may also be used. The total score range of the
modified outcome measure can be derived by simply extending the scoring range of the
original version to accommodate the additional items, or by some other scoring
modification. The additional item content may change the latent trait(s) assessed by the
outcome measure, warranting the need for further validation studies of the additional item
content as well as the modified outcome measure as a whole.10
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2.5

Key Cognitive Outcome Measures

Three main cognitive outcome measures used today include the Mini-Mental State
Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Alzheimer
Disease Assessment Scale – Cognitive Subscale (ADAS-Cog).
The MMSE was developed in 1975 to address the need for an outcome measure to screen
for possible cognitive impairment in several psychiatric conditions including but not
limited to dementia.47 The MMSE contains 11 questions, can be administered in five to
ten minutes, and is scored from 0 to 30 with higher scores reflecting better cognitive
function.47 Domains of cognitive function assessed include orientation, memory,
language, attention, and visuospatial abilities.47,48 Although not developed specifically for
dementia, the MMSE is the most commonly used screening test for dementia, whereby a
score of 23 or 24 is often selected as the cut-off to identify subjects with probable
dementia.48 A meta-analysis of the diagnostic performance of the MMSE across 108
cohort studies with different patient populations found that the overall summary
sensitivity of the MMSE for detecting dementia was 0.81 (95% Confidence Interval (CI)
0.78, 0.84), the specificity 0.89 (95% CI 0.87, 0.91), and the overall accuracy 92% (95%
CI 90, 94).48 Twenty-one cohorts in the same meta-analysis assessed the ability of the
MMSE to detect MCI, yielding a summary sensitivity of 0.62 (95% CI 0.52, 0.71), and
specificity of 0.87 (95% CI 0.80, 0.92).48 This comparatively low performance for
detecting MCI may be because many people meeting the clinical criteria for MCI score in
the “normal” range on the MMSE (over 26 points).49
The MoCA was developed in 2005 for the purpose of improving detection of MCI
specifically.49 The MoCA contains 10 questions, can be administered in under 10
minutes, and is scored from 0 to 30 with higher scores indicating better cognitive
function.48,49 Cognitive domains assessed by the MoCA include memory, executive
function, attention, language, and orientation.48,49 The meta-analysis described above
assessed the diagnostic performance of the MoCA for detecting MCI across nine cohorts,
and found a summary sensitivity of 0.89 (95% CI 0.84, 0.92) and specificity of 0.75 (95%
CI 0.62, 0.85).48
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While the MMSE and the MoCA were developed as screening tools to assist primary care
physicians identify patients with cognitive difficulties, they are also used for group-level
analyses in research studies. The ADAS-Cog is another commonly used cognitive
outcome measure for studies of dementia and pre-dementia syndromes. In contrast to the
MMSE and MoCA which were developed to identify people from a heterogeneous
sample whom may have MCI or dementia, the ADAS-Cog was developed for the purpose
of identifying severity of dysfunction in samples of subjects with known AD.50 The
ADAS-Cog is the current ‘gold standard’ for clinical trials of treatments for dementia,
and is often also used as such in studies of MCI and other pre-dementia syndromes.
Unfortunately, several concerns about the use of the ADAS-Cog have emerged. These
concerns will be a main focus of this thesis. Most notably, the ADAS-Cog appears to
have poor responsiveness to important changes in subjects with pre-dementia syndromes,
and has low content validity since advancements in the study of dementia and predementia syndromes have identified domains not covered by the ADAS-Cog which are
emerging as important components of dementia and pre-dementia syndromes. Chapter
three will provide a comprehensive literature review on the ADAS-Cog, including a
description of individual scale tasks and scoring.

2.6

Summary

Latent traits are underlying dimensions, such as cognitive ability, which people possess
but cannot be observed directly. Latent traits can be divided into categorical, dimensional,
and factor mixed model structures. Cognition can be conceptualized using any of these
structures, depending on the theoretical framework and measurement model being used.
Two main measurement models used to develop outcome measures for latent traits
include CTT and IRT. Three key cognitive outcome measures include the MMSE,
MoCA, and ADAS-Cog. All three were developed using CTT. The ADAS-Cog is the
current ‘gold standard’ outcome measure for clinical trials in dementia and pre-dementia
syndromes, however there is some concern about its utility in studies of pre-dementia
syndromes.
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Chapter 3

3

Literature Review

The purpose of Chapter 3 is to explain how the Alzheimer’s Disease (AD) Assessment
Scale (ADAS) was developed, briefly review measurement properties of the ADAS
Cognitive Subscale (ADAS-Cog) in dementia and pre-dementia populations, and provide
a comprehensive review of all modifications that have been made to the ADAS-Cog and
any assessments of the responsiveness of these modified versions. Please note that only
literature published in the English language, and English language versions of the ADASCog or modifications thereof, were examined.

3.1 Development of the Alzheimer’s Disease Assessment
Scale
The ADAS was originally designed to fulfill the need for a rating scale specific to AD
studies. Goals for the ADAS included being able to assess the severity of cognitive and
non-cognitive dysfunction from mild to severe dementia, while maintaining reliability
and brevity of administration for subjects in different environments.1

3.1.1

Item Selection

Item selection for the ADAS began with calculating the reliability and validity of forty
candidate items in a development sample of 27 subjects with AD and 28 subjects with
normal cognitive function (NC).1 Most of the forty items showed statistically significant
inter-rater reliability and test-retest reliability as assessed by intraclass correlation
coefficients (ICC) and Spearman rank-order correlations, respectively, in the AD and NC
groups separately.1 Practice effects were detected only in the NC group.1 Results from the
AD group alone were used to select the final 21 items, which can be divided into
cognitive and non-cognitive subscales. The ADAS takes about 45 minutes to administer.
It is scored from 0 to 150 by summing the number of errors made on each test item so that
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higher scores indicate worse performance.1 The mean ADAS total score in the 27 subjects
with AD was 37.0 (Standard Deviation (SD)=17.5).1
The non-cognitive subscale (ADAS-Noncog) includes 10 assessments, scored from 0 to
50, which consider mood and behavioural changes. The mean ADAS-Noncog score for
the original 27 subjects with AD was 4.4 (SD=3.5).1 Specific items include:
1. Tearful
2. Appears/reports depressed mood
3. Concentration and distractibility
4. Uncooperative to testing
5. Delusions
6. Hallucinations
7. Pacing
8. Increased motor activity
9. Tremors
10. Increase or decrease in appetite
The cognitive subscale (ADAS-Cog) includes 11 tasks that are either a test to be
completed by a subject or an assessment made by the test administrator about the subject,
and which broadly assess the cognitive domains of memory, language, and praxis. The
ADAS-Cog is scored from 0 to 70, and the mean ADAS-Cog score for the initial 27
subjects with AD was 19.3 (SD=12.1).1 Specific tasks include:
1. Word Recall. A list of 10 words is read by the subject, and then the subject is
asked to verbally recall as many of the words as possible. Three trials of reading
and recalling are performed. The task score is the mean number of words not
recalled across the three trials (range 0 to 10).1
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2. Naming Objects and Fingers. The subject is asked to name the fingers of their
dominant hand as well as twelve objects, including: flower (plastic), bed (doll
house furniture), whistle, pencil, rattle, mask, scissors, comb, wallet, harmonica,
stethoscope, and tongs. The task score is calculated based on the number of
fingers and objects correctly named, and ranges from 0 to 4.1
3. Commands. The subject is asked to perform one to five step commands. For
example, the two step command is to “Point to the ceiling, then to the floor.” The
task score is from 0 to 5, based on the largest number of steps that are correctly
performed (score is 0 if five step command is correctly performed).1
4. Constructional Praxis. The subject is shown four geometric forms (circle, two
overlapping rectangles, rhombus, cube) and asked to copy them on a piece of
paper. The task is scored from 0 to 5 based on the number of correctly drawn
forms.1
5. Ideational Praxis. The subject is asked to pretend to send a letter to themselves.
Scoring is based on difficulty of performing the five components of: fold letter,
put letter in envelope, seal envelope, address envelope, and putting a stamp on the
envelope (range 0 to 5).1
6. Orientation. The subject is asked the date, month, year, day of the week, season,
time of day, place, and person. The number of correct responses is the task score
(range 0 to 8).1
7. Word Recognition. The subject reads twelve words aloud, and then these twelve
words are randomly shuffled with twelve new words, and the subject is asked
whether they have previously seen each of the twenty-four words. Three trials are
performed, and the task score is the mean number of correct responses across the
three trials (range 0 to 12).1
8. Language. After the administration of the Word Recall task (Q1) ten minutes of
open-ended conversation occur between the test administrator and subject, before
the remainder of the tasks are presented. These ten minutes of conversation are
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used to assess language ability. Quality of speech is given a global rating by the
administrator that ranges from 0 to 5.1
9. Comprehension of Spoken Language. This task also relies on the ten minutes of
open-ended conversation. The administrator provides an assessment of how well
the subject can understand speech that ranges from 0 to 5.1
10. Word Finding Difficulty. This task is also rated by the administrator during
spontaneous speech to assess how much difficulty the subject has in finding
desired words from 0 to 5.1
11. Remembering Test Instructions. This task is a rating by the administrator from 1
to 5 according to the number of times that the subject needed to be reminded of
instructions for the Word Recognition task.1
Initially the two memory tasks (numbers 1 and 7) were viewed as a separate memory
subscale and scored out of 22 points, with the remainder of the cognitive tasks scored out
of 48 points (ADAS-Cog 9).1 From here on “ADAS-Cog 11” refers to the full 11-item
version of the ADAS-Cog.

3.1.2

Validation of the Alzheimer’s Disease Assessment Scale

Concurrent criterion validation was assessed in the original sample by correlating ADAS
scores with previously well-established measures used to help assess disease severity.
There were statistically significant correlations between the Sandoz Clinical AssessmentGeriatric and the full ADAS (r=0.52, P<0.02) as well as the ADAS-Cog 9 (r=0.67,
P<0.01), but not the ADAS-Noncog (r=0.25, P>0.10).1 There were statistically
significant correlations between the Memory-Information Test and the full ADAS (r=0.67, P<0.001), the ADAS-Cog (r=-0.78, P<0.001), and the ADAS-Noncog (r=-0.42,
P<0.02).1 There were also statistically significant correlations between the Dementia
Rating Scale and the full ADAS (r=0.64, P<0.001), the ADAS-Cog (r=0.48, P<0.01), and
the ADAS-Noncog (r=0.46, P<0.01).1
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Further concurrent criterion validation was performed in a separate study of 61 subjects
with very mild, mild, moderate, or severe AD, and 52 subjects with NC.2 The ADAS-Cog
11 and a modified ADAS-Noncog (nine items: tearfulness, depression, concentration,
uncooperativeness, delusions, pacing, increased motor activity, tremors, appetite) were
administered. The ADAS-Cog 11 correlated strongly with the Mini-Mental State
Examination (MMSE; r=-0.76, P<0.0001), but there was a weaker correlation between
the modified ADAS-Noncog and MMSE (r=-0.39, P=0.0019).2

3.1.3

Responsiveness to Baseline Discrimination

In the original ADAS development sample, point-biserial correlations were used to show
that the group of subjects with AD had significantly higher scores on the ADAS-Cog 11
(r=0.754, P<0.0001) as well as on all individual ADAS-Cog 11 tasks (all P<0.0001) than
the group of subjects with NC.1 Subjects with AD also scored significantly worse on the
ADAS-Noncog (r=0.487, P<0.003), and three individual ADAS-Noncog items.1 Since
then, several other studies with larger samples have also shown that the ADAS-Cog 11 is
able to discriminate between the diagnostic categories of NC, Mild Cognitive Impairment
(MCI), and AD at one point in time, and that the scores for subjects with NC are
appropriately lower than those with MCI and subsequently AD.2-8 ADAS-Cog 11 scores
have also been shown to discriminate between mild, moderate, and severe AD, but not
between very mild and mild AD.2 This remained true after removing the language tasks
(Language, Comprehension of Spoken Language, Word Finding Difficulty) from the
ADAS-Cog 11.2 Another study including 485 subjects found statistically significant
differences between ADAS-Cog 11 scores from subject groups with Clinical Dementia
Rating (CDR) Scale scores of 0, 0.5, and 1.9
The ability of the ADAS-Cog 11 to act as a diagnostic instrument to classify subjects as
having AD or not was tested by Zec et al. (1992), whereby two SD above the NC group
mean was used as a cut-off for abnormal cognition.2 Only two subjects with AD and one
subject with NC were misclassified.2 Good classification remained after removing the
language tasks from the ADAS-Cog 11.2
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3.1.4

Responsiveness to Disease Progression

Rosen et al. (1984) found a statistically significant worsening on total ADAS (P=0.02),
ADAS-Cog 11 (P=0.01), and ADAS-Noncog (P=0.03) scores over a twelve-month
period for ten subjects with AD, but not for ten of the subjects with NC (all P>0.05) that
were used to develop the ADAS.1 Eight of the subjects with AD showed a worsening on
each individual task.1
Evans et al. (2010) found statistically significant differences (P<0.0005 for all) between
the magnitude of mean 12 month ADAS-Cog 11 change scores for subjects in different
diagnostic categories, adjusted for baseline score, age, and gender, whereby the 99
subjects with AD changed the most (mean change=3.53 points, SD=5.42) compared to
the 231 subjects with MCI (mean change=1.16 points, SD=4.31) and the 131 subjects
with NC (mean change=-0.53 points, SD=2.70).10 Petersen et al. (2010) found statistically
significant differences (P<0.001 for all) between mean ADAS-Cog 11 12 month change
scores for 210 subjects with NC (mean change=-0.5 points, SD=3.0), 357 subjects with
MCI (mean change=1.1 points, SD=4.4), and 161 subjects with AD (mean change=4.3
points, SD=6.6).4 It is important to note that the magnitudes of these changes are small,
especially in MCI and NC groups. Other studies have found similar results. Steenland et
al. (2014) found that ADAS-Cog 11 scores of 191 subjects with NC worsened by an
average 7.5% over 3 years (P=0.0007) after adjusting for age, gender, race, education,
and Apolipoprotein E (APOE) e4 allele presence.11 Podhorna et al. (2016) did not
perform statistical tests, but reported almost no change on the ADAS-Cog 11 in 382
subjects with MCI over 24 months (mean change=0.9 points, SD=4.45) and in 169
subjects with MCI over 36 months (mean change=1.9 points, SD=5.45).12 For an
‘enriched’ subgroup of subjects with MCI who had cerebrospinal fluid (CSF) or APOEe4
allele biomarkers indicative of AD pathology, there was still only a 1.9 mean point
change (SD=4.92) over 24 months (n=206) and 3.7 mean point change (SD=6.21) over 36
months (n=89).12 In 97 subjects with mild AD there was a clinically relevant change over
12 months (mean change=3.5 points, SD=5.59) and for 40 subjects with mild AD over 24
months (mean change=8.3 points, SD=8.96).12
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3.1.5

Minimum Clinically Relevant Change

Schrag et al. (2011) divided the scores of 358 subjects with mild AD into those who were
rated by clinicians as having versus not having experienced clinically relevant worsening
in the domains of memory, non-memory, general cognitive function, and functionality as
assessed by the Functional Activities Questionnaire (FAQ) and CDR Scale.13 The range
of ADAS-Cog score change corresponding to clinically relevant change separated by the
four domains was 2.7 to 3.8 point increase over 6 months.13 For those judged not to have
changed it was a mean 1.2 to 2.0 point increase over 6 months.13 All change scores were
statistically significant (P<0.05).13 Based on these comparisons they determined that a 3
point or larger increase (worsening) on the ADAS-Cog 11 is a clinically relevant
change.13

3.1.6

Summary

The ADAS was developed to assess the severity of cognitive and non-cognitive
dysfunction in people with AD. The ADAS-Cog 11 and ADAS-Noncog are able to
discriminate between groups of subjects with NC and AD, and the ADAS-Cog 11 can
also discriminate MCI from NC and AD. The ADAS-Cog 11 has also been shown to be
able to detect change over time in dementia and pre-dementia samples; however, the
magnitude of the change detected in MCI and NC samples is very small. The ADASNoncog is not widely used and will not be reviewed further.

3.2

Assessment of the ADAS-Cog 11 in Pre-

Dementia Populations
3.2.1

Ceiling Effects

Seven of the eleven ADAS-Cog 11 tasks demonstrate severe ceiling effects in MCI and
NC samples (Table 1), whereby all or most subjects make zero errors on those tasks.5,14-19
A further two tasks show milder ceiling effects.14,15,17-19 Accordingly, 84% of errors made
by subjects with NC and 71% of errors made by subjects with MCI occur on the two
ADAS-Cog 11 tasks which do not demonstrate ceiling effects, Word Recall and Word
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Recognition.5 Item Response Theory (IRT) analyses have also found that those two tasks
have the most difficult ranking among all ADAS-Cog 11 tasks (please consult Section 2.3
for an overview of IRT).20
Table 1 ADAS-Cog 11 Ceiling Effects.
Study data

SIUNAS5

Italian
clinical
trial14

Multiple
pooled
studies15

BCMADC16

ADCS17

ADNI18

ADNI19

ADNI21

Q1

ADNI10

N/A

Q2

N/A

N/A

Q3

N/A

N/A

Q4

N/A

N/A

Q5

N/A

N/A

Q6

N/A

N/A

Q7

N/A

N/A

Q8

N/A

N/A

Q9

N/A

N/A

Q10

N/A

N/A

N/A

N/A

Q11
Total Score

N/A

N/A

Legend: Green=No ceiling effect, Orange=Mild ceiling effect, Red=Severe ceiling effect;
ADCS=Alzheimer's Disease Cooperative Study, ADNI=Alzheimer’s Disease
Neuroimaging Initiative, BCM-ADC=Baylor College of Medicine Alzheimer's Disease
Study, N/A=Not Available, Q1=Word Recall, Q2=Naming Objects and Fingers,
Q3=Commands, Q4=Constructional Praxis, Q5=Ideational Praxis, Q6=Orientation,
Q7=Word Recognition, Q8=Language, Q9=Comprehension of Spoken Language,
Q10=Word Finding Difficulty, Q11=Remembering Test Instructions, SIUNAS=Southern Illinois University Normal Aging Study. All studies included participants
with Mild Cognitive Impairment except BCM-ADC, which included exclusively
cognitively normal controls.

3.2.2

Information Content

An ideal outcome measure for MCI would have the information peaks of all item
information curves generated by an IRT analysis of all individual outcome measure items
in the range of cognitive ability expected to be seen in subjects with MCI. Ueckert et al.
(2014) found that all but three ADAS-Cog 11 tasks have their information peak in a range
that corresponds to levels of cognitive dysfunction more severe than would be expected in
MCI, indicating that they are not optimally sensitive for use with MCI populations.15
Through summation of the information available for each subtask item (individual
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response options), Ueckert et al. (2014) found that the most informative ADAS-Cog 11
tasks for assessing MCI levels of cognitive dysfunction were Word Recall, Orientation,
Word Recognition, and Naming Objects and Fingers.15 Furthermore, an in-depth
evaluation of the Word Recall Task has shown that the Pole response item has a higher
recall probability than other response items for NC, MCI, and AD groups, suggesting that
it is an abnormally easy item on the ADAS-Cog 11.21 These types of in-depth analyses for
other individual ADAS-Cog 11 tasks have not been published.

3.2.3

Invariances

All individual ADAS-Cog 11 tasks as well as the total score have shown measurement
invariance with respect to education and age in MCI samples.5 Measurement invariance
to sex has also been found for the total ADAS-Cog 11 score in MCI samples.5 In samples
with NC, the ADAS-Cog 11 total score also showed measurement invariance with respect
to sex and education, but not for age.2,5,16 Age was significantly correlated with total
ADAS-Cog 11 score as well as the Word Recall task in NC samples.2,5,16 For example,
the ADAS-Cog 11 validation study that included 61 subjects with very mild, mild,
moderate, or severe AD, and 52 subjects with NC recruited an additional 80 subjects with
NC to assess whether age and education correlated with ADAS-Cog 11 scores.2 They
found ADAS-Cog 11 scores from subjects with NC were moderately correlated with age
(r=0.42, P=0.0018), but non-significantly correlated with education (r=-0.21, P=0.13).2
When categorized, age remained significantly correlated and education did not,
suggesting that age but not education may influence ADAS-Cog 11 scores in NC
samples.2 Specifically, among the subjects with NC, those aged 7 to 13 or 60 to 89 years
old performed significantly worse than those aged 14 to 59 years old, although the size of
these differences was small.2 In contrast, among subjects with AD correlations with age
(r=-0.08, P=0.56) and education (r=-0.06, P=0.66) were both small and non-significant.2
Altogether these results suggest that the only threat to measurement invariance is the age
of subjects with NC.
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3.2.4

Reliability

Significant variance in administration procedures and materials used for the ADAS-Cog
11 across clinical trials has been found, which threatens inter-observer, intra-observer,
and test-retest reliability.22 Learning effects may also be a concern as Herholz et al.
(2011) found a statistically significant decline in ADAS-Cog 11 scores in sample of
subjects whom otherwise did not appear to be progressing in symptoms (stable NC)
(ICC=0.47, 95%CI 0.32, 0.63).23

3.2.5

Concurrent Criterion Validation

One study found ADAS-Cog 11 scores significantly correlated with MMSE scores in
both NC (Spearman rho=-0.29, P<0.001) and MCI (Spearman rho=-0.66, P<0.001)
samples, indicating agreement with another well-established assessment of overall
cognitive ability.5 However, the only individual ADAS-Cog 11 tasks significantly
correlated with the MMSE were Word Recognition in subjects with NC (Spearman rho=0.26, P<0.001) and Word Recognition and Word Recall in subjects with MCI (Spearman
rho range -0.36 to -0.49, P<0.001).5 Another study in 124 subjects with NC found the
ADAS-Cog 11 was not significantly correlated with MMSE scores (r=-0.13, P=0.16).16

3.2.6

Responsiveness at the Item Level

Baseline discrimination. All ADAS-Cog 11 tasks have shown statistically significant
differences between NC and MCI subgroups,4,5,17 and all but three tasks (Commands,
Ideational Praxis, Language) have demonstrated significantly higher scores in AD than
MCI subgroups.5 Furthermore, three of the ADAS-Cog 11 tasks (Word Recall, Word
Recognition, Orientation) were found to detect a statistically significant difference
between subjects with MCI and none versus one versus two APOEe4 alleles.24
Disease progression. All individual ADAS-Cog 11 tasks have been found to have
smaller Standardized Response Means (SRM)s than the ADAS-Cog 11 total score, where
the three tasks demonstrating the largest SRM were Word Recall, Orientation, and Word
Recognition.19 Groups of subjects with NC compared to MCI have been found to have
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statistically significant different 12 month change scores on the Word Recall and Word
Recognition tasks.4 The magnitude of 12 month and 24 month change scores for five
ADAS-Cog 11 tasks were similar when comparing MCI and AD groups, while the six
other tasks produced smaller change scores for the MCI group compared to the AD
group.19

3.2.7

Performance of the ADAS-Cog 11 as an Outcome Measure
in Pre-Dementia Studies

Forty-six studies were found which use the ADAS-Cog 11 as an outcome measure to
assess whether there is an association between an exposure or intervention and cognitive
ability. This thesis takes a very rudimentary approach to assessing the performance of the
ADAS-Cog 11 in these studies, and merely examined whether or not the ADAS-Cog 11
produced statistically significant results for these associations. It is assumed that all
studies in this portion of the literature review have an adequately developed theoretical
framework to reasonably expect that a difference in cognitive ability between exposure
groups should exist, either at baseline or over time, even though some of the exposures
may actually be ineffectual towards cognitive ability. Results from other outcome
measures used to assess the same association as the ADAS-Cog 11 in each study may be
used as a sort of proxy for whether the ADAS-Cog 11 is capturing associations which
truly do exist (other measures statistically significant). Please note that due to publication
bias towards positive results, the results presented here may overestimate the proportion
of statistically significant associations detected by the ADAS-Cog 11 in pre-dementia
study samples.
Responsiveness to group-level between-person differences in observed level of
disease severity based on exposure status. Twenty-two studies assessed cross-sectional
associations between exposure status and ADAS-Cog 11 scores in older adults with predementia levels of impairment, as summarized below in Table 2 for NC, Table 3 for MCI,
and Table 4 for mixed NC and MCI samples.4,11,25-44 Within these studies there were
twenty statistically significant associations between exposure status and ADAS-Cog 11
scores (green highlight). There were sixteen non-statistically significant associations
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found between the ADAS-Cog 11 and an exposure, where any other cognitive or brain
imaging outcome measures used to assess the same association also produced nonstatistically significant results (orange highlight). The ADAS-Cog 11 failed to produce a
statistically significant result for eight associations which were statistically significant for
at least one other cognitive or brain imaging outcome measure (red highlight).
Table 2 Normal Cognition Samples: ADAS-Cog 11 responsiveness to group-level
between-person differences in observed level of disease severity based on exposure
status.
First
Author &
Publication
Year

Exposure

Crane
201225

Hippocampal
Volume

Crane
201225

Parahippocampal
Thickness

β=1.30,
P>0.05,
(225)

Crane
201225

Entorhinal
Thickness

β=0.27,
P>0.05,
(225)

Crane
201225

Fusiform
Thickness

β=-0.17,
P>0.05,
(225)

ADNI-Mem,
RAVLT

Daiello
201526

Fish Oil
Supplement vs.
None

β=-7.01,
P<0.01,
(229)

MMSE

Doraiswamy
201227

Aβ positive vs.
negative

P=0.17,
(69)

DSS, WMS
immediate &
delayed
recall

(continuous
variable unless
otherwise
specified)

Association
between
exposure
and ADASCog 11
[Effect
estimate,
P-Value,
(n)]
β=1.03,
P>0.05,
(225)

Other
statistically
significant
outcome
measures

Other
statistically nonsignificant
outcome
measures

Factors controlled
for
(None if blank)

ADNI-Mem,
RAVLT, ADASCog13, ADASRasch, ADASTree, MMSE,
CDR-SB
ADNI-Mem,
RAVLT, ADASCog13, ADASRasch, ADASTree, MMSE,
CDR-SB
ADNI-Mem,
RAVLT, ADASCog13, ADASRasch, ADASTree, MMSE,
CDR-SB
ADAS-Cog13,
ADAS-Rasch,
ADAS-Tree,
MMSE, CDR-SB

Age, education,
gender, APOEe4
allele, intracranial
volume

MMSE, CDR-SB,
verbal fluency
(animals &
vegetables)

Age, education,
gender, APOEe4
allele, intracranial
volume

Age, education,
gender, APOEe4
allele, intracranial
volume

Age, education,
gender, APOEe4
allele, intracranial
volume
Age, gender,
education, race, CVD
risk score, APOEe4
allele, ChEI use
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Doraiswamy
201428

Aβ positive vs.
negative

P=0.20,
(67)

Landau
201229

Brain Glucose
Metabolism

P>0.05,
(126)

Landau
201229

Aβ

rho=0.17,
P=0.06,
(126)

Petersen
20104

Aβ

Steenland
201411

Future
Conversion to
MCI or AD vs.
No Future
Conversion

r=-0.21,
P<0.05,
(229)
P=0.09,
(191)

DSS, WMS
immediate
recall

MMSE, WMS
delayed recall,
CDR-SB, verbal
fluency (animals
& vegetables)

RAVLT trial
5 & short
recall, WMS
immediate &
delayed
logical
memory,
BNT

Mini-Cog,
MMSE, ANART,
Category (animal)
fluency,
TMTA&B, brain
volume measures
(whole brain,
ventricle, left
hippocampus,
right
hippocampus).

Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression
coefficients (β), Spearman rank correlation coefficients (rho), and Pearson correlation
coefficients (r). If a statistical test was performed without an effect estimate reported,
only the P-value is shown. Highlighting refers to results of associations tested using the
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting
responsiveness; Orange=non-statistically significant result where no other cognitive or
neuroimaging outcome measure found a statistically significant association, suggesting
unknown responsiveness; Red=non-statistically significant result where at least one other
cognitive or neuroimaging outcome measure detected a statistically significant result,
suggesting poor responsiveness of the ADAS-Cog.

Table 3 Mild Cognitive Impairment Samples: ADAS-Cog 11 responsiveness to
group-level between-person differences in observed level of disease severity based on
exposure status
First
Author &
Publication
Year

Exposure
(continuous
variable unless
otherwise
specified)

Association
between
exposure
and ADASCog 11
[Effect
estimate,
P-Value,
(n)]

Other
statistically
significant
outcome
measures

Other
statistically
non-significant
outcome
measures

Factors controlled for
(None if blank)
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Crane
201225

Hippocampal
Volume

β=6.32,
P<0.05,
(394)

Crane
201225

Parahippocampa
l Thickness

β=1.63,
P>0.05,
(394)

Crane
201225

Entorhinal
Thickness

β= 7.68,
P<0.05,
(394)

Crane
201225

Fusiform
Thickness

β= 4.46,
P<0.05,
(394)

Cronk
201030
Daiello
201526
Doraiswamy
201227

Body Mass
Index
Fish Oil
Supplement vs.
None
Aβ positive vs.
negative

No statistical
test, (286)
β=-3.29,
P=0.20,
(397)
P=0.06,
(51)

Doraiswamy
201428

Aβ positive vs.
negative

P=0.10,
(47)

Irizarry
200931

Urate Quintiles

P=0.65,
(747)

ADNIMem,
RAVLT,
ADASCog13,
ADASRasch,
ADAS-Tree,
MMSE,
CDR-SB
ADNIMem,
RAVLT,
ADAS-Tree,
CDR-SB
ADNIMem,
RAVLT,
ADASCog13,
ADASRasch,
ADAS-Tree,
MMSE,
CDR-SB
ADNIMem,
RAVLT,
ADASCog13,
ADASRasch,
ADAS-Tree,
MMSE,
CDR-SB

Age, education, gender,
APOEe4 allele,
intracranial volume

ADAS-13,
ADAS-Rasch,
MMSE

Age, education, gender,
APOEe4 allele,
intracranial volume

Age, education, gender,
APOEe4 allele,
intracranial volume

Age, education, gender,
APOEe4 allele,
intracranial volume

MMSE, global
cognition score
MMSE

MMSE, CDR-SB,
DSS, verbal
fluency
(vegetables &
animals), WMS
immediate &
delayed recall
MMSE, CDR-SB,
DSS, verbal
fluency (animal &
vegetable), WMS
immediate &
delayed recall

Age, sex, education
Age, gender, education,
race, CVD risk score,
APOEe4 allele, ChEI
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Kennedy
201232

Aβ < vs. > 192
pG/mL

P=0.002,
(198)

Kennedy
201232

t-Tau/Aβ > vs. <
0.39

P<0.001,
(198)

Kennedy
201433

APOEe4 allele
Carrier vs. NonCarrier
APOEe4 allele
Carrier vs. NonCarrier
Aβ

P<0.001,
(1192)

Kennedy
201634
Landau
201229

WMS
delayed
logical
memory,
RAVLT
delayed
WMS
delayed
logical
memory
delay,
RAVLT
delay
CDR-SB,
MMSE

MMSE, CDR-SB

White
matter
lesion

MMSE

MMSE, CDR-SB

P<0.001,
(1171)
rho=0.24,
P=0.002,
(162 early)
rho=0.29,
P=0.007,
(85 late)
rho=-0.25,
P=0.001,
(162 early)
rho=-0.32,
P=0.003,
(85 late)
P=0.10,
(405)

Landau
201229

Aβ

Landau
201229

Brain Glucose
Metabolism

Landau
201229

Brain Glucose
Metabolism

Mackin
201335

Subsyndromal
Symptoms of
Depression vs.
None

McGough
201336

Gait Velocity

β=-0.19,
P=0.008,
(201)

McGough
201336

Physical
Activity

β=-0.10,
P=0.18,
(201)

McGough
201336

Grip Strength

β=-0.05,
P=0.40,
(201)

TMT A&B,
WMS
logical
memory,
word recall
TMT B,
Word recall

TMT A

Age, sex,
musculoskeletal
comorbidity,
depression symptoms
TMT A, WMS
logical memory I

Age, sex, depressive
symptoms,
musculoskeletal
comorbidity

TMT B, Word
Recall, WMS
logical memory I

Age, sex, BMI,
depressive symptoms,
musculoskeletal
comorbidity
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Petersen
20104

Future
Progression to
AD at 1 year vs.
No Progression
to AD

P<0.001,
(398)

Petersen
20104

Aβ

Portelius
201537

CSF
Neurogranin
Quartiles
Progressive vs.
Stable MCI
Extrapyramidal
Signs vs. None

r=-0.22,
P<0.05,
(398)
No statistical
test, (173)

Rozzini
200638
Rozzini
200839

Schneider
201140

P=0.05,
(74)
P=0.03,
(160)

CDR-SB,
MMSE,
ADAS-Cog
without
word list,
recall, and
recognition
items,
RAVLT,
TMT A&B,
Category
fluency
(animal &
vegetable),
Number
cancellation,
BNT, Digit
backwards,
Clock
drawing

CDR

MMSE

ADAS-Cog
without
memory
tasks

CDR-SB

MMSE, CDR,
ADAS-Cog
memory tasks,
Short Story
(Novelli), Rey's
figure copy,
Phonologic verbal
fluency, Semantic
verbal fluency
MMSE

P<0.001,
(392)

Toledo
201441

ChEI vs. ChEI
and Memantine
Hydrochloride
vs. Neither
CSF levels
Complement 3

β=-0.061,
P=1.0,
(187)

MMSE, memory
& EF summary
scores

Age, gender, education,
APOEe4 allele, tTau/Aβ

Toledo
201441

CSF levels
Factor H

Toledo
201441

Complement
3/Factor H

β=-0.077,
P=1.0,
(187)
β=0.076,
P=1.0,
(187)

MMSE, memory
& EF summary
scores
MMSE, memory
& EF summary
scores

Age, gender, education,
APOEe4 allele, tTau/Aβ
Age, gender, education,
APOEe4 allele, tTau/Aβ
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Whitehair
201042

APOEe4 allele
Carriers vs.
Non-Carriers

P<0.001,
(516)

ADASCog13,
NYU
paragraph
recall
immediate
and delayed
recall,
MMSE,
CDR-SB,
Clock
drawing,
Category
fluency,
Number
cancellation
target hits,
SDMT

Digit backwards
task, BNT,
Number
cancellation target
errors, Maze
tracing

Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression
coefficients (β), Spearman rank correlation coefficients (rho), and Pearson correlation
coefficients (r). If a statistical test was performed without an effect estimate reported,
only the P-value is shown. Highlighting refers to results of associations tested using the
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting
responsiveness; Orange=non-statistically significant result where no other cognitive or
neuroimaging outcome measure found a statistically significant association, suggesting
unknown responsiveness; Red=non-statistically significant result where at least one other
cognitive or neuroimaging outcome measure detected a statistically significant result,
suggesting poor responsiveness of the ADAS-Cog.

Table 4 Mixed Normal Cognition and Mild Cognitive Impairment Samples: ADASCog 11 responsiveness to group-level between-person differences in observed level of
disease severity based on exposure status.
First
Author &
Publication
Year

Exposure

Betterman
201243

Lipid Lowering
Medication vs.
None

Perneczky
200644

Activities of
Daily Living

(continuous
variable unless
otherwise
specified)

Association
between
exposure
and ADASCog 11
[Effect
Estimate, PValue, (n)]
P=0.81,
(3069)

Other
statistically
significant
outcome
measures

Other
statistically
non-significant
outcome
measures

Factors controlled for
(None if blank)

3MSE

r=-0.46,
P<0.01 (75)

Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include a Pearson
correlation coefficient (r). If a statistical test was performed without an effect estimate
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reported, only the P-value is shown. Highlighting refers to results of associations tested
using the ADAS-Cog as an outcome measure: Green=statistically significant result,
suggesting responsiveness; Orange=non-statistically significant result where no other
cognitive or neuroimaging outcome measure found a statistically significant association,
suggesting unknown responsiveness; Red=non-statistically significant result where at
least one other cognitive or neuroimaging outcome measure detected a statistically
significant result, suggesting poor responsiveness of the ADAS-Cog.

Responsiveness to group-level between-person differences of within-person observed
change in those estimated to be different based on baseline exposure status. Twentytwo studies were found which tested for an association between baseline exposure status
and change in ADAS-Cog 11 scores over a follow-up period, as summarized below in
Table 5 for NC and Table 6 for MCI samples.4,10,11,14,23,25,27-29,32,33,35,38-41,43-48 Among these
studies there were forty-three statistically significant associations between baseline
exposure status and ADAS-Cog 11 scores over time (green highlight). There were
twenty-one non-statistically significant associations between baseline exposure and
ADAS-Cog 11 scores over time, whereby any other cognitive or brain imaging outcome
measures also produced non-statistically significant results (orange highlight). The
ADAS-Cog 11 produced a further three non-statistically significant results for
associations found to be statistically significant by at least one other cognitive or brain
imaging outcome measure (red highlight).

Table 5 Normal Cognition Samples: Responsiveness to group-level between-person
differences of within-person observed change in those estimated to be different
based on baseline exposure status.
First
Author &
Publication
Year

Exposure
(continuous
variable
unless
otherwise
specified)

Association
between
exposure
and change
in ADASCog 11
[Effect
Estimate, PValue, (n,
years of
follow-up)]

Other
statistically
significant
outcome
measures

Other
statistically
non-significant
outcome
measures

Factors controlled for
(None if blank)
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Bettermann
201243

Lipid
Lowering
Medications
vs. None

P=0.04,
(2578, 3)

3MSE

Crane 201225

AD CSF
Signature vs.
No Signature

Z=-1.96

ADAS-Cog
13, CDR-SB

Doraiswamy
201227

Aβ Positive
vs. Negative

P=0.005,
(67, 1.5)

Doraiswamy
201227

Florbetapir
SUVr

P=0.095,
(67, 1.5)

Doraiswamy
201428

Aβ Positive
vs. Negative

P=0.001,
(67, 3)

Landau
201229

Aβ Positive
vs. Negative

Age, sex, education

Landau
201229

Brain
Hypometaboli
sm
Aβ

β=0.43,
P<0.001,
(76, 4)
P>0.05,
(76, 4)
P>0.05,
(36, 3)

Age, baseline
biomarker

Lo 201145

(reversed score),

P<0.05,
(112, 3)

CDR-SB

CDR-SB,
DSS, Verbal
fluency
(vegetable)

Age, sex, race,
education, clinic,
treatment group, MCI,
APOEe4 allele, CHD,
stroke
ADNI-Mem,
RAVLT, ADASRasch, ADASTree, MMSE
MMSE, DSS,
Verbal Fluency
(animals &
vegetables),
WMS delayed &
immediate recall
MMSE, CDR-SB,
DSS, Verbal
fluency (animals
& vegetables),
WMS delayed &
immediate recall
Verbal fluency
(animal), WMS
logical &
immediate recall,
MMSE

Age, education, sex,
APOEe4 allele

Age, psychometric
assessment

Age, psychometric
assessment

Age, cognitive function
assessment

Age, sex, education

Lo 201145

Brain Glucose
Metabolism

P>0.05,
(104, 3)

Age, baseline
biomarker value

Lo 201145

Hippocampal
Volume

P>0.05,
(228, 3)

Age, baseline
biomarker value

Petersen
20104

Aβ

Steenland
201411

Age

r=-0.23,
P<0.05,
(229, 1)
β=0.15

Steenland
201411

Male

Steenland
201411

Race, white

(log[ADAS-Cog]),

P=0.003,
(191, 3.1)
β=0.19
(log[ADAS-Cog]),

P=0.0009,
(191, 3.1)
β=0.05
(log[ADAS-Cog]),

P=0.65,
(191, 3.1)

Gender, race,
education, APOEe4
allele, time
Age, race, education,
APOEe4 allele, time
Age, gender, education,
APOEe4 allele, time
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β=-0.03

Steenland
201411

Education

Steenland
201411

APOEe4
allele

Steenland
201411
Steenland
201411

Category
(Animal)
Fluency
Whole Brain
Volume

Steenland
201411

Hippocampal
Volume

Steenland
201411

t-Tau

Steenland
201411

p-Tau

P=0.006,
(191, 3.1)

Steenland
201411

Aβ

P=0.0007,
(191, 3.1)

Steenland
201411

t-Tau/Aβ

P=0.01,
(188, 3.1)

Steenland
201411

p-Tau/Aβ

P=0.003,
(191, 3.1)

Steenland
201411

Mini-cog

P>0.05,
(191, 3.1)

Steenland
201411

MMSE

P>0.05,
(191, 3.1)

Steenland
201411

ANART

P>0.05,
(191, 3.1)

Steenland
201411

RAVLT trial
5

P>0.05,
(191, 3.1)

Steenland
201411

RAVLT short
recall

P>0.05,
(191, 3.1)

Steenland
201411

TMT A or B

P>0.05,
(191, 3.1)

Steenland
201411

WMS Logical
Memory
(immediate or
delayed)

P>0.05,
(191, 3.1)

(log[ADAS-Cog]),

P=0.002,
(191, 3.1)
β=0.14
(log[ADAS-Cog]),

P=0.03,
(191, 3.1)
P=0.05,
(191, 3.1)
P=0.02,
(191, 3.1)
P=0.02 (left)
P=0.008
(right),
(186, 3.1)
P=0.04,
(188, 3.1)

Age, gender, race,
APOEe4 allele, time
Age, gender, race,
education, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
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Steenland
201411

Boston
Naming Test

P>0.05,
(191, 3.1)

Steenland
201411

Ventricle
Volume

P>0.05,
(191, 3.1)

Ye 201646

Serum Uric
Acid
(Females)

β=0.10,
P=0.02,
(137, 2.9)

MMSE

Ye 201646

Serum Uric
Acid (Males)

β=0.01,
P=0.88,
(134, 2.9)

MMSE

Age, gender, race,
education, APOEe4
allele, time
Age, gender, race,
education, APOEe4
allele, time
Age, sex, education,
BMI, race, APOEe4
allele, cardiovascular
risk factors, study site
Age, sex, education,
BMI, race, APOEe4
allele, CVD risk
factors, study site

Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression
coefficients (β), Z-scores from mixed effects models (Z), and Pearson correlation
coefficients (r). If a statistical test was performed without an effect estimate reported,
only the P-value is shown. Highlighting refers to results of associations tested using the
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting
responsiveness; Orange=non-statistically significant result where no other cognitive or
neuroimaging outcome measure found a statistically significant association, suggesting
unknown responsiveness; Red=non-statistically significant result where at least one other
cognitive or neuroimaging outcome measure detected a statistically significant result,
suggesting poor responsiveness of the ADAS-Cog.

Table 6 Mild Cognitive Impairment Samples: Responsiveness to group-level
between-person differences of within-person observed change in those estimated to
be different based on baseline exposure status.
First Author
&
Publication
Year

Bettermann
201243

Exposure
(continuous
variable unless
otherwise
specified)

Lipid
Lowering
Medications
vs. None

Association
between
exposure
and change
in ADASCog 11
[ Effect
Estimate, PValue, (n,
years of
follow-up)]
P>0.05,
(491, 3)

Other
statistically
significant
outcome
measures

Other
statistically nonsignificant
outcome
measures

Factors controlled
for
(None if blank)

3MSE

Age, sex, race,
education, clinic,
treatment group,
MCI, APOEe4
allele, CHD, stroke
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Cardinali
201247

Melatonin vs.
None

ZMW=-5.73,
P<0.001,
(96, 5)

Crane 201225

AD CSF
Signature vs.
No Signature

Z=-4.39,
P<0.05,
(193, 3)

Cronk 201030

BMI

Doraiswamy
201227

Aβ positive
vs. negative

Wald
X2=6.7,
P=0.02.
(286, 1)
P=0.001,
(46, 1.5)

Doraiswamy
201227

Florbetapir
SUVr

r=0.41,
P=0.006,
(46, 1.5)

Doraiswamy
201428

Aβ positive
vs. negative

P=0.001,
(46, 3)

Evans 201010

Brain Atrophy
Rates

Evans 201010

MMSE,
Mattis'
score, DSS,
TMT A&B,
RAVLT
ADNI-Mem,
RAVLT,
ADASCog13,
ADASRasch,
ADAS-Tree,
MMSE,
CDR-SB
MMSE,
Global
composite

Age, education,
sex, APOEe4 allele

CDR-SB

Age, education, sex

MMSE,
CDR-SB,
DSS, Verbal
fluency
(vegetables),
WMS
delayed &
immediate
recall
MMSE,
CDR-SB,
DSS, WMS
immediate
recall

Verbal fluency
(animals)

Age, baseline
psychometric score

Verbal fluency
(animal &
vegetable), WMS
delayed recall

Age, baseline
psychometric score

Verbal fluency
(animal), WMS
logical &
immediate
memory
TMT A

Age, baseline
cognitive function
scores

P<0.0001,
(231, 1)

CDR-SB,
DSS, verbal
fluency
(vegetable),
MMSE
MMSE,
TMT B

Ventricular
Expansion

P<0.0005,
(231, 1)

MMSE,
TMT B

TMT A

Furio 200748

Melatonin vs.
None

ZMW=-5.55,
P=0.001,
(50, 1.5)

DSS

Herholz
201123

Progressive
vs. NonProgressive
MCI

Cohen
D=0.30,
P>0.05,
(94, 1)

MMSE,
Mattis'
score, TMT
A&B,
RAVLT
PET
measure

Baseline brain
volume,
neuropsychological
score, age, gender
Baseline brain
volume,
neuropsychological
score, age, gender
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Herholz
201123

Irizarry
200929

Kennedy
201634
Landau
201229
Landau
201229

Lo 201145

Progressive
vs. NonProgressive
MCI
Plasma Urate

Cohen
D=0.60,
P=0.006
(94, 2)
P>0.05,
(747, 3)

APOEe4 allele
Present vs.
Absent
Aβ Positive
vs. Negative

P<0.001,
(1171, 3)

Brain Glucose
Hypometaboli
sm Positive
vs. Negative
Aβ

PET
measure

Age, sex, BMI,
APOEe4 allele,
current smoking,
history of alcohol
abuse, CVD,
hypertension, use
of nonsteroidal
anti-inflammatory
drugs and thiazide
diuretics

β=0.83,
P=0.004,
(81, 4)
β=1.48,
P<0.001,
(81, 4)

Age, sex, education

P<0.05,
(54, 3)

Age, baseline
biomarker value

Age, sex, education

Lo 201145

Brain Glucose
Metabolism

P<0.001,
(203, 3)

Age, baseline
biomarker value

Lo 201145

Hippocampal
Volume

P<0.001,
(390, 3)

Age, baseline
biomarker value

Mackin
201335

Subsyndromal
Symptoms of
Depression vs.
None
Aβ

βGEE=0.51,
P=0.28,
(405, 2)

APOEe4 allele

Petersen
20104

r=-0.29,
P<0.05,
(398, 1)
β=0.002,
P=0.0002,
(173, 9)

Portelius
201537

CSF
Neurogranin
Quartiles

Schneider
201140

ChEIs vs.
None

β=0.78,
P=0.03,
(392, 2)

Schneider
201140

ChEI and
Memantine
Hydrochloride
vs. None

β=0.86,
P=0.14,
(251, 2)

MMSE,
hippocampal
volume,
cortical
glucose
metabolism
MMSE,
CDR-SB

MMSE,
CDR-SB

Age, sex, education

Age, APOEe4
allele, education,
baseline ADASCog or CDR-SB
Age, APOEe4
allele, education,
baseline ADASCog or CDR-SB
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Schneider
201140

P>0.05,
(177, 1.5)

Toledo
201441

ChEIs and
Memantine
Hydrochloride
vs. ChEIs only
CSF levels
Complement 3

MMSE,
CDR-SB

β=-0.12,
P=0.04,
(160, 1.5)

MMSE, Memory
assessment, EF
assessment

Toledo
201441

CSF levels
Factor H

β=-0.08,
P=0.04,
(160, 1.5)

MMSE, Memory
assessment, EF
assessment

Toledo
201441

Complement
3/Factor H

β=-0.18,
P=0.06,
(160, 1.5)

MMSE, memory
assessment, EF
assessment

Whitehair
201042

APOEe4
Allele Present
vs. Absent

P<0.001,
(516, 3)

Ye 201646

Serum Uric
Acid

β=-0.5,
P<0.001,
(244, 2.9)

Ye 201646

Serum Uric
Acid

β=-0.001,
P=0.99,
(352, 2.9)

ADASCog13,
Delayed
work list
recall,
MMSE,
Digit
backwards,
BNT, Clock
drawing,
Category
fluency,
New York
University
immediate &
delayed
paragraph
recall,
Number
cancellation
target hits,
SDMT,
CDR-SB
MMSE

Number
cancellation task
target errors, maze
tracing

MMSE

Age, gender,
APOEe4 allele,
education, tTau/Aβ
Age, gender,
APOEe4 allele,
education, tTau/Aβ
Age, gender,
APOEe4 allele,
education, tTau/Aβ
Age, sex,
education, baseline
CDR-SB

Age, sex,
education, BMI,
race, APOEe4
allele, CVD risk
factors, study site
Age, sex,
education, BMI,
race, APOEe4
allele, CVD risk
factors, study site
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Zanotta
201414

Phytotherapeu
tic Compound
plus
PhosphatidylS
erine and
Vitamin E vs.
Placebo

P<0.001,
(102, 0.16)

Clock
drawing test,
MMSE

Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression
coefficients (β), parameters from generalized estimating equations (βGEE), Pearson
correlation coefficients (r), and Z-scores from mixed effects models (Z) or Mann-Whitney
U tests (ZMW). If a statistical test was performed without an effect estimate reported, only
the P-value is shown. Highlighting refers to results of associations tested using the
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting
responsiveness; Orange=non-statistically significant result where no other cognitive or
neuroimaging outcome measure found a statistically significant association, suggesting
unknown responsiveness; Red=non-statistically significant result where at least one other
cognitive or neuroimaging outcome measure detected a statistically significant result,
suggesting poor responsiveness of the ADAS-Cog.

Responsiveness to treatment effects. Seventeen clinical trials using the ADAS-Cog 11
as an outcome measure in pre-dementia samples were found, and are summarized in
Table 7, below.49-65 The ADAS-Cog 11 was able to detect seven statistically significant
treatment effects (green highlight). The ADAS-Cog 11 did not find a significant effect for
eleven interventions (orange or red highlight), four of which demonstrated a treatment
effect for at least one other outcome measure (red highlight). Note that only results from
the final time point of each study are presented, and subgroup analyses are only presented
when the primary analyses did not include the ADAS-Cog 11 in a sample composed
completely of older adults with pre-dementia levels of disease severity.

Table 7 ADAS-Cog 11 Responsiveness to Treatment Effects in Pre-Dementia
Clinical Trials
First
Author &
Publication
Year

Treatment vs. Placebo
(unless otherwise
specified)

Treatment
effect
[P-Value,
(n, years of
follow-up)]

Other outcome
measures
(* if sig effect)

ADAS-Cog
as primary
outcome?

Factors
controlled
for
(None if
blank)
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De
Beaumont
201649

Donepezil

Yes

Age, sex,
baseline
ADAS-Cog

Buschert
201150

Multicomponent
Cognitive Group
Intervention

MMSE, RBANS
(story memory,
recall*), TMT A&B,
MADRS*, QoL-AD
RBANS (immediate*,
delayed), TMT A&B,
MMSE, MADRS,
QoL-AD
CIBIC-Plus

Yes

Age,
education

Buschert
201251

Multicomponent
Cognitive Group
Intervention

P=0.04,
(24, 2.3)

Chiu 200852

Omega-3
Polyunsaturated Fatty
Acids
Pro-Cholinergic Drug

P=0.03,
(23, 0.5)

Yes

Age, gender,
education

CDR-SB, CVLT(free
immediate recall
Monday list &
Tuesday list*, short
delay free and cued
recall, long delay free
and cued recall),
Fluency test, TMT
A&B, DSST, Global
improvement
evaluated by
investigator &
patient, ADL, AI
MMSE*

Yes

Country

Forster
201154

Cognitive Intervention

P=0.045,
(21, 0.5)

Yes

Education,
age

Kile 201555

Immunoglobulin

P=0.03,
(49, 2)

Annualized percent
change in ventricular
volume, MMSE*,
CDR-SB

No

Lin 201456

Sodium Benzoate

P=0.23,
(31, 0.46)

CIBIC-Plus,
Cognitive composite

Yes

Luchsinger
201657

Metaformin

P=0.34,
(80, 1)

SRT*, Glucose
uptake in posterior
cingulate-precuneus,
Aβ

Yes

Miao 201258

Chinese Herbal
Medicine vs. Donepezil

P=0.11,
(72, 1)

MMSE, ADL,
Syndrome
Differentiation Scale

Yes

Dubois
201253

Stratified by
genotype
BCHE-K*:
P<0.01;
BCHE-K
wild type:
P>0.05;
APOEe4+:
P>0.05;
APOEe4-:
P>0.05,
(408, 3)
P=0.02,
(22, 0.5)

P=0.37,
(241, 0.46)

Yes
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Petersen
200559

Donepezil and Vitamin E

P>0.05,
(769, 3)

De Gobbi
Porto 201560

Aerobic Training

P<0.001,
(40, 0.46)

Reuter
201261

Cognitive
Training+Transfer
Training+Psychomotor
Training vs. CT+TT vs.
CT
Computerized
Multidomain Cognitive
Training

P<0.001,
(223, 0.58)

Singh 201462

High Intensity
Progressive Resistance
Training

P=0.08,
(49, 1.5)

Snitz 200963

G Biloba Extract

Suzuki
201364

Thal 200565

Singh 201462

MMSE, CDR, CDRSB, ADL, Global
deterioration scale,
Neuropsychological
battery, Time to
development of AD
Neuropsychological
battery*

No

SCOPA-Cog*, BADS
(zoo*, instruction*, 6
elements*), Paced
auditory serial
addition test*
Standardized global
cognition score,
WAIS-III similarities
& matrices, Category
fluency, COWAT,
Memory function,
BVRT, Immediate &
Delayed & Domain
memory scores,
SDMT, ADL
Standardized global
cognition score,
WAIS-III Similarities
& matrices*,
Category fluency,
COWAT, Memory
function, BVRT,
Immediate & Delayed
& Domain Memory
scores, SDMT, ADL

Yes

P=0.97,
(3069, 7.3)

3MSE, Tests of
memory, attention,
visual-spatial
construction,
language, and EF

Yes

Multicomponent
Exercise with Multitask
Conditions vs.
Educational Classes

P=0.16,
(100, 0.5)

No

Rofecoxib

P>0.05,
(1457, 4)

MMSE, WMS-logical
memory I & II,
Volume of medial
temporal areas
including the
entorhinal cortex,
Whole brain cortices
% patients convert to
AD*, CDR-SB, SRT,
MMSE

P=0.69,
(51, 1.5)

Yes
Age, sex,
education

Yes

Yes

No

Legend: See List of Abbreviations (pages xii to xvi). P-values refer to statistical tests
performed to assess whether a treatment effect was present. Highlighting refers to results
of associations tested using the ADAS-Cog as an outcome measure: Green=statistically
significant result, suggesting responsiveness; Orange=non-statistically significant result
where no other outcome measure found a statistically significant association, suggesting
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unknown responsiveness; Red=non-statistically significant result where at least one other
outcome measure detected a statistically significant result, suggesting poor
responsiveness of the ADAS-Cog.

Sample size estimates from simulation studies. Four studies estimated the sample size
needed to detect a treatment effect using the ADAS-Cog 11 in a clinical trial of predementia syndromes, and as summarized in Table 8 below, the ADAS-Cog 11 was never
the outcome measure requiring the smallest sample size.66-69 A separate study found that
increasing the proportion of APOEe4 allele carriers in clinical trial simulations, a method
employed to try and increase the level of impairment of a sample, did not lead to
meaningful increases in power to detect a treatment effect with the ADAS-Cog 11.31
Furthermore, the ADAS-Cog 11 failed to produce statistically significant treatment
effects in several situations where one was hypothesized to be present based on other
indicators of disease progression.32

Table 8 Sample Size Estimates to Detect Treatment Effects in Pre-Dementia Clinical
Trials
First
Study Details
Author &
Publication
Year
Caroli
201566

Estimate n per treatment arm
needed to detect 20% reduction in
disease progression over 24
months, with beta=0.20, and
alpha=0.05.
MCI with Aβ
MCI with Hippocampal Atrophy

Grill 201367

Estimate n per treatment arm
required to detect 25% treatment
effect in cognitive measures over
24 and 36 months with beta=0.20
and alpha=0.05. Assessed
different sample enrichment
strategies.

ADAS-Cog 11 rank versus other outcome
measures

6th (n=568) of 6; best=brain atrophy rate (n=46)
6th (n >1000) of 6; best=brain atrophy rate
(n=77)
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Ho 201068

NC with APOEe4 allele, 36
months
MCI with APOEe4 allele, 24
months
NC with Aβ, 36 months

6th (No decline) of 6; best=RAVLT (n=499)

MCI with Aβ, 36 months

3rd (n=639) of 6; best=CDR-SB (n=292)

NC with Total CSF Tau, 36
months
MCI with Total CSF Tau, 24
months
NC with CSF Tau phosphorylated
at threonine 181, 36 months
NC with CSF Tau phosphorylated
at threonine 181, 24 months
NC with CSF Total Tau/Aβ, 36
months
MCI with CSF Total Tau/Aβ, 24
months
NC with CSF pTau/Aβ, 36
months
MCI with CSF pTau/Aβ, 24
months
NC with Brain Glucose
Hypometabolism, 36 months
MCI with Brain Glucose
Hypometabolism, 24 months
NC with Hippocampal Volume,
36 months
MCI with Hippocampal Volume,
24 months
NC with Lateral Ventricle
Volume, 36 months
MCI with Lateral Ventricle
Volume, 24 months
Estimate n per treatment arm to
measure 25% reduction in rate of
change over 12 months,
beta=0.20 and alpha=0.05.

6th (no decline) of 6; best=RAVLT (n=817)

MCI

4th (n=1183) of 5; best=Rate of Annual Brain
Volume Loss (n=108)

5th (n=908) of 6; best=CDR-SB (n=329)
6th (n=420495) of 6; best=RAVLT (n=1090)

4th (n=537) of 6; best=CDR-SB (n=292)
6th (n=2200678) of 6; best=RAVLT total score
(n=559)
3rd (n=714) of 6; best=CDR-SB (n=296)
6th (no decline) of 6; best=RAVLT (n=559)
4th (n=676) of 6; best=CDR-SB (n=258)
6th (n=214455) of 6; best=RAVLT (n=552)
3rd (n=696) of 6; best=CDR-SB (n=313)
6th (n=13136) of 6; best=CDR-SB (n=1039)
3rd (n=357) of 6; best=MMSE (n=314)
6th (n=21359) of 6; best=CDR-SB (n=1057)
5th (n=754) of six; best=CDR-SB (n=300)
Tied for 6th (no decline) of 6; best=RAVLT
delayed recall (n=1039)
3rd (n=666) of 6; best=CDR-SB (n=381)
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Hua 200969

Estimate n required to detect 25%
reduction in rate of decline over
12 months with beta=0.20 or 0.10
and alpha=0.05.
MCI, 80% power

MCI, 90% power

6th (n=6797) of 6; best=Atrophy using
symmetric Kullback-Leibler S9L5 distance
(n=85)
6th (n=9092) of 6; best=Atrophy using
symmetric Kullback-Leibler S9L5 distance
(n=114)

Legend: See List of Abbreviations (pages xii to xvi).

3.2.8

Summary of ADAS-Cog 11 Performance in Pre-Dementia
Studies

ADAS-Cog 11 scores in pre-dementia populations are driven primarily by the Word
Recall and Word Recognition tasks, and age may influence scores for older adults with
NC. Despite this, ADAS-Cog 11 scores do generally appear able to detect differences in
cognitive ability in groups separated by an exposure that is expected to be associated with
cognitive ability, although the magnitude of the differences detected tends to be small and
are possibly attenuated by the nine tasks that demonstrated ceiling effects in pre-dementia
populations. Responsiveness of the ADAS-Cog 11 to treatment effects appears low
compared to other global outcome measures, and compared to outcome measures
designed to assess subdomains of cognition or other aspects of dementia and predementia syndromes. Nonetheless, caution must be maintained when interpreting these
findings because an in-depth exploration of whether there truly should be an association
between cognition or disease severity and any given exposure or treatment, and the
potential magnitude and direction of these associations, was not explored. Overall, the
ADAS-Cog 11 seems able to provide a measure of disease severity in pre-dementia
syndromes, but there is room for improvement.

3.3

Modifications of the ADAS-Cog 11

This section reviews all modifications that have been made to the ADAS-Cog 11, as well
as other outcome measures which have been combined with some or all of the individual
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ADAS-Cog 11 tasks for the purpose of measuring disease severity in studies of dementia
or pre-dementia syndromes. The organizational structure of this section is to introduce an
outcome measure, review available information about responsiveness to baseline
discrimination, disease progression, and treatment effects, and then summarize the
performance of that outcome measure in comparison with the ADAS-Cog 11 (See Section
2.2.7 for responsiveness definitions). A visual representation of the modification history
of the ADAS-Cog 11 is presented below in Figure 6, and a summary of each measure
including coefficient of variation (CV) calculations can be found in Appendix A.

Figure 6 Timeline of ADAS-Cog 11 modifications.

3.3.1

ADAS-Cog 13

Mohs et al. (1997) identified several cognitive domains hypothesized to be important to
detect treatment effects in clinical trials of antidementia drugs that are not assessed by the
ADAS-Cog 11.70 Accordingly, tests of attention and concentration, planning and
executive function, verbal memory, nonverbal memory, and praxis were considered for
addition to the ADAS-Cog 11.70 Recommendations about which specific tests to add to
the ADAS-Cog 11 were based on assessments of reliability, influence of age and
education on change scores, learning effects (one month interval), ability to assess full
range of dementia severity, floor and ceiling effects, and ability to measure 12 month
longitudinal change in 64 subjects with NC, 50 subjects with mild AD, 47 subjects with
moderate AD, and 46 subjects with moderately severe AD.70 In summary, the authors
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recommended adding items such as a four-trial learning plus delayed word recall task,
one or two simple mazes, or number cancellation tasks for clinical trials involving
subjects with mild AD or pre-dementia.70 A commonly used adaptation of these
suggestions is the ADAS-Cog 13 which includes all ADAS-Cog 11 items as well as a test
of delayed word recall and a number cancellation or maze task. Errors on the additional
task are summed together with scores from the original 11 tasks to give a final ADASCog 13 score from 0 to 85.
Baseline discrimination. Skinner et al. (2012) found the mean score on the ADAS-Cog
13 was lower for 229 subjects with NC (mean=9.5, SD=4.1) than 394 subjects with MCI
(mean=18.6, SD=6.2) and 187 subjects with AD (mean=28.9, SD=7.6).3 In a separate
analysis, Podhorna et al. (2016) found the mean ADAS-Cog 13 score for 382 subjects
with MCI (mean=15.23, SD=6.68) was lower than that of 97 subjects with mild AD
(mean=29.91, SD=7.44).12 Podhorna et al. (2016) further divided the 382 subjects with
MCI into two groups depending on whether a CSF or APOEe4 allele biomarker of AD
pathology was present.12 The 206 subjects with MCI and an indication of AD pathology
(enriched subgroup) had worse scores at baseline (mean=17.52, SD=6.81) on the ADASCog 13 than the 176 subjects with MCI but no such AD biomarkers present (mean=12.55,
SD=5.43).12 Statistical significance of the above differences was not tested.
Disease progression. Hobart et al. (2009) used Rasch Analysis to compare the ADASCog 11 and ADAS-Cog 13 on scale performance and person measurements in 371
subjects with MCI and 217 subjects with AD.71 Although they found that the ADAS-Cog
13 evaluates more cognitive domains than the ADAS-Cog 11, it was not better at
measuring clinically significant changes in subjects with MCI.71 Podhorna et al. (2016)
had similar results. They found little change on the ADAS-Cog 13 for 382 subjects with
MCI over 24 months (mean change=1.34 points) or for 168 subjects with MCI over 36
months (mean change=2.59 points).12 There was slightly more change detected in the
enriched MCI subgroup (mean 24 month change=2.63 points; mean 36 month
change=5.02 points), and no meaningful change on the ADAS-Cog 13 in the nonenriched MCI subgroup (mean 24 month change=-0.18 points, mean 36 month change=0.15 points).12 Among 97 subjects with mild AD there was a modest change in mean
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ADAS-Cog 13 score over 12 months (mean change=4.35 points) and among 38 subjects
with AD over 24 months (mean change=9.46 points).12 The SRM for change over 24
months in 382 subjects with MCI, adjusting for baseline age, baseline MMSE score, sex,
and APOEe4 allele, was 0.39 (95% CI 0.16, 0.60) for the ADAS-Cog 13 compared to
0.37 (95% CI 0.15, 0.57) for the ADAS-Cog 11.12 The SRM for change over 12 months
in 97 subjects with AD was 0.98 (95% CI 0.58, 1.26) for the ADAS-Cog 13 and 0.87
(95% CI 0.46, 1.13) for the ADAS-Cog 11.12 Skinner et al. (2012) found the Z-statistic
for change over time in 394 subjects with MCI was slightly larger for the ADAS-Cog 13
(Z=10.70) than for the ADAS-Cog 11 (Z=9.44), adjusting for age, education, gender, and
APOEe4 allele.3 Raghavan et al. (2013) also found the ADAS-Cog 13 had larger
standardized two-year change than the ADAS-Cog 11 in an MCI sample.19
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to
detect a 25% decrease over 12 months in subjects with MCI with 80% power and an
alpha of 0.05 was smaller for the ADAS-Cog 13 (n=900) than for the ADAS-Cog 11
(n=1230).3 Raghavan et al. (2013) found the estimated sample size to detect a
hypothetical 25% treatment effect over 2 years in subjects with MCI with 80% power was
also smaller for the ADAS-Cog 13 (n=582) than for the ADAS-Cog 11 (n=772).19
Summary. The ADAS-Cog 13 appeared able to discriminate between groups of subjects
with MCI and mild AD at one point in time. For subjects with AD, the responsiveness of
the ADAS-Cog 13 to disease progression was better than that of the ADAS-Cog 11. For
subjects with pre-dementia syndromes, the ADAS-Cog 13 demonstrated similar or only
slightly better responsiveness to disease progression than the ADAS-Cog 11.
Responsiveness to treatment effects in MCI was better for the ADAS-Cog 13 than the
ADAS-Cog 11.

3.3.2

Vascular Dementia Assessment Scale

To address the need for a primary outcome measure for clinical trials in Vascular
Dementia (VaD), Ferris et al. (1999) suggested using the ADAS-Cog 11 as a starting
point because many of the cognitive domains affected by VaD are also affected in AD.72
Cognitive domains important for VaD include memory, attention, processing speed,
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visuospatial function, language, executive function, and abstraction.72 The original
VaDAS included items suggested by Mohs et al. (1997) for the ADAS-Cog 13.70,72 An
updated version had additional items to further target frontal lobe functions.73 This
updated VaDAS includes all tasks from the ADAS-Cog 11 as well as a delayed recall
portion added to the Word Recall task (memory), two number cancellation tasks
(attention), a maze (executive function), symbol digit modalities
(attention/concentration), backwards digit span (working memory), and animal category
retrieval (verbal fluency) tasks.73 At the time of development, evaluation of the VaDAS
was left to be done in future clinical trials.73
Disease Progression. The VaDAS showed improvement over 18 weeks for both placebo
and donepezil groups in an 18 week randomized clinical trial of donepezil versus placebo
for 168 subjects with cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (least squares mean change from baseline: placebo=-0.81,
donepezil group=-0.85).74
Treatment effect. No statistically significant treatment effect was found using the
VaDAS, which was congruent with a version of the ADAS-Cog 13 (ADAS-Cog 11,
number cancellation, maze), ADAS-Cog 11, and MMSE.74
Summary. Theoretically the VaDAS should be better than the ADAS-Cog 11 at
detecting VaD dysfunction and assessing change in this dysfunction over time; however,
further studies are needed to definitively evaluate whether this is true. Analyses of
baseline discrimination have also not been performed.

3.3.3

ADAS-Cog 12

A common modification to the ADAS-Cog 11 is to add a Delayed Word Recall task
which provides a subject three trials to recall as many of the ten words from the Word
Recall task after a period of time (delay).17 The task is scored from 0 to 10 based on the
number of words not recalled (errors), and added to the ADAS-Cog 11 score to give a
total score of 0 to 80.
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Lowe et al. (2015) used IRT methods with 788 subjects ranging from pre-dementia
syndromes (Subjective Cognitive Impairment (SCI), MCI) to severe stages of AD to
determine where along the continuum of disease progression the Delayed Word Recall
task provides the most information about cognitive ability, and if it alters the
measurement precision of the ADAS-Cog 11.75 ICCs from the IRT analysis showed that
in general memory tasks of the ADAS-Cog 12 are the most sensitive to the earlier stages
of disease progression, and the Delayed Word Recall task provides the most information
in the mildest range of cognitive impairment.75 Area under the curve (AUC) analyses
found statistically significant differences in the overall average distance between the ICC
for the Delayed Word Recall task and for the Word Recall task.75 The Delayed Word
Recall task does not however have much sensitivity for more severe cognitive
dysfunction such as that seen with AD.75 Floor effects (10 errors) on the Delayed Word
Recall task were seen for 9% of the MCI group and 52% of the AD group at baseline.75
Baseline discrimination. Grundman et al. (2004) found statistically significant different
mean scores in the ADAS-Cog 12 between groups of subjects with aMCI (n=769), NC
(n=107), very mild AD (n=122), and mild AD (n=183). Furthermore, subjects with MCI
performed an average 2.1 SD higher than subjects with NC on the Delayed Word Recall
task compared to an average of 1.8 SD higher on the original immediate Word Recall
task.17 Sano et al. (2011) showed that 111 subjects with AD had significantly higher mean
scores (two samples t-test, t = 15.3, P<0.001) on the ADAS-Cog 12 (mean=33.27 points,
SD=10.3) than 259 subjects with MCI (mean=17.22 points, SD=5.9).7 Test information
curves for the ADAS-Cog 11 and ADAS-Cog 12 show that both scales are maximally
precise around mild to moderate AD, but the ADAS-Cog 12 is more precise, or holds
more information about underlying cognitive impairment, in earlier stages of disease
progression than the ADAS-Cog 11.75 The ADAS-Cog 12 maintains similar precision to
the ADAS-Cog 11 for more severe stages of cognitive impairment, namely AD.75 Labos
et al. (2011) compared performance on the MMSE, ADAS-Cog 11, traditional memory
ADAS-Cog 11 tasks (immediate Word Recall and Word Recognition), and an additional
Delayed Word Recall task in 230 subjects divided into NC, SCI, amnestic MCI (aMCI),
multidomain MCI, and dementia categories.76 The scores from all four tests or subtasks
were able to distinguish the group of subjects with dementia from subjects with NC, SCI,
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aMCI, and multidomain MCI.76 The MMSE did not significantly discriminate between
any other groups. Scores on the ADAS-Cog 11 as well as the isolated memory tasks were
similar for groups with NC and SCI, but NC group scores were significantly better than
the two MCI subtype groups, which were not distinguishable.76 The Delayed Word Recall
task score was comparable for groups with NC and SCI, but the group with NC scored
significantly worse than both MCI subtype groups.76 Furthermore, the aMCI scores were
significantly worse than those for multidomain MCI.76
Disease progression. Sano et al. (2011) found that 12 month unadjusted change scores
were significantly different between MCI and AD groups for the ADAS-Cog 11 (t=4.26,
P<0.001) and ADAS-Cog 12 (t=3.89, P<0.001), but the Delayed Word Recall task on its
own was not (t=-0.45, P=0.654).7 Among the MCI group, the 12 month SRM was lower
for the ADAS-Cog 11 (0.142) than for the ADAS-Cog 12 (0.160).7 The ratio of the SRM
for the ADAS-Cog 12 divided by the SRM for the ADAS-Cog 11 was used to show that
including Delayed Word Recall with the ADAS-Cog 11 increased the SRM by 12%
(more responsive).7 For the AD group, the 12 month SRM was similar between the
ADAS-Cog 11 (0.589) and ADAS-Cog 12 (0.569).7
Treatment effect. The estimated sample size required to detect a 33% treatment effect in
MCI with 80% power was over 600 subjects lower for the ADAS-Cog 12 than the
ADAS-Cog 11.7 In contrast, the ADAS-Cog 12 did not outperform the ADAS-Cog 11 for
estimations of sample size needed for a trial of AD.7
Summary. The ADAS-Cog 12 has demonstrated the ability to discriminate between
groups of subjects with MCI and AD, as well as between MCI subtypes. The ADAS-Cog
12 demonstrated more responsiveness to disease progression and treatment effects in MCI
than the ADAS-Cog 11. Further along the disease continuum responsiveness to disease
progression and treatment effects of the ADAS-Cog 11 and 12 were comparable.
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3.3.4

Test for the Early Detection of Dementia from Depression –
Cognitive

The Test for the Early Detection of Dementia from Depression (TE4D) was initially
developed in the German language to differentiate early dementia from depression.6
Mahoney et al. (2005) modified the TE4D with the intention of using it as a screening
tool to detect MCI in English-speaking populations with AD (TE4D-Cog).6 The TE4DCog is scored from 0 to 45, and has eight items among seven subscales which assess
immediate recall, semantic memory, clock drawing, category fluency, orientation, and
following commands (from ADAS-Cog 11).6 The TE4D-Cog was tested in a sample of
178 subjects with AD and 25 subjects with NC, where it was found to have good
concurrent criterion validity with the ADAS-Cog 11 (r=-0.90, P<0.001) and MMSE
(r=0.92, P<0.001), high inter-rater reliability, and good internal consistency.6
Baseline discrimination. Twenty-five subjects with NC scored significantly better on the
TE4D-Cog than 178 subjects with AD both in terms of overall score (Mann-Whitney U
test (U)=24.0, P<0.001), and each of the seven subscales (P<0.001).6 The ability of the
TE4D-Cog to serve as a screening tool for dementia was compared with the MMSE by
assessing sensitivity and specificity at different cut-points and calculating the area under
the receiver operating characteristic (ROC) curve.6 The cut-point giving maximum
(100%) sensitivity for the TE4D-Cog (score > 35) corresponded to a specificity of 84.0%.
Using a cut-point for maximum sensitivity of the MMSE (score > 29) corresponded to a
specificity of 32.0%.6 When set at maximum specificity (100%), the sensitivity of the
TE4D-Cog drops to 79.5% and the MMSE to 65.9%. The AUC for the TE4D-Cog was
0.98, and 0.96 for the MMSE.6
Disease progression. In a subsample of 148 subjects with AD, baseline (mean=16.2,
SD=11.1) and six month follow-up scores (mean=14.2, SD=10.8) on the TE4D-Cog were
correlated (r=0.90, P<0.001) and there was a statistically significant worsening in scores
over time (Wilcoxon signed rank test; Z=-4.9, P<0.001).6
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Summary. The TE4D-Cog demonstrated the ability to discriminate between NC and AD
groups, and demonstrated responsiveness to disease progression in AD. Responsiveness
to treatment effects and comparison with the ADAS-Cog 11 was not tested.

3.3.5

Pooled Index

Carusone et al. (2006) were the first to add measures of functionality rather than just
measures of cognition to the ADAS-Cog 11. They used data from a clinical trial
involving 101 subjects with mild to moderate AD, and combined the following six scales
using a pooled index approach: ADAS-Cog 11, Geriatric Depression Scale, Dysfunctional
Behaviour Rating Instrument (DBRI), MMSE, Activities of Daily Living (ADL), and
DBRI frequency.77
Treatment effect. Effect sizes were calculated for each individual subscale measure as
well as the Pooled Index for 3, 6, and 12 months of follow-up (Effect size=linear
regression coefficient/SE of linear regression coefficient). None of the individual subscale
measures demonstrated a statistically significant treatment effect at more than one time
point.77 The Pooled Index found a statistically significant treatment effect at the 3 month
and 12 month, but not 6 month, follow-up assessments.77
AUC analyses of individual scores plotted against time were performed for both the
standardized ADAS-Cog 11 and the Pooled Index. The standardized ADAS-Cog 11
showed a statistically significant difference between treatment and placebo groups at the
finite time period of 6 months, but not when assessing the 12 month time period as a
whole.77 The Pooled Index showed statistically significant difference between placebo
and treatment groups over the entire 12 month period, and at the individual time points of
3 and 12 months, but not at 6 months.77
Summary. The Pooled Index was more responsive to treatment effects than the ADASCog 11 in a clinical trial for mild to moderate AD. Responsiveness to baseline
discrimination and to disease progression was not explored.
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3.3.6

ADAS-Rasch

Wouters et al. (2008) identified three problematic aspects of the ADAS-Cog 11 scoring
methodology, whereby the total score is arrived at by summing points across tasks
without recognition of how these individual tasks or subtask item response options may
differ.78 Specifically, they found ADAS-Cog 11 tasks do not have equal measurement
precision, several subtask item response categories are disordered in terms of difficulty,
and a difference of a certain number of points at the low end of the scoring range does not
equal the same amount of difference in cognitive ability as a difference of the same
number of points at the higher end of the scoring range.78 This last limitation suggests that
summed ADAS-Cog scores should not be treated as an interval-ratio level measure and
analyzed using parametric statistics such as t-tests and linear regression models.
To address the first two limitations Wouters et al. (2008) developed an alternate scoring
method for the ADAS-Cog 11 using Rasch analysis. In brief, response categories with the
same level of difficulty for each task on the ADAS-Cog 11 were collapsed so that the
ADAS-Rasch has hierarchically ordered categories, and each task is weighted according
to its measurement precision.78 The total possible score for each task of the ADAS-Rasch
is the product of the number of different categories of difficulty present for the items of
that task and the weight assigned to the task: Word Recall (total possible points for
ADAS-Cog 11=10 versus total possible points for ADAS-Rasch=12), Naming (5 versus
6), Commands (5 versus 8), Constructional Praxis (5 versus 4), Ideational Praxis (5 versus
6), Orientation (8 versus 6), Word Recognition (12 versus 3), Remembering Test
Instructions (5 versus 5), Language Ability (5 versus 5), Word-Finding Difficulty (5
versus 4), Comprehension (5 versus 5), total score (70 versus 64).78 ADAS-Rasch scores
are backwards-compatible to a Classical Test Theory-derived ADAS-Cog 11 sum score.
The third scoring limitation (non-equal intervals) remains for both the ADAS-Cog 11 and
the ADAS-Rasch.
The ADAS-Rasch was developed from baseline data of the placebo arms of three clinical
trials that included 706 subjects with mild to moderate dementia.78 External criterion
validation was performed in 456 patients from a different trial with similar inclusion and

70

exclusion criteria.78 There was a high correlation between ADAS-Rasch and ADAS-Cog
11 scores (r=0.93), and a moderate correlation between ADAS-Rasch and MMSE scores
(r=-0.72).78
Baseline discrimination. One-to-one correspondence between the ADAS-Rasch total
score and level of cognitive impairment was demonstrated in both the development and
external-validation samples.78 This one-to-one correspondence was not present for the
ADAS-Cog 11, meaning two individuals with the same score may have different levels of
cognitive impairment.78 In a later study, Skinner et al. (2012) found that mean scores on
the ADAS-Rasch were lower for 229 subjects with NC (mean=4.8, SD=3.5) than for 394
subjects with MCI (mean=11.8, SD=5.5), or 187 subjects with AD (mean=19.5,
SD=7.4).3 Crane et al. (2012) found comparable results.25 Statistical tests of these
differences were not performed.
Disease progression. Skinner et al. (2012) found the Z-score for change over time in 394
subjects with MCI, adjusted for age, education, gender, and APOEe4 allele, was smaller
for the ADAS-Rasch (Z=8.50) than the ADAS-Cog 11 (Z=9.44).3 Similar analyses
performed by Crane et al. (2012) found adjusted Z-scores for time were smaller for the
ADAS-Rasch than ADAS-Cog 11 in NC (ADAS-Rasch=3.10, ADAS-Cog 11=3.20),
MCI (ADAS-Rasch=-10.51, ADAS-Cog 11=-10.78), and AD (ADAS-Rasch=-11.28,
ADAS-Cog 11=-12.25) samples.25
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to
detect a 25% decrease over 12 months in MCI with 80% power and an alpha of 0.05 was
larger for the ADAS-Rasch (n=1409) than for the ADAS-Cog 11 (n=1230).3 Crane et al.
(2012) found that the ADAS-Rasch required a larger estimated sample size than the
ADAS-Cog 11 to detect a 25% decrease over 12 months, with 80% power and an alpha of
0.05, for NC (41,295 versus 37,971), MCI (1692 versus 1651), and AD (346 versus
242).25
Summary. The ADAS-Rasch improved two of three problem areas with traditional
ADAS-Cog 11 scoring methodology, and appeared to demonstrate better baseline
discrimination than the ADAS-Cog 11. Responsiveness to disease progression and
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treatment effects was worse for the ADAS-Rasch than the ADAS-Cog 11 in NC, MCI,
and AD.

3.3.7

ADAS-Tree

Llano et al. (2011) developed an alternative weighting scheme for scoring the ADAS-Cog
13 to identify subjects with MCI who have a high risk of converting to AD.18 The
rationale for this was to increase the efficiency of a clinical trial by using conversion from
MCI to AD as an outcome, and then enrolling subjects with a particularly high risk of this
conversion.18 A second purpose of the ADAS-Tree is to discriminate between subjects
with different levels of disease severity at the start of a clinical trial.18 Results for this
baseline discriminative ability will be reviewed, but not results pertaining to the ability of
the ADAS-Tree to predict conversion from MCI to AD as risk prediction is less relevant
for this thesis.
To develop the ADAS-Tree, the Random Forests (RF) tree-based algorithm was used to
derive weights for each task of the ADAS-Cog 13 based on their ability to discriminate
between subjects with NC, MCI, and AD. Briefly, ten thousand bootstrap datasets were
taken from baseline data of 229 subjects with NC, 397 subjects with MCI, and 193
subjects with AD.18 The RF algorithm was applied in each bootstrap dataset to develop a
classification tree for NC, MCI, and AD diagnostic categories.18 Each bootstrap dataset
was the same size as the original sample, but because datasets were obtained using
random sampling with replacement, about one third of the original sample was not
selected for any given bootstrap (some observations were sampled multiple times).18
These left out samples were used to obtain an estimate of predictive accuracy by
comparing diagnoses predicted by the majority of classification trees (RF model) with
original diagnoses.18 Weights for each task of the ADAS-Cog 13 were derived by
comparing the predictive accuracy of the RF model fit using the full ADAS-Cog 13 to the
predictive accuracy of a RF model fit when one ADAS-Cog 13 task was replaced by
noise, repeated for all tasks.18 Tasks that led to a large decrease in predictive accuracy
when excluded were given the highest weights in the ADAS-Tree as this reflects a
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relatively large contribution to the ability of the ADAS-Cog 13 to discriminate between
NC, MCI, and AD.18
Item weights of the ADAS-Tree are: 1.05 Word Recall, 0.38 Commands, 0 Construction,
1.17 Delayed Word Recall, 0.61 Naming, 0.13 Ideational Praxis, 1.13 Orientation, 0.41
Word Recognition, 0.54 Recall Instructions, 0.49 Spoken Language, 0.69 Word Finding,
0.39 Comprehension, 0.69 Number Cancellation.18
Baseline discrimination. The ADAS-Tree was able to discriminate between NC, MCI,
and AD diagnostic categories (P<0.0001).18 Furthermore, the Kruskal-Wallis test statistic
used to assess the magnitude of difference between these categories was larger for the
ADAS-Tree (401.1) than the ADAS-Cog 13 (393.3), ADAS-Cog 11 (378.9), and MMSE
(368.8).18 A separate study found ADAS-Tree scores were lower for 229 subjects with
NC (mean=7.9 points, SD=3.5) than 394 subjects with MCI (mean=15.9 points, SD=5.1),
and 187 subjects with AD (mean=24.2 points, SD=5.6).3 A third study similar differences
in scores between NC, MCI, and AD diagnostic categories.25
Disease progression. Skinner et al. (2012) found that for 394 subjects with MCI the
ADAS-Tree had a larger Z-score for time (Z=12.04) than the ADAS-Cog 11 (Z=9.44),
adjusted for age, education, gender, and APOEe4 allele.3 Crane et al. (2012) also found
that the ADAS-Tree had a larger adjusted Z-score for time than the ADAS-Cog 11 in
MCI (ADAS-Tree: Z=-13.67, ADAS-Cog 11: Z=-10.78) and AD (ADAS-Tree: Z=14.05, ADAS-Cog 11: Z=-12.25), but not NC (ADAS-Tree: Z=0.73, ADAS-Cog 11:
Z=3.20) samples.25
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to
detect a 25% decrease over 12 months in MCI with 80% power and an alpha of 0.05 was
smaller for the ADAS-Tree (n=733) than for the ADAS-Cog 11 (n=1230).3 Crane et al.
(2012) demonstrated that the ADAS-Tree required a larger estimated sample size than the
ADAS-Cog 11 to detect a 25% decrease over 12 months, with 80% power and an alpha of
0.05, for subjects with NC (573,996 versus 37,971), and a smaller estimated sample size
than the ADAS-Cog 11 for subjects with MCI (981 versus 1651) or AD (214 versus 242)
hypothetical clinical trials.25
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Summary. The ADAS-Tree demonstrated greater baseline discrimination ability than the
ADAS-Cog 11 for detecting a difference among NC, MCI, and AD diagnostic categories.
Responsiveness to disease progression and treatment effects appears to be improved by
the ADAS-Tree in MCI and AD, but not NC.

3.3.8

Computerized ADAS-Cog

The National Institute on Aging funded the development of a computerized version of the
ADAS-Cog (cADAS-Cog) to try to increase consistency between and decrease errors
made by administrators of the ADAS-Cog.79 The cADAS-Cog includes a computerized
version of all ADAS-Cog 11 items plus Delayed Recall, Number Cancellation, and Maze
tasks. It is administered using a Computerized Multiphasic Interactive Neurocognitive
Dual Display System (CMINDS).79 The first step at any testing session is for the subject
to practice using CMINDS via a Perception Response Evaluation (PRE) module.79 A
secondary purpose of the PRE module is to ensure subjects have sufficient perceptual and
response abilities to take the computerized test.79 Next, the cADAS-Cog is administered
on one monitor display while the test administrator uses the second monitor to control the
speed of the testing, request repeated test instructions, and receive information on the
subject’s progress throughout the test.79
A sample of 88 subjects with mild to moderate AD were administered both the
computerized and paper ADAS-Cog versions three times, four months apart.79 Different
versions were given on alternate time points, each one month apart.79 Both computerized
and paper tests took approximately 44 minutes to administer.79 High concurrent criterion
validity between the cADAS-Cog and paper version total scores, and all individual task
scores was suggested by ICCs (all P<0.001), Pearson’s correlation coefficients (all
P<0.01), and paired sample t-tests of differences between intra-subject scores (all
P>0.10).79 High test-retest reliability was found over approximately five month (P<0.001)
and ten month periods (P<0.001).79 Paired sample t-tests showed that the reliability
across cADAS-Cog scores was significantly better than that of the paper administration
method over five and ten month periods (5 month: mean cADAS-Cog ICC=0.87, mean
paper ICC=0.80, t=2.88, P<0.02; 10 month: mean cADAS-Cog ICC=0.83, mean paper
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ICC=0.77, t=2.54, P<0.03).79 Agreement was also demonstrated with a Bland-Altman
plot of the differences between total scores.79
Summary. The cADAS-Cog improved the reliability and standardization of an extended
version of the ADAS-Cog 13, and may be considered as an alternative mode of
administration especially when ADAS-Cog scores from multiple different administrators
are going to be compared. Explicit tests of responsiveness were not conducted.

3.3.9

Touch Panel-Type Dementia Assessment Scale

Inoue et al. (2011) created a computerized version of a modified ADAS-Cog 11 that can
be administered in 30 minutes.80 This Touch Panel-Type Dementia Assessment Scale
(TDAS) has a 14” touch panel display and includes the seven tasks of the ADAS-Cog 11
which they could computerize (Word Recognition, Following Commands, Orientation,
visual-spatial perception (modified Constructional Praxis), Naming Fingers, object
recognition (modified Naming Objects), accuracy of the order of a process (modified
Ideational Praxis) as well as tests for money calculation and clock time recognition (nondigital).80 The scoring range is 0 to 101, with lower scores indicating worse performance.
A limitation of the TDAS is that people with severe AD or visual and/or hearing
impairment require assistance or may not be able to finish the test.80
Thirty-four subjects with AD were administered both the TDAS and a paper version for
concurrent criterion validation analyses.80 Total scores from the two tests were
significantly correlated (r=0.69, P<0.01).80 Kendall coefficients of concordance were
calculated to assess agreement between six of the TDAS tasks and six of the paper
ADAS-Cog 11 tasks.80 Three tasks showed acceptable concordance [Word Recognition
(0.57), Orientation (0.41), and Naming Objects and Fingers (0.32)], while three showed
poor concordance [Following Commands, Constructional Praxis, Ideational Praxis (all
Kendall’s coefficients <0.3)].80
Summary. The TDAS is a computerized test of cognitive ability which includes some
modified items of the ADAS-Cog 11. Preliminary tests of agreement were mixed. Further
tests would help to establish responsiveness of the TDAS.
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3.3.10

Computerized Adaptive Testing of the Cambridge Cognitive
Examination – Plus

The Cambridge Cognition Examination (CAMCOG)-Plus is composed of a battery of
neuropsychological tests including the ADAS-Cog 11.81 Wouters et al. (2011) used
Computerized Adaptive Testing (CAT) to administer the CAMCOG and CAMCOG-Plus
to 41 subjects with NC, 21 subjects with MCI, and 22 subjects with dementia to see
whether the CAT version maintains diagnostic accuracy while decreasing length of
administration.81
The CAT procedure begins by asking subjects a series of standard questions which an
internal algorithm uses to estimate cognitive ability.81 Each time a question is answered
throughout the entirety of the testing procedure (i.e. during CAMCOG or CAMCOG-Plus
administration) the algorithm updates the estimate of cognitive ability and uses the
response to select the difficulty of the next question to be administered.81 Correct
responses lead to the administration of more difficult questions while incorrect responses
lead to the administration of easier ones.81 Difficulty levels of test items were initially
estimated using a one parameter logistic model.81 The updating process is continued until
25 items are administered or a standard error of measurement corresponding to 90%
reliability for cognitive ability is reached.81
In the original sample an estimate of cognitive ability was reached using the CAT
CAMCOG-Plus after administering 53% fewer items than are included in the full test
battery.81 Time to administer was reduced by 54%.81 The CAT CAMCOG-Plus had
excellent agreement for estimating cognitive ability with the paper CAMCOG-Plus (ICC
0.98, P<0.001) and the paper CAMCOG (ICC 0.99, P<0.001).81 Concurrent criterion
validity was found between the CAMCOG-Plus and MMSE (Spearman’s rho=0.80,
P<0.001) and Informant Questionnaire on Cognitive Decline in the Elderly (Spearman’s
rho=-0.54, P<0.025).81
Baseline Discrimination. The CAT CAMCOG-Plus but not CAT CAMCOG was better
at discriminating between the diagnostic categories of NC, MCI, and dementia than the
MMSE, as assessed by AUCs and optimal sensitivity and specificity values.81
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Summary. The CAT CAMCOG-Plus demonstrated the ability to discriminate between
NC, MCI, and dementia diagnostic categories. Direct comparisons with the ADAS-Cog
11 were not performed, nor were assessments of responsiveness to disease progression
and treatment effects.

3.3.11

ADAS-Cog-5-Subset and ADAS-Cog-6-Subset

Ihl et al. (2012) used a subsetting analysis approach to develop two separate subsets of
ADAS-Cog 11 tasks based on the ability of individual tasks to detect a treatment effect in
three 24 week randomized controlled trials of a total of 855 subjects with mild to
moderate AD.82 The objective of the subsetting analysis was to remove tasks from the
ADAS-Cog 11 that demonstrated low sensitivity for detecting a treatment response.82
The first step of the subsetting analysis was to calculate the pre-post difference for all
ADAS-Cog 11 tasks.82 If the pre-post difference on the task score was less than or equal
to 0 (did not get worse over time; treatment responder) a binary variable for ‘response’
was given the value 1.82 If the pre-post difference was greater than 0 (subject got worse
over the course of the study; treatment non-responder) the binary ‘response’ variable was
coded as 0.82 Importantly, a “responder” was defined as a subject who showed no
worsening on any task of a given subset of tasks over the course of the study.82
Responders could be in the placebo or treatment group. A mathematical algorithm was
then used to identify subsets of ADAS-Cog 11 tasks which could identify groups of
responders, and Wilcoxon rank-sum tests were used to find subsets with statistically
significant differences in the proportion of responders between treatment and placebo
groups.82 The subset with the lowest P-value was selected as the collection of ADAS-Cog
11 tasks with the most potential for detecting a treatment response.82
The primary result of this analysis was the ADAS-Cog-5-Subset: Ideational Praxis,
Remembering Test Instructions, Language, Comprehension, and Word Finding Difficulty
tasks. Internal consistency of the ADAS-Cog-5-Subset (Chronbach’s alpha=0.81) was
close to that of the ADAS-Cog 11 (Chronbach’s alpha=0.82).82
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Tasks not selected for the primary subset were combined to create the ADAS-Cog 6Subset: Word Recall, Naming Objects and Fingers, Commands, Constructional Praxis,
Orientation, and Word Recognition.82
Treatment effect. The ADAS-Cog-5-Subset found statistically significant differences in
the proportion of responders in the treatment compared to control groups for the overall
study population (P=0.0001), as well as subgroups of subjects with mild AD (P=0.01),
and moderate AD (P=0.01).82 The ADAS-Cog-6-Subset found statistically significant
treatment effects for the overall study population (P=0.0016) and the moderate AD
subgroup (P=0.0002), but not among the subgroup of mild AD subjects (P=0.53).82 The
ADAS-Cog 11 found no statistically significant difference between the proportion of
responders in the treatment versus control group.82
Summary. Both the ADAS-Cog-5-Subset and the ADAS-Cog-6-Subset were more
responsive than the ADAS-Cog 11 to treatment effects in AD. The ADAS-Cog-5-Subset
was the most sensitive for detecting a memantine treatment response in mild AD. The
ADAS-Cog-6-Subset was the most sensitive for detecting a memantine treatment
response in moderate AD. Although subsetting analysis requires longitudinal data from a
clinical trial, future studies may evaluate the ability of the Subsets to detect within-person
change over time in observational studies. One limitation, common to other validation
analyses, is that the Subsets were statistically optimized for sampling and measurement
error of the test dataset and will not likely have the same performance characteristics in a
new study.

3.3.12

The ADAS-Cog-Plus (ADAS-Bifactor, ADAS-Plus-EF, ADASPlus-EF&FA)

Skinner et al. (2012) used two strategies to modify the ADAS-Cog 13 to try and improve
responsiveness to changes in MCI.3 First, alternative weights to tasks of the ADAS-Cog
13 were applied based on latent trait analysis with IRT. This resulted in a bi-factor model
that accounted for correlations between Word Recognition and Word Recall tasks, and for
correlations between the four examiner-rated tasks.3 The variance of the primary factor
was fixed at one, and loadings were freely estimated.3 Scores for follow-up visits were
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computed using item parameters from this baseline model transformed to a standard
normal distribution (mean=0 and SD=1).3 Second, two other variants of the ADAS-Cog
13 were created by adding tasks to assess Executive Functioning (EF) and informant
reports of daily function (FA). The ADAS-Plus-EF consists of the ADAS-Cog 13 plus an
additional task for category (vegetable) fluency.3 The ADAS-Plus-EF&FA consists of the
ADAS-Cog 13 plus category (vegetable) fluency, Trail Making Tests (TMT) A and B,
Digit Symbol Substitution (DSS) Test, and five Pfeffer FAQ items.3 These modifications
were developed using data from 811 subjects with a range of cognitive abilities, validated
in a subset of 394 subjects with MCI, and then compared to the ADAS-Cog 11, ADASCog 13, ADAS-Rasch (Section 3.3.6), and ADAS-Tree (Section 3.3.7).3
Baseline discrimination. Plots of test information curves (Monte Carlo integrated test
information versus cognitive ability) showed that the ADAS-Plus-EF&FA model had the
highest test information over all levels of cognitive ability, followed by the ADAS-PlusEF, and then the ADAS-Bifactor.3 In general, the amount of information any of the three
variants held about cognitive ability increased as cognitive ability worsened.3
Disease progression. The Z-score for change over time in the validation sample adjusting
for age, education, gender and APOEe4 allele was larger for the ADAS-Plus-EF&FA
(Z=11.81) than the ADAS-Plus-EF (Z=10.61), ADAS-Bifactor (Z=10.26), and ADASCog 11 (Z=9.44).3
Treatment effect. Estimated sample sizes to detect a 25% change in cognition over 12
months with 80% power and alpha of 0.05 were calculated.3 The ADAS-Plus-EF&FA
required a smaller sample size (n=547) than the ADAS-Plus EF (n=883), ADAS-Bifactor
(n=1103), and ADAS-Cog 11 (n=1230).3
Summary. The ADAS-bifactor, ADAS-Plus-EF, and ADAS-Plus EF&FA all
demonstrated the ability to provide information about cognitive ability across various
levels of cognitive impairment, suggesting they may be responsive to baseline
discrimination. The ADAS-Bifactor, ADAS-Plus-EF, and ADAS-Plus EF&FA all
showed superior responsiveness to disease progression in MCI than the ADAS-Cog 11,
but were not better than the previously developed ADAS-Tree. Out of all measures
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assessed, the ADAS-Plus EF&FA appeared to be the most responsive to treatment effects
in MCI.

3.3.13

Common Item Pooling

Wouters et al. (2012) pooled data from 1863 subjects (585 NC, 66 MCI, 1012 AD, 133
non-AD dementia, 67 unknown psychiatric diagnosis) across multiple data sets which
each included some or all of the CAMCOG, modified ADAS-Cog (ADAS-Cog 12 plus a
concentration task), and MMSE.20 Data pooling was performed using a method of
“common item equating”, and Rasch measurement models were used to estimate the
difficulty of each test item and the cognitive ability of each participant.20 The purpose
was to locate an underlying dimension of cognitive ability common to all three outcome
measures so that their scores could be compared (the score from any one test can be
translated to the level of underlying cognitive ability, and then translated back into a score
on one of the other tests).20 Items showing systematic differences in level of difficulty
between data sets, or for which valid estimates of difficulty level could not be obtained,
were excluded from common item pooling.20
Rasch measurement theory was also applied to assess whether adding neuropsychological
tests of episodic or semantic memory and executive function to the modified ADAS-Cog,
CAMCOG, and MMSE increased precision for discriminating between levels of early
cognitive decline and detecting mild dementia.20 Neuropsychological tests were found to
be more difficult than the modified ADAS-Cog, MMSE, and CAMCOG items with
difficulty levels compatible with NC to MCI and mild dementia.20 In contrast, the
modified ADAS-Cog had only a few tasks with difficulty levels appropriate for predementia cognitive abilities.20
Baseline discrimination. The measurement precision for assessing levels of latent
cognitive ability varied between the individual outcome measures as well as between
different combinations of the outcome measures. For subjects with below average levels
of cognitive ability, adding the MMSE and modified ADAS-Cog together (T-score range
50 to 60) improved precision for estimating underlying cognitive ability over either test
alone.20 For subjects with above average cognitive ability, adding neuropsychological
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tests to the MMSE was the best measurement combination (T-score range 50 to 60).20
The estimated difficulty level of the neuropsychological tests (T-score range 50-65) was
more comparable with NC and MCI or mild dementia levels of cognitive ability than
from the estimated difficulty level of the CAMCOG, MMSE, or modified ADAS-Cog
tasks.20 The neuropsychological tests were not however helpful for more severely
impaired populations either alone, or when added to another measure.20
Summary. The CAMCOG, MMSE, and modified ADAS-Cog estimate a common
underlying dimension of cognitive ability. At mild levels of cognitive impairment, adding
neuropsychological tests to the MMSE without the modified ADAS-Cog was
recommended to maximize measurement precision, but for more severe levels of
cognitive impairment adding the modified ADAS-Cog to the MMSE is advantageous
over the modified ADAS-Cog alone. Formal assessments of responsiveness or
comparisons to the ADAS-Cog 11 were not performed.

3.3.14

Alzheimer’s Disease Neuroimaging Initiative Memory
Composite

Crane et al. (2012) used modern psychometric approaches to develop and test the validity
of a composite score for memory (ADNI Memory Composite) made up of the Rey
Auditory Verbal Learning Test (RAVLT), ADAS-Cog 13 Delayed Word Recall task,
ADAS-Cog 11 Word Recognition task, MMSE three word memory task with distractors,
and the Logical Memory test which involves attempting to recall facts from a passage.25
Initial analyses of the ADNI Memory Composite involved 225 subjects with NC, 394
subjects with MCI, and 184 subjects with AD.25 Psychometric approaches determined
that a bi-factor model was not a substantially better fit than a single factor model for the
ADNI Memory Composite, so a single factor model was maintained.25 Concurrent
criterion validation found the ADNI Memory Composite performed at least as well as the
RAVLT in all analyses.25
Baseline discrimination. The ADNI Memory Composite score was slightly higher for
subjects with NC (mean=1.0 points, SD=0.5) than subjects with MCI (mean=-0.1 points,
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SD=0.6) and subjects with AD (mean=-0.8 points, SD=0.5).25 No statistical tests of these
differences were performed.
Disease progression. Ability of the ADNI Memory Composite to detect change over
time in subjects with NC, MCI, and AD was evaluated using standardized regression
coefficients for time, controlling for age, education, and sex, and presence of at least one
APOEe4 allele.25 Coefficients for time were statistically significant for the ADNI
Memory Composite in NC (3.02), MCI (-9.43), and AD (-11.59) subgroups (all
P<0.05).25 In comparison, coefficients for the ADAS-Cog 11 were larger in the NC
(3.20), MCI (-10.78), and AD (-12.25) subgroups (all P<0.05).25
Treatment effect. Standardized coefficients and adjusted SD were used to estimate the
sample size needed to detect a 25% reduction in rate of cognitive decline over 12 months
with 80% power in a hypothetical two-arm clinical trial.25 The ADNI Memory Composite
required a smaller sample size than the ADAS-Cog 11 for a hypothetical trial of NC
(28,512 versus 37,971), but required a larger sample size than the ADAS-Cog 11 for MCI
(2,167 versus 1,651) and AD trials (568 versus 242).25
Summary. The ADNI Memory Composite appeared able to discriminate between NC,
MCI, and AD diagnostic categories. Although it demonstrated responsiveness to disease
progression in NC, MCI, and AD samples, this performance was not better than that of
the ADAS-Cog 11. The ADNI Memory Composite was more responsive to treatment
effects in subjects with NC than the ADAS-Cog 11, but not more responsive to treatment
effects for MCI and AD levels of disease severity.

3.3.15

ADAS-Cog IRT

Balsis et al. (2012) developed an IRT scoring methodology for the ADAS-Cog 11 in
1,240 subjects with varying levels of dementia severity.83 Although the primary focus was
on identifying limitations to traditional ADAS-Cog 11 scoring methodology, they also
showed how using IRT to model a subject’s score along with the difficulty of individual
items can increase precision for estimating cognitive ability.83
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Verma et al. (2015) found, using multidimensional IRT on data from three cohort studies,
that the ADAS-Cog 11 is most appropriately modelled using three latent factors
corresponding to the cognitive domains of memory, language, and praxis in a large
sample of older adults with NC to AD.84 The memory domain includes the Word Recall,
Orientation, and Word Recognition tasks.84 The Language domain includes the Naming
Objects and Fingers, Language, Comprehension of Spoken Language, Word Finding
Difficulty, and Remembering Test Instructions tasks.84 The praxis domain includes the
Commands, Constructional Praxis, and Ideational Praxis tasks.84
Verma et al. (2015) evaluated their multidimensional IRT scoring methodology for the
ADAS-Cog 11 using data from the treatment arms of 11 clinical trials that enrolled older
adults with AD. Their ADAS-Cog IRT uses ICCs from patient responses on the ADASCog 11 to provide an assessment of cognitive impairment based on maximum likelihood
estimation.84 Differential Item Functioning (DIF) analyses were used to adjust item slopes
and intercepts so that patient characteristics other than cognitive ability did not cause
large variations in scores.84 To maintain non-negative integer final scores, the summary
scores for memory, language, and praxis domains were linearly scaled by multiplying by
a factor of 15 and adding 50.84 This ADAS-Cog IRT scoring methodology demonstrated
good accuracy as assessed by root mean squared error of observed compared to predicted
ADAS-Cog 11 scores (6.05 points).84 Precision was assessed using item information
functions. Memory tasks showed good precision across the entire range of memory
impairment, however precision for measuring language and praxis impairment was only
good at lower levels of cognitive ability.84
Baseline discrimination. The application of IRT scoring methodology to the ADAS-Cog
11 provided the same score to all subjects with the same cognitive ability.83 In contrast, it
was found that when using traditional ADAS-Cog 11 scoring methodology two subjects
with the same cognitive ability may score differently, and two subjects with different
scores on the ADAS-Cog 11 may have the same underlying cognitive ability.83
Treatment effect. Verma et al. (2015) used clinical trial simulations to compare the
ADAS-Cog 11 and ADAS-Cog IRT in terms of the power needed to detect a prespecified treatment effect for various sample sizes (n=200 to 1,000) over 24 months, and
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for various lengths of follow-up with the sample size set at 400.84 Both ADAS-Cog IRT
scoring methodology and original ADAS-Cog 11 scoring with an Analysis of Covariance
test for a treatment effect showed low power (< 80%) for detecting a mild treatment effect
regardless of the sample size or trial duration.84 For a moderate treatment effect, ADASCog IRT methodology reached 80% power with a smaller sample size and shorter trial
duration compared to original ADAS-Cog 11 methods.84 Sensitivity analysis in a real
clinical trial was also performed where the ADAS-Cog IRT scoring methodology
detected a larger treatment effect than original ADAS-Cog 11 methods.84
Summary. The ADAS-Cog IRT demonstrated more precise estimates of cognitive ability
than original ADAS-Cog 11 scoring methodology, which is expected to improve
responsiveness to baseline discrimination, and the ADAS-Cog IRT demonstrated greater
responsiveness to moderately large treatment effects in AD. The finding that the ADASCog 11 was best modelled using multiple latent cognitive domains suggests that the
unidimensional assumption used in CTT may not be appropriate for assessing the ADASCog 11. Responsiveness to disease progression was not evaluated.

3.3.16

ADAS-3

Raghavan et al. (2013) aimed to improve sensitivity to change and reduce variability of
the ADAS-Cog 11 for MCI and early AD trials by removing uninformative items from
the ADAS-Cog 11 and adding in more responsive measures of cognition or function.19 A
total of six novel measures were derived based on analyses of cognitive and functional
measures in 229 subjects with NC, 377 subjects with MCI, and 192 subjects with AD.19
The criterion for an individual test item to be considered for inclusion in a novel
composite was a standardized two-year change score of at least 0.4 for MCI
participants.19 Three of the novel measures were composed solely of cognitive test items
(Section 3.3.16 and 3.3.17), and three included cognitive items as well as measures of
daily function (Section 3.3.18). Bootstrap validation was performed for the entire
selection process. Performances of the six novel measures for detecting change over time
were compared with each other as well as with other outcome measures, including the
ADAS-Cog 11 and ADAS-Cog 13, using data from two-years of follow-up of 198
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subjects with NC, 138 subjects with stable MCI, 139 subjects who converted from MCI to
dementia, and 131 subjects with AD.19
The first cognitive measure, the ADAS-3, includes ADAS-Cog 11 tasks which did not
exhibit ceiling effects and surpassed the 0.4 threshold for standardized two-year change
scores. ADAS-3 tasks include: Word Recall, Delayed Word Recall, and Orientation.19
Disease progression. The standardized two-year change of the ADAS-3 was larger than
that of the ADAS-Cog 11 and all individual tasks of the ADAS-Cog 11, but smaller than
that of the other five novel composites.19
Summary. The ADAS-3 was more responsive to disease progression than the ADASCog 11 among a sample of subjects with NC to AD levels of disease severity, but it was
the worst performing novel composite developed by Raghavan et al (2013).
Responsiveness to baseline discrimination and treatment effects was not evaluated.

3.3.17

Cognitive Composites 1 and 2

The second novel composite developed by Raghavan et al. (2013), the Cognitive
Composite (CC) 1 (CC1), includes the same items as the ADAS-3 as well as the RAVLT
immediate recall test, and the MMSE.19
The third novel composite developed by Raghavan et al. (2013), the CC2, consists of the
ADAS-3 and the cognitive portion of the Clinical Dementia Rating Scale – Sum of Boxes
(CDR-SB).19
Criterion validation was performed for both the CC1 and CC2 using Spearman’s
correlations between two-year change scores for each of the composites and reference
standards such as the ADAS-Cog 11 and CDR-SB, and factor analysis was used to assess
the latent structure of each novel composite measure.19
Baseline discrimination. For the CC1, subjects with MCI scored worse (mean=0.15
points, SD=1.64) than subjects with AD (mean=3.15 points, SD=1.68), or subjects with
MCI and Aβ pathology (mean=0.49 points, SD=1.55).19 The same was true for the CC2,
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whereby subjects with MCI scored worse (mean=0.07 points, SD=0.94) than subjects
with AD (mean=2.38 points, SD=1.28), or subjects with MCI and Aβ pathology
(mean=0.22 points, SD=0.95).19 Statistical significance of these differences was not
assessed.
Disease progression. The CC1 and CC2 demonstrated greater standardized two-year
mean change than the ADAS-Cog 11 and all individual items of the ADAS-Cog 11, and
the ADAS-3.19 The CC2 was the most responsive purely cognitive measure developed by
Ragavan et al. (2013), producing a standardized two-year change score only slightly
smaller than the best performing composite incorporating items of cognition and
functionality.19 Two-year change scores from the CC1 were more strongly correlated with
ADAS-Cog 11 (Spearman’s rho=0.61) than CC2 with the ADAS-Cog 11 (Spearman’s
rho=0.54).19
Treatment effect. The estimated sample size required to detect a hypothetical 25%
treatment effect with 80% power in a two-arm clinical trial of subjects with MCI was
smaller for the CC2 (n=300) than the CC1 (n=477), the ADAS-Cog 11 (n=772), and the
CDR-SB (n=375).19
Summary. The CC1 and CC2 both appeared able to discriminate between groups of
subjects with MCI and AD, and were more responsive than the ADAS-Cog 11 to disease
progression in subjects with NC to AD. Results also suggest that both the CC1 and CC2
are more responsive to treatment effects in subjects with MCI than the ADAS-Cog 11.
The CC2 demonstrated similar responsiveness to the novel composites which include
functional measures, while maintaining lower variability.

3.3.18

Cognitive Functional Composites 1 and 2

The fourth novel measure developed by Raghavan et al. (2013), the Cognitive Functional
Composite (CFC) 1 (CFC1), was the first of their three novel composites which included
measures to assess both cognition and daily functioning.19 The CFC1 is composed of the
CC1 and the FAQ.19
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The fifth composite derived by Raghavan et al. (2013), the CFC2, includes the CC2 and
the FAQ.19
The sixth composite was the only novel measure derived by Raghavan et al. (2013) which
did not incorporate any ADAS-Cog 11 items (CFC3: CDR-SB and FAQ).19 For that
reason, it will not be reviewed in the same manner as the other novel composites.
Correlations between the cognitive portions of each of the CFCs with the FAQ were used
to demonstrate that change scores on the CFCs were due to changes on both cognitive and
functional sub-tasks rather than just being driven by one of the two domains.19
Baseline discrimination. For the CFC1, subjects with MCI scored worse (mean=-0.11
points, SD=1.02) than subjects with AD (mean=2.4 points, SD=1.42), or subjects with
MCI and Aβ pathology (mean=0.06 points, SD=0.98).19 The same was true for the CFC2,
whereby subjects with MCI scored worse (mean=-0.13 points, SD=1.0) than subjects with
AD (mean=2.48 points, SD=1.51), or subjects with MCI and Aβ pathology (mean=0
points, SD=1.01).19 Statistical significance of these differences was not assessed.
Disease progression. Among MCI participants, the two-year standardized mean change
of the CFC1 and CFC2 were larger than that of the ADAS-Cog 11, the CDR-SB, and all
individual items of the ADAS-Cog 11.19 The CFC2 demonstrated the largest standardized
mean change of all novel measures developed by Raghavan et al. (2013).19 Spearman’s
correlation between two-year change scores on the CFC1 and on the ADAS-Cog 11
(rho=0.54) was slightly higher than for the CFC2 and the ADAS-Cog 11 (rho=0.48).19
Treatment effect. The estimated sample size required to detect a hypothetical 25%
treatment effect with 80% power in a two-arm clinical trial of subjects with MCI was
smaller for the CFC2 (n=302) than the CFC1 (n=348), the ADAS-Cog 11 (n=772), and
the CDR-SB (n=375).19
Summary. The CFC1 and CFC2 appeared able to discriminate between MCI and AD
groups, and both were more responsive than the ADAS-Cog 11 to disease progression in
subjects with NC to AD. It was also suggested that both the CFC1 and CFC2 would be
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more responsive than the ADAS-Cog 11 to treatment effects in MCI. Overall, the CFC2
was the most responsive measure developed by Raghavan et al. (2013).

3.3.19

Item Response Theory and Pharmacometric ADAS-Cog 13

Ueckert et al. (2014) used IRT and pharmacometric modelling to explore different
methods for analyzing ADAS-Cog 13 scores.15
First, an IRT model to estimate baseline cognitive ability was created using data from
2,744 subjects with NC, MCI, or mild AD.15 The IRT baseline model models cognitive
ability as a subject specific random effect following a standard normal distribution (Zscore), with no limits on the upper or lower extremes of cognitive ability.15 The
probability of a subject responding a certain way on an ADAS-Cog 13 task or task
subitem, given their underlying cognitive ability, was described using four different test
item specific models. First, tasks or subitems that are scored as correct or incorrect (e.g.
Orientation subitem: correctly state the month) were modeled with a three-parameter
binary model that accounts for item discrimination, item difficulty, and the probability
that a subject with no cognitive disability would get the item incorrect.15 Second, tasks or
task subitems involving words were modeled with a binomial model (uses the number of
words correctly identified out of the total number possible), with slightly different failure
probabilities depending on the task (Word Recall: failure probability = three-parameter
binary model described above; Word Recognition: failure probability = same as for Word
Recall plus a fourth parameter to account for the maximal probability that a subject with
severe cognitive dysfunction would correctly categorize words as seen or not).15 All
words were assumed to hold the same amount of information about underlying
cognition.15 Third, the Number Cancellation task was modelled using a generalized
Poisson model, which included the same three test item parameters as the three-parameter
binary model plus a fourth parameter for dispersion, and a factor to ensure predicted
scores are in the range of 0 to 40.15 Fourth, tasks on the ADAS-Cog 13 that are rated by
the examiner (e.g. Comprehension of Spoken Language) were modeled using a
proportional odds, ordered categorical model with five possible categories (none to
severe impairment) and parameters for item difficulty and discrimination.15
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Next, three different means for assessing cognitive change over time were devised. The
latter two are extensions of the baseline IRT model:
i)

A Least-Square Mean Analysis Model used change in ADAS-Cog 13 score as
the outcome variable, treatment as the exposure variable, visit as a repeated
factor, baseline ADAS-Cog 13 score as a covariate, a treatment-by-visit
interaction term, and a grouping factor of subjects nested within treatment.
This represents more “traditional” ADAS-Cog scoring methodology.15

ii)

The baseline IRT model was extended to create a Longitudinal IRT Model by
adding a hidden variable to account for disease progression over time.15
Disease progression was assumed to be linear (based on a previously
published model), subject-specific, and modelled through random-effects. A
hazard function for the probability that a subject will drop out of a longitudinal
study was also included.15 To assess the performance of the longitudinal IRT
model, Z-score estimates of underlying cognitive ability for an 18-month long
clinical trial were translated back to the original ADAS-Cog 13 scoring scale
and compared with observed ADAS-Cog 13 scores from 322 real subjects in
the 18-month clinical trial.15 More specifically, two-hundred Monte-Carlo
simulations from the IRT model and the original clinical trial data were used
to compare the proportion of subjects from the original data whose task-level
scores would fall in the 95% prediction interval from the score produced by
IRT models.15 Total ADAS-Cog 13 score comparisons were done in a similar
manner, except 200 non-Bayesian simulations were performed and the 95% CI
for the median, 2.5th, and 97.5th percentile of total simulated scores were
compared to the clinical trial percentiles.15 ADAS-Cog 13 scores for the
clinical trial were plotted with the median, 2.5th, and 97.5th percentile of the
real scores observed in the clinical trial. When plotted on top, the median
value of the real scores fell within the 95% CI predicted by the IRT model for
all but the final 18-month follow-up assessment.15 Comparisons were also
made for drop-out patterns over the course of the clinical trial.15
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iii)

The Pharmacometric Total ADAS-Cog Score Model of analysis was based on
a previously published disease progression model and modified according to
the results of goodness of fit plots, residual plots, and visual prediction
checks.15 This model was further refined and tested using a simulated data set
from the longitudinal IRT model.15 Similar to the longitudinal IRT model
analyses whereby estimated ADAS-Cog 11 total scores were compared to
observed scores in a real clinical trial, the performance of the pharmacometric
total ADAS-Cog 13 score model was assessed with visual predictive checks of
whether the 95% CI for the ADAS-Cog 13 scores estimated from the
pharmacometric model included the 2.5th, 97.5th, and median ADAS-Cog 13
scores from the ADAS-Cog Longitudinal IRT model based simulated data
set.15 The final pharmacometric total ADAS-Cog 13 score model assumes a
linear progression of cognitive dysfunction (increasing scores), and models
individual subject baseline scores with a Box-Cox distribution and normally
distributed individual slope parameters correlated with baseline random
effect.15

Treatment effect. The longitudinal IRT model was used to simulate 20-month two-arm
clinical trials with a 20% treatment effect for 100, 200, 400, or 800 subjects with mild to
moderate AD.15 Five hundred simulations were run for each sample size.15 Type I error
and power to detect the treatment effect of the three different methods of longitudinal data
analysis described above were compared.15 The IRT based pharmacometric model
required 71% fewer subjects than the Least-square mean analysis, and 23% fewer
subjects than the pharmacometric model, to detect a treatment effect with 80% power and
no inflation of Type I error.15
Summary. Using both IRT and pharmacometric modelling demonstrated greater
precision of cognitive ability estimates at baseline, and appeared more responsive to
treatment effects in AD, compared to traditional ADAS-Cog scoring and methods of
analysis. Responsiveness to baseline discrimination and disease progression was not
assessed.
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3.3.20

integrated Alzheimer’s Disease Rating Scale

Wessels et al. (2015) used a theoretical framework to guide the combination of existing
scales of cognition and function to create a sensitive measure to the natural history of AD
and to detect treatment effects in clinical trials.85 For subjects with mild AD and MCI,
preliminary tests found the combination of ADAS-Cog 13 and the FAQ was most
sensitive, and the combination of the two scales performed better than either one
individually.85 Data from treatment trials in AD did not have those two measures
specifically, so they were approximated with the ADAS-Cog 14 and the ADCSinstrumental Activities of Daily Living (iADL) which formally make up the integrated
Alzheimer’s Disease Rating Scale (iADRS).85
iADRS score = [-1(ADAS-Cog 14) + 90] + iADL, where the ADAS-Cog 14 (ADAS-Cog
11, Delayed Word Recall, Maze, and Digit Cancellation tasks) and iADL are summed
normally and the total range of the iADRS is 0 to 146 with lower scores indicating worse
performance.85
Psychometric analyses showed that the iADRS is composed of two principal components
(cognition and instrumental function) for assessment at one point in time, and the
majority of the variability for subjects with MCI was due to cognitive items of the
ADAS-Cog.85 For change over time, the iADRS items load on a single component, and
variance of change scores was driven by both cognitive and function items.85
Disease progression. SRMs with 95% CIs were compared using separate forest plots for
different levels of disease severity. The iADRS had the largest SRM for MCI and mild
and moderate AD compared to the ADAS-Cog 11, ADAS-Cog 13, MMSE, FAQ, CDRSB, and several other measures of cognition.85
Treatment effect. For several clinical trials including subjects with MCI or mild AD the
iADRS was able to detect a statistically significant treatment effect, however the
magnitude of this effect was not consistently better than that detected by the ADAS-Cog
14.85
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Summary. The iADRS was more responsive to disease progression in MCI and AD than
the ADAS-Cog 11, however it was not more responsive than the ADAS-Cog 14 for
treatment effects in MCI and mild AD. Comparison of responsiveness to treatment effects
with the ADAS-Cog 11 was not performed, and baseline discrimination ability was not
evaluated.

3.3.21

Straightforward Sensitive Scale

Huang et al. (2015) designed a scale including cognitive and functional measures for the
purpose of tracking disease progression over time and detecting potential treatment
effects in clinical trials for MCI and early AD, while maintaining good reliability and
validity as subjects progress to more severe stages of AD.86 Selection of measures to
include in the composite scale was performed in a stepwise manner. First, SRMs of many
candidate measures were calculated and the candidate measures with the highest SRMs
were combined to create a composite measure.86 In general, the minimum SRM for a
candidate measure to be considered was 0.45 for the group of 397 subjects with MCI,
0.50 for an APOE enriched subgroup, and 0.55 for hippocampal volume and Aβ enriched
subgroups.86 The SRMs of all possible combinations of candidate measures were
calculated to determine the composite scale most sensitive to disease progression and
treatment effects.86 This “straightforward sensitive scale” (SSS) consisted of the CDRSB, FAQ, and three ADAS-Cog 13 items (Word Recall, Delayed Word Recall,
Orientation).86
Disease progression. The SRM of the SSS in subjects with MCI was greater than that of
the CDR-SB alone or the ADAS-Cog 13 over 1 year (SRM: SSS=0.62, CDR-SB=0.55,
ADAS-Cog 13=0.28), two years (SRM: SSS=0.82, CDR-SB=0.74, ADAS-Cog 13=0.56),
three years (SRM: SSS=0.93, CDR-SB=0.76, ADAS-Cog 13=0.65), and when assuming
a hypothetical treatment effect delayed disease progression by one year (SRM: SSS=0.37,
CDR-SB=0.35, ADAS-Cog 13=0.29).86 The SSS maintained the highest SRMs for
subgroups of subjects with MCI and biomarkers indicating increased risk of disease
progression.86
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Treatment effect. The SSS was estimated to require a smaller sample size (n=189) to
detect a hypothetical treatment effect that slows disease progression by 50% in a two-year
MCI trial compared to the CDR-SB (n=231) and ADAS-Cog 13 (n=402).86
Summary. The SSS appeared more responsive to disease progression and treatment
effects in MCI than the ADAS-Cog 13, but direct comparison with the ADAS-Cog 11
was not performed nor were tests of baseline discrimination.

3.3.22

ADAS-Cog 3b

Podhorna et al. (2016) removed eight tasks from the ADAS-Cog 11 that demonstrate
ceiling effects in MCI. The three remaining tasks comprise the ADAS-Cog 3b: Word
Recall, Orientation, and Word Recognition.12 The ADAS-Cog 3b assesses only memory
and has a scoring range of 0 to 30.12
Baseline Discrimination. ADAS-Cog 3b scores for 382 subjects with MCI (mean=8.23
points, SD=3.76) were on average lower than those of 97 subjects with mild AD
(mean=15.95 points, SD=4.15).12 Podhorna et al. (2016) further divided the 382 subjects
with MCI into two groups depending on whether CSF and APOEe4 biomarkers of AD
pathology were present. The enriched MCI subgroup (n=206) had worse scores at
baseline (mean=9.43 points, SD=3.92) on the ADAS-Cog 3b than the non-enriched MCI
subgroup (n=176, mean=6.82 points, SD=3.02).12 Podhorna et al. (2016) also found
scores on the ADAS-Cog 11 were lower in MCI (mean=9.50 points, SD=4.29) than mild
AD (mean=19.66 points, SD=6.30) groups, and in the non-enriched (mean=7.94 points,
SD=3.50 points) compared to the enriched MCI subgroup (mean=10.83, SD=4.46).12
Tests of statistical significance for these differences were not performed.
Disease progression. Podhorna et al. (2016) found very little change on the ADAS-Cog
3b in 382 subjects with MCI over 24 months (mean=0.71 points, SD=3.56) and in 169
subjects with MCI over 36 months (mean=1.23 points, SD=4.00).12 There was very little
change in the enriched MCI subgroup (mean 24 month change=1.48 points, SD=3.78;
mean 36 month change=2.55 points, SD=4.40), and almost no change in the non-enriched
subgroup (mean 24 month change=-0.19 points, SD=3.06; mean 36 month change=-0.25
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points, SD=5.12).12 Among 97 subjects with mild AD there was also very little change in
mean ADAS-Cog 3b score over 12 months (mean=1.82 points, SD=3.91) and 24 months
(mean=3.81 points, SD=5.12).12 The SRM for change over 24 months in 382 subjects
with MCI was 0.42 (95% CI 0.20, 0.61) for the ADAS-Cog 3b and 0.37 (95% CI 0.15,
0.57) for the ADAS-Cog 11, adjusting for baseline MMSE, age, sex, APOEe4 allele.12
The SRM for change over 12 months in 97 subjects with mild AD was 0.81 (95% CI
0.43, 1.09) for the ADAS-Cog 3b and 0.87 (95% CI 0.46, 1.13) for the ADAS-Cog 11,
adjusting for baseline MMSE, age, sex, APOEe4 allele.12 SRMs were not statistically
different from each other (all P>0.10).12
Summary. The ADAS-Cog 3b appeared able to discriminate between groups of subjects
with MCI and mild AD, however responsiveness to disease progression in MCI or mild
AD was not superior to the ADAS-Cog 11. Responsiveness to treatment effects was not
assessed.

3.3.23

ADAS-Cog 5

Podhorna et al. (2016) created the ADAS-Cog 5 by adding to the ADAS-Cog 3b Delayed
Word Recall, and Digit Cancellation tasks.12 The additional tasks assess attention and
executive function, and the ADAS-Cog 5 is scored from 0 to 45.12
Baseline Discrimination. ADAS-Cog 5 scores for 382 subjects with MCI (mean=13.96
points, SD=6.17) were lower than those of 97 subjects with mild AD (mean=26.20 points,
SD=5.31).12 The 382 subjects with MCI were further divided into two groups depending
on whether CSF and APOEe4 biomarkers of AD pathology were present.12 The enriched
MCI subgroup (n=206) had worse scores on the ADAS-Cog 5 at baseline (mean=16.12
points, SD=6.28) than the non-enriched subgroup (n=176, mean=11.43 points,
SD=4.99).12 Statistical significance of the above differences was not tested.
Disease progression. Podhorna et al. (2016) found almost no change on the ADAS-Cog
5 in 382 subjects with MCI over 24 months (mean change=1.13 points, SD=4.87) or in
168 subjects with MCI over 36 months (mean change=1.95 points, SD=5.58).12 There
was very little difference in the enriched MCI subgroup (mean 24 month change=2.21

94

points, SD=5.58; mean 36 month change=3.82 points, SD=6.03), and in the non-enriched
subgroup scores there was no meaningful change (mean 24 month change=-0.11 points,
SD=4.12; mean 36 month change=-0.16 points, SD=4.15).12 Among 97 subjects with
mild AD there also was very little change on the ADAS-Cog 5 score over 12 months
(mean change=2.64 points, SD=4.39) and 24 months (mean change=5.48 points,
SD=6.13).12 The SRM for the ADAS-Cog 5 for 382 subjects with MCI over 24 months
was 0.42 (95% CI 0.19, 0.63), adjusting for baseline MMSE, age, sex, APOEe4 allele.12
The SRM for change on the ADAS-Cog 5 over 12 months in 97 subjects with mild AD
was 0.93 (95% CI 0.52, 1.22), adjusting for baseline MMSE, age, sex, APOEe4 allele.12
SRMs for the ADAS-Cog 5 were not significantly different than SRMs for the ADASCog 11, ADAS-Cog 13, or ADAS-Cog 3b (all P>0.10).12
Summary. The ADAS-Cog 5 appeared able to discriminate between groups of subjects
with MCI and mild AD, however responsiveness to disease progression in MCI was not
superior to the ADAS-Cog 11. Responsiveness to treatment effects was not evaluated.

3.3.24

ADAS-13 Re-Weighted

Grochowalski et al. (2016) created three different versions of the ADAS-Cog 13 (Section
3.3.1) using data from 153 subjects with AD and 352 subjects with MCI in an effort to
improve reliability of ADAS-Cog 13 change scores.87 Improved reliability would reduce
variability and ultimately improve the ability of the ADAS-Cog 13 to track changes in
cognition over time. The three versions included a re-weighted ADAS-Cog 13, a
lengthened ADAS-Cog 13, and a re-weighted and lengthened ADAS-Cog 13.87 To obtain
these three different variants the ADAS-Cog 13 was divided into three subsections based
on task scoring procedures.87 Each section was given a separate weight, calculated as the
number of tasks in that section divided by the total number of tasks in the test.87 This
resulted in a section of verbal memory with weight 0.10, a section of clinician-rated tasks
with weight 0.45, and a section for general cognitive tasks with weight 0.45.87
Lengthening the test, either with or without re-weighting, did not substantially improve
score reliability so the authors concluded that the ADAS-Cog 13 with re-weighted
sections was the best variant for improving reliability of change scores (ADAS-13RW).87
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Criterion validation was performed by analysing correlations between the ADAS-13RW
and the ADAS-11, ADAS-13, RAVLT, and MMSE.87
Disease progression. Reliability of change scores of the ADAS-13RW was better than
the ADAS-Cog 13, but only of an “acceptable” magnitude for change scores defined by
cut-score dependability (compare subject’s scores to pre-set criterion value of 4 points
change).87 Relative change score reliability (rank subject’s change relative to another
subject’s change) and absolute change score reliability (estimate of subject’s true
individual change score) were not of an acceptable magnitude.87
Summary. Re-weighting and/or lengthening the ADAS-Cog 13 did not improve the
reliability of change scores for MCI to a level recommended for assessing meaningful
clinical change. Assessments of responsiveness were not performed.

3.3.25

Alzheimer’s Disease Composite Score

Wang et al. (2016) developed the Alzheimer’s Disease Composite Score (ADCOMS)
from outcome measures previously shown to be sensitive to AD-specific clinical decline
and treatment effects in subjects with MCI.88 A partial least squares procedure was used
to fit a linear model characterizing disease progression and variable importance
projections (VIP) for numerous candidate items.88 The ADCOMS was derived by
combining the twelve items that demonstrated a VIP value of 0.8 or greater using their
partial least squares coefficients as a weighting factor.88 Specific items included four
ADAS-Cog 12 tasks (Delayed Word Recall, Orientation, Word Recognition, Word
Finding Difficulty), two MMSE items (Orientation time, Drawing), and six CDR-SB
items (Personal Care, Community Affairs, Home and Hobbies, Judgement and Problem
Solving, Memory, Orientation).88
Disease progression. The 12-month SRM of the ADCOMS (0.419) was larger than that
of the ADAS-Cog 12 (0.196), MMSE (0.221), and CDR-SB (0.353) for a pooled aMCI
sample, as well as subgroups of aMCI subjects with genetic or CSF AD biomarkers
present.88
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Treatment effect. The ADCOMS was able to detect a statistically significant treatment
effect for donepezil compared to placebo for aMCI participants (P=0.02), which was also
found by the MMSE (P=0.02), but not by the ADAS-Cog 12 (P=0.12) or CDR-SB
(P=0.11).88 The ADCOMS did not find a statistically significant effect for vitamin E in
subjects with aMCI (P=0.89), nor did the ADAS-Cog 12 (P=0.76), MMSE (P=0.59), or
CDR-SB (P=0.42).88 The ADCOMS was also able to detect a statistically significant
treatment effect for donepezil in subjects with mild AD (P<0.0001) as did the ADAS-Cog
12 (P=0.0008), MMSE (P=0.001), and CDR-SB (P=0.02).88
Summary. The ADCOMS demonstrated better responsiveness to disease progression and
treatment effects in MCI than the ADAS-Cog 12, but the ADAS-Cog 11 was not
analyzed. Tests of baseline discrimination were also not performed.

3.3.26

Summary of Modifications Made to the ADAS-Cog 11

A total of thirty-one modifications of the ADAS-Cog 11 were found. Five of these
modifications altered the scoring methodology for the original ADAS-Cog 11, four
maintained the original scoring methodology and added additional tasks, and twenty-two
altered both scoring methodology and included additional item content.
Results from studies which compared the modified outcome measure to the ADAS-Cog
11 suggested that 13 modification approaches demonstrated responsiveness to group-level
between person differences in stage of disease progression at one point in time (baseline
discrimination), seven improved responsiveness to group-level within-person observed
change measured over time (disease progression; natural history) for MCI samples, three
were more responsive to this type of change than the ADAS-Cog 11 for dementia
samples, and five were more responsive to this type of change than the ADAS-Cog 11 in
samples with various levels of cognitive ability (mixed dementia and pre-dementia
syndromes). One modification was found to improve responsiveness to group-level
between-person differences of within-person observed change over time (treatment
effect) in subjects with NC, ten were more responsive to treatment effects in subjects with
MCI, and six were more responsive to treatment effects in subjects with dementia than
the ADAS-Cog 11. It is possible that several of the other modified versions of the ADAS-
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Cog 11 also improved performance, but these have not yet been evaluated or compared to
the ADAS-Cog 11. In general, the CV (Section 2.2.5 for more information on CV) for the
ADAS-Cog 11 and modified versions was reduced as disease severity worsened, and
several of the modifications reduced the CV within each diagnostic category of NC, MCI,
and dementia (Appendix A).

3.4

Summary of Chapter 3

The ADAS-Cog 11 was developed to assess cognitive dysfunction in moderate to severe
AD. Since the time of development there has been a shift in the field of dementia research
towards studying pre-dementia syndromes. The ADAS-Cog 11 continues to be used for
these pre-dementia studies, however its performance is limited due to ceiling effects,
suboptimal scoring methodology, and poor content validity. Modifying the scoring
methodology of the ADAS-Cog 11 improves its responsiveness to several types of
change, as does adding additional item content. In particular, tasks assessing EF, delayed
recall, and daily functioning, which are now known to be important components of predementia disease severity and progression, improve the content validity of the ADASCog 11 as well as its responsiveness. None of the modifications of the ADAS-Cog 11
included assessments of motor performance, which has also been shown to be an
important component of pre-dementia syndromes and disease progression.
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Chapter 4
Research Question and Objectives

4

The purpose of Chapter 4 is to present the research question and objectives of this thesis.

4.1 Research Question
Does adding assessments of motor function to the Alzheimer’s Disease Assessment
Scale-Cognitive Subscale (ADAS-Cog 11) improve responsiveness among older adults
with pre-dementia syndromes, wherein responsiveness is contextualized by the type of
change being assessed?
We hypothesized that adding assessments of motor function to the ADAS-Cog 11 using a
pooled index approach would improve responsiveness in a sample of older adults with
Normal Cognition (NC), Subjective Cognitive Impairment (SCI), and Mild Cognitive
Impairment (MCI).

Objectives

4.2
4.2.1

Objective 1

Use a pooled index approach to develop an outcome measure that can be backwards
compatible to the ADAS-Cog 11 and includes measures of quantitative gait and dual-task
gait cost.

4.2.2

Objective 2

Compare the responsiveness of the ADAS-Cog 11* and the novel outcome measure to
group-level between-person differences in stage of pre-dementia disease progression at
one point in time (baseline discrimination between groups of subjects classified as having
NC, SCI, MCI).
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4.2.3

Objective 3

Compare the responsiveness of the ADAS-Cog 11*, the novel outcome measure, and the
ADAS-Cog combined, using a pooled index approach, with each individual component of
the novel outcome measure to group-level within-person observed change over time in
subjects with pre-dementia levels of impairment (disease progression or measured change
over the course of a prospective cohort study).

4.3

Conclusion

The next chapter provides an overview of the rationale, methods, and results pertaining to
the research question and objectives.
*Note: Secondary data analysis was used to achieve these objectives. Due to limitations
in the availability of data, not all necessary assessments of older adults with pre-dementia
syndromes were present in a single database. To obtain a preliminary answer to the
research question, a statistical model was developed and then used to estimate ADASCog 11 scores in a database with quantitative motor function assessments. Details about
this “ADAS-Cog-Proxy” model are summarized in Chapter 5 (Section 5.2.2.1), and
described in detail in Chapter 6 (Section 6.1.1).
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Chapter 5

5

Integrated Article: Cognition and Motor Function: The
Gait and Brain Pooled Index

Chapter 5 includes a version of a manuscript that will be submitted to the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) for review, and then pending approval by
ADNI, to the Journals of Gerontology: Medical Sciences for publication. Due to the
nature of an integrated manuscript thesis format, there is some overlap between the
information presented in Chapter 5 and the rest of the thesis. Also, in the interest of
clarity the ADAS-Cog 11 is simply referred to as the ADAS-Cog throughout Chapter 5.
Please see Chapter 6 for more detailed methods and results, which go beyond what may
be submitted for a peer reviewed publication.
In accordance with the ADNI data use agreement, on the by-line of the submitted
manuscript, after the named authors, the phrase “for the Alzheimer’s Disease
Neuroimaging Initiative*” will be included, with the asterisk referring to the following
statement: “*Data used in preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the
investigators within the ADNI contributed to the design and implementation of ADNI
and/or provided data but did not participate in analysis or writing of this report. A
complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf”.

5.1 Introduction
The Alzheimer’s Disease (AD) Assessment Scale–Cognitive Subscale (ADAS-Cog) was
developed in 1984 for the purpose of assessing cognitive dysfunction in AD.1 Since then,
the ADAS-Cog became widely adopted for use in studies of AD and related disorders,
and is now considered the ‘gold standard’ for assessing treatment efficacy in clinical trials
of antidementia medications. However, two shifts in the field since its development have
called into question the continued use of the original ADAS-Cog. The first shift has been
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towards studying pre-dementia syndromes, such as Mild Cognitive Impairment (MCI),
and testing interventions aimed at slowing or preventing progression to dementia rather
than intervening at the dementia stage. The second shift includes postulating motor
function as an important component of dementia and pre-dementia syndromes. These
shifts have elicited the need for an outcome measure that reflects current research focus,
incorporates all important disease components, and is more responsive than the ADASCog to clinically important changes in pre-dementia syndromes.
In short, responsiveness is a form of validity defined as the ability to accurately detect
change.2–5 Change can be contextualized using three aspects: group versus individual
level of measurement, between-person versus within-person comparison, and the type of
change one is interested in detecting.5 The responsiveness of any outcome measure is
population and context specific.3,5
While the ADAS-Cog has demonstrated responsiveness to multiple types of change in
dementia populations, concerns have been raised about its responsiveness at pre-dementia
stages where changes are subtler in magnitude and slower in rate of progression. Several
modifications have improved the responsiveness of the ADAS-Cog in pre-dementia
syndromes. These include alternative scoring applied to the original summation of errors
made across ADAS-Cog tasks that gives a final score from 0 to 70, removing tasks with
ceiling effects, and the addition of higher order assessments of delayed word recall,
executive function, or the ability to perform activities required for daily independent
living.6–14 The advantage of modified measures that are backwards compatible with the
original ADAS-Cog is that they maintain consistency with previous studies and do not
become a limiting factor if one wants to compare novel study findings with the large
literature base that has used the ADAS-Cog. To ensure backwards compatibility, the
ADAS-Cog must be administered in its original form so that raw scores may be obtained
regardless of any modifications made thereafter.
The emergence of motor function decline as a potential biomarker for dementia and predementia syndromes opens a unique opportunity for precise objective motor function tests
to help assess severity or stages of disease impairment not captured by traditional
cognitive tests.15,16 Poor performance on motor function tests has been associated with an
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increased risk of disease progression,17-22 and combined cognitive and motor function
impairments have been associated with a greater risk of further cognitive decline and
conversion to dementia than either component alone.23,24 The mechanistic rationale for
motor function being an integral component of dementia and pre-dementia syndromes is
that neuropathology which contributes to cognitive impairment traditionally associated
with dementia may also give rise to motor impairment.15,25,26 Brain regions hypothesized
to underlie simultaneous decline in cognition and motor function, such as gait control,
includes the frontal and temporal lobes, and frontal-hippocampal and thalamic-striatal
circuits.15,25,26 Quantitative gait parameters, such as velocity or variability in step time,
have been associated with concurrent levels of global and domain specific cognitive
ability, have demonstrated the ability to discriminate between subtypes of MCI, and have
shown responsiveness to changes in cognition over time.17,19,23,27-30 Changes in gait
parameters between when a participant is asked to walk as they usually would and while
performing a cognitive task, termed dual-task cost (DTC), have also been associated with
cognitive abilities and pre-dementia syndromes.28,31 Importantly, the ability to maintain
gait control while walking and thinking (low DTC) underlies functionality, defined as the
ability to perform daily activities required for independent living, such as cooking and
cleaning.32
A review of the literature failed to reveal an outcome measure developed for any
population that includes the addition of single-task motor assessments or DTC to the
ADAS-Cog. We hypothesized that adding assessments of motor function to the ADASCog would improve responsiveness among older adults with pre-dementia syndromes.
Due to the lack of a database with both the ADAS-Cog and quantitative motor
assessments, we developed a statistical model that uses alternative cognitive outcome
measures to approximate ADAS-Cog scores (ADAS-Cog-Proxy). This ADAS-Cog-Proxy
model was applied in a database that includes the necessary alternative cognitive
measures and quantitative gait assessments. Our objectives were: 1) use a pooled index
(PI) approach33,34 to develop an outcome measure that can be backwards compatible to
the ADAS-Cog and includes quantitative gait and DTC assessments, 2) compare the
responsiveness of the ADAS-Cog-Proxy and the novel PI to group-level between-person
differences in stage of disease progression at one point in time (baseline discrimination),
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and 3) compare the responsiveness of the ADAS-Cog-Proxy, the novel PI, and the
ADAS-Cog-Proxy combined using a PI approach with each individual component of the
novel PI, to group-level within-person measured change over time in a pre-dementia
sample (disease progression).

5.2
5.2.1

Methods
Study Population

The Gait and Brain Study (GABS) is an ongoing prospective cohort study based in
London, Ontario aimed at assessing how changes in gait may precede dementia and falls
(Research Ethics Board approval number 17200). Participant recruitment began in 2007
from Geriatrics and Memory clinics at hospitals affiliated with Western University.
Inclusion criteria were 65 to 85 years old, able to walk 10 meters without assistance, and
absence of dementia. Exclusion criteria were lack of English proficiency, Parkinsonism or
other neurological disorder affecting motor function (e.g. stroke), musculoskeletal
disorders or joint replacements that affect gait performance (clinician assessed),
osteoarthritis affecting lower limbs, use of psychotropics that can influence motor
performance (e.g. benzodiazepines), and major depression. Eligible participants were
divided into three diagnostic categories based on performance in cognitive testing and
clinical evaluation. Normal Cognition (NC) criteria included normal age-, sex-, and
education-adjusted scores on the Mini-Mental State Examination (MMSE) and Montreal
Cognitive Assessment. Subjective Cognitive Impairment (SCI) criteria were the same as
that for NC, except patients reported persistent decline in cognition that was not
explainable by an acute event, and answered yes to both, “Do you feel like your memory
or thinking is becoming worse?” and “Does this concern you?”. MCI criteria included 1)
a score of 0.5 on the Clinical Dementia Rating (CDR) Scale, 2) subjective cognitive
complaints, 3) measured cognitive impairment in memory, executive function, attention,
and/or language domains 4) intact Lawton-Brody Activities of Daily Living, and 5)
absence of dementia based on Diagnostic and Statistical Manual of Mental Disorders
version IV-TR or V criteria.35,36 Additional information can be found at clinicaltrial.gov,
study identifier NTC03020381.
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5.2.2
5.2.2.1

Measures
Cognition

ADAS-Cog-Proxy scores were estimated in GABS using a generalized additive model
(GAM)37-39 developed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI),
which contains the ADAS-Cog as well as several cognitive measures administered in the
GABS.
The ADNI began in 2003 as a public-private study partnership with the primary goal of
testing whether neuroimaging, biological, clinical, and neuropsychological assessments
can be combined to measure progression from MCI to early AD (adni.loni.usc.edu). Dr.
Michael W. Weiner is the Principal Investigator of ADNI, and study sites are located
throughout North America. Frequently updated information on ADNI can be found at
www.adni-info.org. ADNI data was downloaded on October 26, 2016.
The process from ADAS-Cog-Proxy development to estimation in GABS is outlined in
Figure 7 as five key steps (grey boxes), which are briefly described below.
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Figure 7 ADAS-Cog-Proxy model development and application.
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Participants in the first of three ADNI phases (ADNI 1) with NC or MCI were divided
into a 70% subset for model development and a 30% subset for testing model accuracy
(Step 1). Five candidate models were constructed in the development subset (Step 2), and
preliminary accuracy was assessed as the percentage (%) of participants for whom each
candidate model predicted ADAS-Cog scores within three points of their observed
(‘true’) score; three points is often considered a clinically relevant change.40 Five ADNI
participants were missing at least one covariate value for candidate Model 5 (M5) and
were excluded solely from analyses that included M5. Diagnostics for all candidate
models were assessed in the development subset (Appendix B, Figures B.1 to B.5).
The best candidate model was selected based on preliminary accuracy estimates in the
development subset and on similarity of covariates to ADAS-Cog tasks such that they
assessed cognitive domains covered by the ADAS-Cog (memory, language, praxis) with
minimal coverage of additional areas. Accuracy of the best candidate model was
estimated (Step 3) using ‘new’ ADNI participants in the testing subset as the percentage
of participants who had scores predicted within three and five points of their true ADASCog scores. Spearman’s rank correlation (rho) between predicted and observed scores
was also calculated. The final GAM used for estimation of ADAS-Cog-Proxy scores in
GABS was built on recombined development and testing subsets (Step 4).38 In order to
obtain ADAS-Cog-Proxy scores for all participants in GABS, Multivariate Imputation by
Chained Equations (MICE) was used to impute missing GAM covariate values (Step
5).41,42 Predictor variable selection was guided by the suggestions of van Buuren et al.41
and included diagnostic, cognitive, functional, and motor assessments. Five imputed
datasets were created using the imputation method of predictive mean matching. Imputed
values were viewed to ensure plausibility, and imputation streams plotted to assess
convergence (Appendix B, Figures B.6 to B.11). The ADAS-Cog-Proxy GAM was
applied to each of the five imputed data sets, and the mean of the five estimated scores for
each participant taken as their final ADAS-Cog-Proxy score. This process of imputing
missing covariate values, applying the GAM to each completed dataset, and then
averaging the five estimated ADAS-Cog-Proxy scores was repeated for 6, 12, 24, 36, and
48 month follow-up visits.
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5.2.2.2

Motor function

Quantitative gait performance was assessed under four conditions using an electronic
walkway system (GAITRite™). To avoid capturing acceleration and deceleration phases,
start and end points of the walkway were marked one metre away from the ends of a 6metre recording distance. The four testing conditions were one single-task condition
where participants were asked to walk as they usually would, and three dual-task
conditions (see below). Reliability of gait parameters under single and dual-task
conditions have been described elsewhere.43 The following spatio-temporal gait
parameters were captured: velocity (cm/s), stride time (ms), step time (ms), stride length
(cm), step length (cm), double support time (ms), swing time (ms), stride width (cm),
stride velocity (cm/s), and cadence (steps/min). The Coefficient of Variation
(CV=Standard Deviation (SD)/Mean*100) standardizes variability estimates to mean
values, thus allowing direct comparison of variability across variables measured using
different units. The CV was calculated for all gait parameters except velocity.

5.2.2.3

Motor-cognitive performance

The dual-task gait paradigm was used to capture motor-cognitive performance. The three
dual-task gait conditions included walking as usual while: i) counting backwards from
100 by ones, ii) counting backwards from 100 by sevens, and iii) naming animals.
Participants were not instructed to prioritize the cognitive or walking task. DTC (%) was
calculated for three gait parameters under all three secondary task conditions, using the
formula: [(single-task condition – dual-task condition)/single-task condition]*100.31 The
three parameters of velocity, stride time, and stride time CV were selected based on
literature supporting their importance in dementia and pre-dementia syndromes.16,28,31,43

5.2.3
5.2.3.1

Data Analysis
Outcome measure development

Advantages of using a PI approach for our outcome measure are that it allows variables
with different scoring ranges to be combined into a single summary score, and when
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component variables have low pairwise correlations the SD of the derived score decreases
as the number of variables increases.34,45 PI scores were obtained by first ensuring all
variables were coded so that higher values indicate greater dysfunction, calculating Zscores for each variable (Z=(observation – group mean) / SD), and then averaging those
Z-scores.33,45 The statistical advantages of the PI diminish after six component variables,
and are greatest when pairwise correlations are less than 0.2, and slightly less so up to
0.4.34
Variable selection for our PI was thus guided by pairwise correlation coefficients and by
theoretical considerations. For example, we aimed to include at least one variable from
each of the categories of cognition, motor function, and motor-cognitive performance, by
selecting at least one single-task and at least one DTC variable to combine with the
ADAS-Cog-Proxy. To do this we first assessed pairwise correlations between the ADASCog-Proxy and each of the single-task and DTC gait variables separately. Variables were
retained when |rho|<0.2 or when |rho|=0.2 to 0.4 with evidence supporting that
parameter’s involvement in dementia or pre-dementia syndromes. Pairwise correlation
coefficients were calculated for all retained single-task gait and DTC variables. In looking
for at least one weakly intercorrelated pair, when numerical considerations were similar,
we chose variables that had greater evidence from previous studies supporting their
involvement in pre-dementia or dementia syndromes. When both numerical and
theoretical considerations were similar, box plots were created to assess which of the
contending individual gait or DTC parameters, if any, demonstrated a stepwise
progression from NC to SCI to MCI diagnostic categories. Scatterplots were consulted to
ensure low correlations were not the result of a strong non-linear relationship. Ease of
assessment was also considered for both individual variables and the PI as a whole.

5.2.3.2

Baseline discrimination

Due to skewness and small sample sizes non-parametric tests were used to evaluate
responsiveness to baseline discrimination. Kruskal-Wallis tests were used to assess
whether the ADAS-Cog-Proxy and PI could detect a significant difference among the
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diagnostic categories of NC, SCI, and MCI. Mann-Whitney U tests were used to assess
all pairwise comparisons.

5.2.3.3

Change over time

Standardized Response Means (SRM=mean difference score/SD of difference score)
were calculated for 6, 12, 24, 36, and 48 month follow-up periods for the PI, the ADASCog-Proxy, and the ADAS-Cog-Proxy plus each individual component of the PI
combined using a PI approach. Standardization was always performed with respect to the
baseline distribution of participants present at the follow-up visit of interest. No
distinction was made between diagnostic categories for SRM calculations.
All analyses were conducted with RStudio, version 1.0.136.46

Results

5.3
5.3.1

Baseline Characteristics

Baseline characteristics for the 573 ADNI participants used to build the ADAS-CogProxy GAM can be found in Table 9, and for the 109 participants in GABS in Table 10.
One GABS participant with SCI did not have single-task gait recorded at baseline and
was omitted from PI development and subsequent analyses. GABS participants who
converted to dementia were included in analyses for time points prior to their dementia
diagnosis. Two participants converted by six months of follow-up, one by 12 months,
four by 24 months, and one by 36 months. A summary of the number of missing GAM
covariates that were imputed using MICE can be found in Chapter 6 (Table 14).
Table 9 Alzheimer's Disease Neuroimaging Initiative Baseline Characteristics
Characteristic

Overall (n=573)

Mean (SD)
Minimum, Maximum
Number of missing values (if applicable)
unless otherwise specified

Age (years)
Education (years)

75.17 (6.56)
54.40, 89.60
15.84 (2.94)
6.00, 20.00
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Sex
Female n (%)
Male
Alzheimer’s Disease Assessment ScaleCognitive Subscale
Mini-Mental State Examination
Rey Auditory Verbal Learning Test
(3 trials)
Clinical Dementia Rating Scale-Sum of
Boxes
Trail Making Test A

Trail Making Test B

Digit Span Forward Test
Digit Span Backward Test

228 (40%)
345
9.51 (4.63)
0, 28
27.78 (1.84)
23, 30
18.34 (5.64)
5, 38
1.02 (1.03)
0.00, 4.50
41.41 (20.08)
17.00, 188.00
4
114.8 (65.62)
34.0, 348.0
5
6.64 (1.05)
4, 8
4.71 (1.19)
0, 7

Table 10 Gait and Brain Study Baseline Characteristics
Characteristic
Mean (SD)
Minimum, Maximum
Number of missing
values (if applicable)
unless otherwise
specified

Age (years)
Education
(years)
Sex
Female n (%)
Male
Medications (#)
Comorbidities
(#)
Geriatric
Depression
Scale

Overall
(n=109)

Normal
Cognition
(n=12)

Subjective
Cognitive
Impairment
(n=19)

Mild
Cognitive
Impairment
(n=78)

74.22 (6.33)
63.00, 92.00
13.85 (2.92)
6.00, 20.00

73.50 (4.58)
67.00, 82.00
16.33 (3.06)
10.00, 20.00

70.00 (4.59)
65.00, 85.00
14.42 (2.81)
10.00, 20.00

75.36 (6.52)
63.00, 92.00
13.33 (2.74)
6.00, 20.00

58 (53)
51
7.62 (4.52)
0, 21
6.06 (2.85)
0, 13
2.35 (2.14)
0, 10
22

7 (58)
5
6.42 (4.06)
2, 16
4.33 (1.44)
2, 7
1.60 (1.14)
0, 3
7

15 (79)
4
6.53 (5.26)
0, 21
4.79 (2.02)
1, 8
2.25 (1.89)
1, 5
15

36 (49)
42
8.06 (4.37)
0, 21
6.64 (2.98)
0, 13
2.40 (2.21)
0, 10
0
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General
Physical
Activity Level
Vigorous: n (%)
Moderate: n (%)
Seldom: n (%)
Missing: n
Lawton-Brody
Activities of
Daily Living
Instrumental
Activities of
Daily Living
Basic Activities
of Daily Living
ADAS-CogProxy
Montreal
Cognitive
Assessment
Mini-Mental
State
Examination
Clinical
Dementia
Rating Scale
Rey Auditory
Verbal Learning
Test (3 trials)
Gait Velocity
(cm/s)

Stride Time (s)

Stride Time
Coefficient of
Variation (CV)
(%)
Dual-Task Gait
Velocity Cost
with Counting
(%)

63 (58)
29 (27)
16 (25)
1
5.99 (0.11)
5, 6
22
7.69 (0.94)
2, 8
22
0.42 (0.97)
0, 5
22
9.46 (2.34)
3, 16
24.45 (3.82)
12, 30

6 (50)
5 (42)
1 (8)

13 (68)
4 (21)
2 (11)

6.00 (0.00)
6, 6
7
8.00 (0.00)
8, 8
7
0.80 (0.84)
0, 2
7
7.59 (1.32)
4, 9
27.25 (1.48)
24, 30

5.75 (0.50)
5, 6
15
7.75 (0.50)
7, 8
15
0.75 (0.96)
0, 2
15
7.96 (1.93)
3, 12
27.89 (2.45)
21, 30

27.74 (2.52)
18, 30

28.83 (1.80)
24, 30

28.89 (1.45)
24, 30

27.29 (2.69)
18, 30

0.99 (0.89)
0.0, 4.0
68
17.20 (5.35)
8.0, 33.0
29
108.40
21.27
57.27, 165.2
1
1.14 (0.10)
0.93, 1.41
1
2.47 (1.48)
0.62, 9.73
1

0.0 (0.0)
0.0,0.0
9
23.40 (5.18)
19.0, 32.0
7
124.80
15.78
99.65, 155.80

19
24.75 (6.65)
17.0, 33.0
15
114.10
17.59
82.17, 141.00

1.07 (0.88)
0.0, 4.0
40
16.34 (4.71)
8.0, 28.0
7
104.60
21.47
57.27, 165.20

5.51 (10.68)
-16.04, 34.61
1

3.10 (11.52)
-8.16, 34.61

1.11 (0.08)
0.95, 1.20
2.08 (0.76)
1.14, 4.04

44 (56)
20 (26)
13 (17)
1
6.00 (0.00)
6, 6
0
7.67 (0.99)
2, 8
0
0.38 (0.98)
0, 5
10.11 (2.24)
5, 16
23.18 (3.60)
12, 30

1.10 (0.08)
0.97.0, 1.26
1
2.49 (2.02)
1.16, 9.73
1

1.16 (0.10)
0.93, 1.41

2.58 (5.48)
-11.05, 10.82
1

6.55 (11.35)
-16.04, 31.12

2.53 (1.43)
0.62, 7.89
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Dual-Task
Stride Time
Cost with Serial
Sevens (%)
Dual-Task
Stride Time CV
Cost with
Naming
Animals (%)

5.3.2

-16.93 (18.42)
-75.93, 6.30
3

-24.06 (29.08)
-75.93, 3.74

-8.23 (9.87)
-38.54, 2.74
1

-17.86 (17.37)
-69.50, 6.30
2

-133.40
(270.66)
-1382.00,
77.58
1

-214.80
(416.11)
-1382.0, 63.87

-44.54
(80.73)
-240.3, 53.55
1

-141.30
(269.59)
-1200.00,
77.58

ADAS-Cog Proxy Model

Covariates for the GAM selected to estimate ADAS-Cog-Proxy scores included the sum
of the first three trials of the Rey Auditory Verbal Learning Test (RAVLT), the MMSE,
and the CDR-Sum of Boxes (CDR-SB) score. This ADAS-Cog-Proxy model estimated
69% of participant scores within three points and 88% of participant scores within five
points of their observed (‘true’) ADAS-Cog score in the testing subset of ADNI (Figure
7). Spearman’s rank correlation coefficient between predicted and observed ADAS-Cog
scores was 0.70 (P<0.001). Baseline ADAS-Cog-Proxy scores in GABS are included in
Table 10.

5.3.3

Gait and Brain Pooled Index

Variables selected for inclusion in the PI include the ADAS-Cog-Proxy, gait velocity
multiplied by negative one, and DTC for gait velocity with the secondary task of counting
backwards from 100 by ones. Pairwise correlation coefficients ranged in magnitude from
0.27 to 0.32 (Chapter 6, Table 20).

5.3.4

Baseline Discrimination

Both the ADAS-Cog-Proxy and the PI showed an overall statistically significant
difference in mean ranks across the three diagnostic categories (ADAS-Cog-Proxy:
Kruskal-Wallis H(2) value=24.13; PI: H(2)=22.36, both P<0.001). Statistically significant
pairwise comparisons were found for SCI versus MCI (ADAS-Cog-Proxy: MannWhitney U test statistic=331, P=0.0002; PI: U=348, P=0.0009) and NC versus MCI
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(ADAS-Cog-Proxy: U=153, P=0.0002; PI: U=148, P=0.0001), but not NC versus SCI
diagnostic categories (ADAS-Cog-Proxy: U=93, P=0.41; PI: U=75, P=0.17).

5.3.5

Change Over Time

Adding only gait velocity to the ADAS-Cog-Proxy using a PI approach always increased
responsiveness to decline (less negative or more positive SRM), while adding only DTC
to the ADAS-Cog-Proxy showed mixed results (Table 11). The full PI had a larger SRM
than the ADAS-Cog-Proxy for 6 month (SRM: ADAS-Cog-Proxy=0.14, PI=0.23) and 48
month (SRM: ADAS-Cog-Proxy=0.60, PI=0.65), but not 36 month (SRM: ADAS-CogProxy=0.23, PI=0.18) follow-up periods. For 12 and 24 month follow-up periods the
ADAS-Cog-Proxy detected overall improvement (SRM: 12 month=-0.08, 24 month=0.24), while the full PI detected almost no change (SRM: 12 month=0.04, 24
month=0.01).
Table 11 Standardized Response Means: Responsiveness to group-level within-person
measured change over time
n

Time

ADASp

ADASp+GV

ADASp+DTC

86

6m

0.14

0.17

0.18

ADASp+GV+
DTC
(Full PI)
0.23

73

12m

-0.08

-0.05

0.01

0.04

55

24m

-0.24

-0.11

-0.07

0.01

35

36m

0.23

0.34

0.11

0.18

24

48m

0.60

0.68

0.59

0.65

Notes: Comparisons of the magnitude of standardized response means should only be
made across rows because due to the nature of using data from an ongoing cohort study,
not all participants have had the chance to reach all follow-up visits, and participants who
converted to dementia were only included in calculations before the point of conversion.
Legend: ADASp=Alzheimer’s Disease Assessment Scale-Cognitive Subscale-Proxy,
DTC=Dual Task Cost (Gait Velocity (GV) with secondary task of counting backwards by
ones), PI=Pooled Index, m=months.
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5.4

Discussion

A PI approach combining assessments of motor function, specifically gait velocity and
DTC gait velocity, with an ADAS-Cog-Proxy cognitive measure demonstrated
comparable responsiveness to baseline discrimination between pre-dementia diagnostic
categories and generally comparable or increased responsiveness to measured change
over time as compared to the ADAS-Cog-Proxy cognitive measure alone.
More specifically, both the PI and ADAS-Cog-Proxy detected statistically significant
differences between NC and MCI, and SCI and MCI predementia diagnostic categories
but not between NC and SCI. This latter finding may have been due to small sample sizes
rather than an inability to distinguish between the two mildest stages of disease
progression. For all but one follow-up period the PI demonstrated greater responsiveness
than the ADAS-Cog-Proxy to measured decline over time; however, there were two
follow-up periods where the ADAS-Cog-Proxy detected improvement while the PI
detected worsening. This group-level improvement measured by the ADAS-Cog-Proxy
may be capturing the fact that the cognitive trajectory from NC to dementia is not linear
such that some of the participants with MCI or SCI may have reverted to more normal
levels of cognition. Also, excluding participants after conversion to dementia removed the
participants who are expected to have experienced the largest decline. Further research is
needed to assess whether the PI is detecting a more realistic overall assessment of the
change in functionality over time than the ADAS-Cog-Proxy, as both cognitive and motor
function are important for everyday living.
The improvements in responsiveness to group-level within-person measured change over
time that occurred by adding gait and DTC assessments to the ADAS-Cog-Proxy were
made without adding tests of delayed recall or executive function which have previously
been found to improve the responsiveness of the ADAS-Cog in pre-dementia
syndromes.8-11 These cognitive abilities are thought to be important in pre-dementia
syndromes but are not included on the original ADAS-Cog.1,9,47 Our results align with
research exploring motor function as a biomarker for cognitive impairment and predementia syndromes.15,28
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Key advantages of using quantitative gait assessments for outcome measurement include
language independence, non-invasive administration procedures, avoidance of ceiling
effects across the disease spectrum, and when DTC is used to assess the impact of a
secondary cognitive task each participant serves as their own control. Further advantages
of gait velocity are that it can be easily measured using only a stop watch and defined
walking distance.
In addition to our findings that gait parameter tests of motor function may be valuable
additions to cognitive assessments for use in pre-dementia studies, the creation of the
ADAS-Cog-Proxy may provide a framework when there is an appropriate research
question but not all necessary variables present in a single available database. Using a
predictive model to obtain estimates of a missing variable allows preliminary tests of
hypotheses without the time and resources that would be required to collect new data.
Main limitations of our study include small sample sizes, missing data, and reliance on a
‘proof of principle’ approach as we were unable to use the original ADAS-Cog. Two
ADAS-Cog-Proxy GAM covariates were collected one month prior to the ADAS-Cog
administration, which may have contributed extra noise to the GAM development and led
to an underestimate of accuracy. Furthermore, the inclusion of only two variables on top
of the ADAS-Cog-Proxy in our PI did not take advantage of statistical advantages that
may be gained by including additional lowly correlated yet informative variables, such as
other gait parameters or cognitive tests. Restricting our PI to only gait velocity single and
DTC with the ADAS-Cog-Proxy represents the trade-off in information value between
practicality and measurement intensiveness. The derived units of the PI are also difficult
to interpret and are not directly comparable to ADAS-Cog scores. Selection bias, such as
towards highly educated participants, may also limit the generalizability of our results.
Future steps include re-creating the PI using the original ADAS-Cog, assessing
responsiveness with new participants across all levels of disease severity from NC to
dementia, and assessing responsiveness to treatment effects in pre-dementia populations.
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Chapter 6
Detailed Methods

6

The purpose of Chapter 6 is to provide a more detailed description of methods and
supplementary results that are not presented in Chapter 5. To minimize redundancy not all
methods details and results presented in Chapter 5 also appear in Chapter 6, but some
overlap was necessary to maintain comprehension. Chapter 6 is organized according to
thesis objective, and information on the development of the Alzheimer’s Disease
Assessment Scale-Cognitive Subscale-Proxy measure (ADAS-Cog-Proxy) is included
under the first objective.

6.1

Objective 1

Objective 1 was completed in a three-step process. First, the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database was used to build an ADAS-Cog-Proxy
statistical model which could be used to obtain estimates of Alzheimer Disease
Assessment Scale-Cognitive Subscale (ADAS-Cog 11) scores in the Gait and Brain Study
(GABS) database. This step was necessary as there is no database with both the ADASCog 11 and quantitative motor assessments, and developing a proxy measure to use a
‘proof of principle’ approach to the objectives allows a preliminary test of hypotheses
before investing time and resources in a new study that could collect all necessary
measures together. Second, additional measures in GABS were selected to add to the
ADAS-Cog-Proxy. Third, the selected measures and ADAS-Cog-Proxy were combined
using a pooled index (PI) approach.

6.1.1

Step 1: Develop an Alzheimer’s Disease Assessment Scale
– Cognitive Subscale Proxy

ADNI wave selection and data obtainment. ADNI contains three waves of participants:
ADNI 1, ADNI Grand Opportunities, and ADNI 2. Of these, ADNI 1 has the largest
overlap of available cognitive tests with GABS (Table 12), and therefore was selected to
build the ADAS-Cog-Proxy.
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Table 12 Cognitive Tests in Available Databases at Baseline
Tests

GABS

ADNI1

ADAS-Cog 11 Total

X

ADAS-Cog Items

X

MMSE Total

X

MMSE Items

X
X

MoCA

X

MoCA Subscores

X

CDR-SB

X

X

TMTA

X

X

TMTB

X

X

Digit Span Forward

X

X

Digit Span Backward

X

X

Letter Number Sequence

X

RAVLT
(sum of 3 trials)

X

BNT

X

FAB

X

X (via
item-level
data)

Legend: X indicates the test listed in the leftmost column of the row is present in the
database at the column head. GABS=Gait and Brain Study, ADNI 1=Alzheimer’s Disease
Neuroimaging Initiative wave 1, ADAS-Cog 11=Alzheimer’s Disease Assessment ScaleCognitive Subscale 11 item version, MMSE=Mini-Mental State Examination,
MoCA=Montreal Cognitive Assessment, CDR-SB=Clinical Dementia Rating Scale-Sum
of Boxes, TMTA= Trail Making Test Part A, TMTB=TMT Part B, RAVLT=Rey
Auditory Verbal Learning Test (immediate recall), BNT=Boston Naming Test,
FAB=Frontal Assessment Battery. Note that ADNI administered a modified version of
BNT whereby only odd questions were used. This modified version was not directly
comparable with the full BNT version administered in GABS, and item level data was not
available in GABS to create an odd question only version.
Inclusion criteria for ADNI 1 was Hachinski score less than or equal to 4, aged 55 to 90
years old, stability of ADNI permitted medications, Geriatric Depression Scale less than
6, study partner with at least 10 hours of contact with the participant per week, visual and
auditory acuity adequate for neuropsychological testing, good general health, unable to
bear children, willing and able to complete three year imaging study including no medical
contraindications to magnetic resonance imaging, education level of grade 6 or work
history, fluent English or Spanish speaking ability, agrees to DNA for Apolipoprotein
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(APOE) e4 allele testing and banking, agrees to blood and urine samples for biomarker
testing, and not enrolled in other trials or studies. There were further inclusion criteria
specific to diagnostic categories of Normal Control or Cognition (NC), Mild Cognitive
Impairment (MCI), and Alzheimer’s Disease (AD) groups. Inclusion criteria for NC was
no abnormal memory complaints, normal memory function scores on the Logical
Memory II subscale, Mini-Mental State Exam (MMSE) score between 24 and 30, Clinical
Dementia Rating (CDR) score of 0 and Memory Box score of 0, and no abnormal levels
of cognitive function or activities of daily living. Inclusion criteria for MCI categorization
was memory complaint by the participant or participant’s study partner, abnormal
memory function score on the Logical Memory II subscale, MMSE between 24 and 30,
CDR score of 0.5 with Memory Box score of at least 0.5, and insufficient cognitive and
functional impairment to allow a diagnosis of AD. Inclusion criteria for AD will not be
reviewed as those participants were excluded from analyses in this thesis.
The online ADNI database is divided into several data tables, which are defined by the
types of variables they contain. Some overlap between data tables exists. The “Item Level
Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]” and “Key ADNI tables merged into
one table” data tables were downloaded from the ADNI website
(http://adni.loni.usc.edu/data-samples/access-data/) on October 26, 2016. All cognitive
test scores were treated as numeric variables. All cognitive tests of interest were
administered at a single baseline visit except the MMSE and CDR-SB, which were
administered one month earlier at the ADNI 1 screening visit.
Baseline observations for participants in ADNI 1 with NC or MCI diagnostic status were
retained from the “Key ADNI tables merged into one table” data table.
Baseline data from the “Item Level Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]”
data table was used to create a three trial Rey Auditory Verbal Learning Test (RAVLT)
score. The RAVLT involves reading a list of 15 words to a participant and then asking
the participant to recall as many words as possible immediately after the list is read (trial
1). The same list of words is read a second time, and the participant is given up to four
more trials (trials 2 to 5) to recall as many of the words as possible. ADNI performed a
total of five trials while GABS performed three. To create a compatible three trial
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summary score in ADNI, the number of words recalled on the first three trials were
treated as numerical variables (0=not recalled, 1=recalled for each of the 15 words on
each of the three trials) and summed together to give a score from 0 to 45. Twelve
participants without item level RAVLT data were excluded.
This RAVLT sum of 3 trials score as well as total test scores for the Digit Span Forward
and Backward Tests, and Trail Making Test parts A and B (TMT A & B), which were
also included in the “Item Level Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]” data
table, were merged with the selected “Key ADNI tables merged into one table”
observations using Roster Identification Number (RID) such that observations needed to
be included in both data tables (matching RID) to be retained. This method of merging
ensured that participants with AD from the “Item Level” data, where diagnostic
information was not recorded, were excluded. After merging, four participants did not
have TMT A scores and five did not have TMT B scores. These participants were only
excluded from analyses which required TMT A or B scores (candidate ADAS-Cog-Proxy
Model 5).
Data splitting. ADNI data was split into 70% development (n=401) and 30% testing
(n=172) subsets using random sampling without replacement via the sample.split
command from the R package caTools with seed value set at 100.1
Candidate model building and selection in development subset. Five candidate models
were built, including one linear model and four generalized additive models (GAM).
Candidate covariates (the seven cognitive tests available in both ADNI and GABS) were
added to subsequent GAMs in order of theoretical similarity to the ADAS-Cog 11.
Rather than requiring a linear function to explain the relationship between the covariate(s)
and outcome, GAMS allow a degree of nonlinearity in the dependence of the outcome on
covariates.2,3 This is achieved by summing together smooth functions of covariates.
Smooth functions are established for individual covariates by selecting a basis. A thin
plate regression spline basis was used for all smooth functions in all candidate GAMS,
and the basis dimension, which sets an upper limit to the number of degrees of freedom
that the smooth function may take on, was set manually for each covariate based on visual
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assessment of model plots. If a covariate was included in multiple candidate GAMs, the
basis dimension was reassessed for each GAM as the amount of smoothing appropriate
for a given covariate is influenced by other covariates in the model. In general, larger
basis dimensions allow more degrees of freedom, which allows more nonlinearity in the
smooth function. The amount of this “allowed” nonlinearity actually used (effective
degrees of freedom (edf)) for a smooth function was selected through generalized cross
validation as part of the standard model fit process in R. An edf of one indicates that a
linear term was deemed acceptable by the GAM. R package mgcv was used to implement
GAMs.4
The five candidate models were:
1. A linear model with the MMSE as the sole covariate. The MMSE is a global
measure of cognition, shares many similar test items to the ADAS-Cog 11, and
was selected as a starting point as it was expected to be the candidate covariate
best able to independently predict ADAS-Cog 11 scores. The MMSE was
included in all candidate models.
2. A GAM with the MMSE (basis=4, edf=2.7) as the sole covariate. This nonlinear
model was superior to the previous linear model, so all subsequent candidate
models were built as GAMs.
3. A GAM with the MMSE (basis=5, edf=3.7) and RAVLT (basis=10, edf=1.0) tests
as covariates. The RAVLT is a test of episodic memory and resembles the ADASCog 11 Word Recall task, which is one of the two items on the ADAS-Cog 11
where most errors are accumulated in pre-dementia populations. Due to this
similarity, and the fact that the Word Recall task was identified as one of the most
important ADAS-Cog 11 sub-items for assessing cognitive ability in pre-dementia
populations, the RAVLT was the second covariate to be included.
4. A GAM with the MMSE (basis=6, edf=4.2), RAVLT (basis=10, edf=1.0), and
CDR-SB (basis=7, edf=4.1) tests as covariates. The CDR-SB contains some
similar assessments to the ADAS-Cog 11 (memory, orientation), but also includes
report from a close relative, friend, or caregiver about functional activities
(judgment, community affairs, home and hobbies, personal care items) that are not
assessed directly by the ADAS-Cog 11.
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5. A GAM with the MMSE (basis=6, edf=4.1), RAVLT (basis=10, edf=1.0), CDRSB (basis=7, edf=4.1), TMT A (basis=5, edf=1.0), TMT B (basis=5, edf=1.0),
Digit Span Forward (basis=5, edf=3.4), and Digit Span Backward (basis=5,
edf=1.6) tests as covariates. The TMT parts A and B are both tests of executive
function and processing speed, which are cognitive abilities not covered by the
ADAS-Cog 11. The Digit Span Forwards and Backwards tests assess working
memory and attention, which are also not directly assessed by the ADAS-Cog 11.
All four of these tests covering additional cognitive domains were added at once
to the final candidate GAM to assess how preliminary accuracy was changed by
adding covariates that theoretically should not be very informative for estimating
ADAS-Cog 11 scores.
Model 4 was selected as the best candidate model as it had better preliminary accuracy
than Model 3, and only slightly worse preliminary accuracy than Model 5.
Candidate model diagnostics were assessed in the development subset to ensure model fit
was okay. The corresponding plots can be found in Appendix B (Figures B.1 to B.5).
Accuracy estimation in testing data. Candidate Model 4 predicted 68.6% of ADASCog 11 scores within 3 points of actual observed values (Figure 8, below), and 88.4%
within 5 points. The Spearman rank correlation between predicted and observed ADASCog scores was strong (rho=0.70, P<0.001).
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Figure 8 Residuals between observed and predicted ADAS-Cog scores in the ADNI
testing data.
Comparison with previously published model. As a final check of Candidate Model 4
performance, the accuracy of a previously published univariate linear model for
converting between MMSE and ADAS-Cog 11 scores was assessed.5 This model was
developed in a sample of older adults with MCI and AD, which indicates higher levels of
cognitive dysfunction than the ADNI or GABS sample, suggesting the model may not
perform well enough for the purpose of approximating ADAS-Cog 11 scores in GABS.
Indeed, this model predicted 53.2% of ADAS-Cog 11 scores within three points and
76.1% within five points of observed ADAS-Cog 11 scores on combined development
and testing ADNI data.
Building the final ADAS-Cog-Proxy model. Candidate Model 4 was rebuilt on
combined development and testing ADNI data, and is plotted in Figure 9.
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Figure 9 ADAS-Cog-Proxy model.
Shown are plots of the smooth terms (y-axis, number in brackets = effective degrees of
freedom) against observed data points (x-axis) for each of the ADAS-Cog-Proxy
generalized additive model covariates.

Assessing similarity of participants in ADNI and GABS. For optimal model
performance, the participants in ADNI used to build the ADAS-Cog-Proxy model should
be similar to the participants in GABS whom will be obtaining estimates of ADAS-CogProxy scores. Given that both ADNI and GABS contain older adults along the predementia disease continuum from NC to MCI, their cognitive abilities are expected to be
similar. To ensure this was the case the range of ADAS-Cog-Proxy GAM covariates were
compared between the ADNI data used to build the GAM, and observed GABS data, as
presented in Table 13.
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Table 13 Range of ADAS-Cog-Proxy Covariate Scores in ADNI and GABS
Covariate
MMSE
RAVLT
Range (min, max)
0, 30
0, 45
ADNI data used to build ADAS-Cog-Proxy model
Observed Range
23, 30
5, 38
GABS Baseline
Observed Range
18, 30
8, 33
n below/above
7/0
0
Total n out of range 7
0
GABS 6-month follow-up
Observed Range
21, 30
5, 34
n below/above
3/0
0
Total n out of range 3
0
GABS 12-month follow-up
Observed Range
20, 30
6, 39
n below/above
2
0/1
Total n out of range 2
1
GABS 24-month follow-up
Observed Range
21, 30
9, 43
n below/above
2/0
0/1
Total n out of range 2
1
GABS 36-month follow-up
Observed Range
20, 30
6, 38
n below/above
1/0
0
Total n out of range 1
0
GABS 48-month follow-up
Observed Range
22, 30
5, 38
n below/above
1/0
0
Total n out of range 1
0

CDR-SB
0, 4.5
0, 4.5
0, 4
0
0
0, 4
0/0
0
0, 2.5
0/0
0
0.5, 5
0/1
1
0.5, 3.5
0/0
0
0.5, 4.0
0/0
0

Multiple Imputation by Chained Equations and ADAS-Cog-Proxy estimation in
GABS. To allow all participants in GABS to obtain ADAS-Cog-Proxy scores, rather than
omitting people who had at least one of three missing covariate values, Multiple
Imputation by Chained Equations (MICE) was used (R package ‘mice’) to impute
missing covariate values for all timepoints of interest.6-8
The number of missing ADAS-Cog-Proxy covariate values in GABS can be found in
Table 14, below. CDR-SB missing values were coded as 999 if no collaborator, and NaN
if unknown reason for missingness. This distinction in missingness was captured for
Table 14, and then all missing values coded as NA so that MICE could be run.
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Table 14 Missing ADAS-Cog-Proxy Covariates in the Gait and Brain Study
Timepoint

n

MMSE

RAVLT

0
6m
12m
24m
36m
48m

109
86
73
55
35
24

0
0
0
0
0
0

29
28
16
3
0
0

CDR-SB
Total (no
collaborator)
68 (53)
63 (50)
57 (40)
39 (33)
21 (21)
20 (19)

CDR-SB
&
RAVLT
24
25
15
3
0
0

Legend: MMSE=Mini-Mental State Examination, RAVLT=Rey Auditory Verbal
Learning Test (3 trials), CDR-SB=Clinical Dementia Rating Scale-Sum of Boxes,
m=months.
The imputation method of predictive mean matching (default) was using to impute
missing values for both CDR-SB and RAVLT. Predictive mean matching is a semiparametric imputation method which generates a prediction for missing values using
other variables in the predictor matrix, and then selects an observed value from the
predictor matrix that is similar to the predicted value. The default visit sequence of
imputing variables in order from left to right was used, and five multiply imputed datasets
were created.
MICE was performed on extracted predictor matrices whereby only the final pooled
ADAS-Cog-Proxy scores were merged back into the original GABS dataset, rather than
performing MICE on the entire GABS database, due to multicollinearity and
computational restrictions.6,7 The creation of predictor matrices for each time point also
allowed the exclusion of observations that were missing simply because the
corresponding participants did not have the follow-up visit. Furthermore, it has been
suggested that there is no advantage in terms of accuracy for imputations when using
more than 15-25 predictor variables.6 In accordance with published guidelines, predictor
matrices included all GAM covariates, predictors of the outcome ADAS-Cog scores,
variables that include a lot of variance as roughly identified by correlation with the target
variables to be imputed (Table 15), and no variables that had a lot of missing values
within the subgroup of people with missing RAVLT and CDR-SB scores.6–8 It has also
been suggested to include variables related to non-response. The main reason CDR-SB
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scores are missing is if no collaborator was present to report on behalf of the patient;
however, there was not a variable in the dataset expected to provide indication of this.

Table 15 Correlation Coefficients for Potential Predictor Matrix Variables
Candidate Predictor Variable

Activities of Daily Living (ADL)
Age (years)
Balance-Rigid Surface Eyes Open
Balance-Rigid Surface Eyes Shut
Balance-Disturbed Surface Eyes Open
Balance-Disturbed Surface Eyes Shut
Basic ADL
Boston Naming Test
Clinical Dementia Rating Scale
Diagnostic Category
Digit Forward Span
Digit Backward Span
Education (years)
Frontal Assessment Battery
Gait Velocity
Gait Velocity while Counting
Geriatric Depression Scale
Instrumental ADL
Letter Number
Mini-Mental State Examination
Montreal Cognitive Assessment (MoCA)
MoCA Attention Index Score
MoCA Executive Index Score
MoCA Language Index Score
MoCA Memory Index Score
MoCA Orientation Index Score
MoCA Visuospatial Index Score
Number of falls in the past 12 months
Physical Activity Scale for the Elderly
Rey Auditory Verbal Learning Test
Trail Making Task A
Trail Making Task B

Pearson
Correlation
Coefficient
with CDR
NA
0.07
0.28
0.11
0.03
0.06
0.05
-0.40
1.00
NA
0.24
-0.21
-0.11
-0.55
-0.38
-0.29
0.03
-0.37
-0.32
-0.56
-0.67
-0.26
-0.46
-0.26
-0.48
-0.64
-0.27
-0.26
-0.09
-0.46
0.28
0.49

Pearson
Correlation
Coefficient
with RAVLT
-0.12
-0.23
-0.09
-0.17
-0.11
-0.06
0.02
0.34
-0.46
NA
0.20
0.20
0.03
0.28
0.17
0.22
-0.05
0.07
0.29
0.28
0.38
0.25
0.20
0.29
0.41
0.27
0.02
0.05
-0.09
1.00
-0.44
-0.25

Include
variable in
predictor
matrix?
No
No
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes

The following variables were included in predictor matrices for each time point: Baseline
Diagnosis, MMSE, MoCA, MoCAMIS, MoCAEIS, MoCAVIS, MoCALIS, MoCAAIS,
MoCAOIS, CDR, Trail A, Trail B, Digit Forward, Digit Backward, Letter Number,
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RAVLT, BNT, FAB, number of falls in past 6 months, IADL, RSEO (balance), Gait
Velocity, and Gait Velocity while counting backwards by ones, from the time point of
interest, as well as CDR and RAVLT scores from the previous visit (T6 to T48 visit
imputations) or a future visit (baseline visit imputations). Participant ID was included in
the predictor matrix to allow re-merging of data, but was omitted as a predictor variable.
After model specification and predictor matrix creation, MICE was performed in 3 main
stages,6,8 and repeated for each timepoint.
1) The imputation stage created five multiply imputed datasets. Although only CDR-SB
and RAVLT imputations were required, to remove a variable from being imputed it must
also be removed as a predictor variable, so imputations were allowed for predictor
variables that had missing values themselves. Imputations for RAVLT and CDR-SB were
inspected visually to ascertain the plausibility of imputed values. Convergence of the
MICE algorithm was also assessed by plotting imputations streams for the mean and
standard deviation (y-axes) of the five imputations against the iteration number (x-axes),
as shown in Figures B.6 to B.11 in Appendix B. Imputation streams that are intermingled
without definite trends may be considered as support for convergence.6
2) The analysis stage included applying the ADAS-Cog-Proxy GAM to each of the five
complete datasets, which resulted in five estimated ADAS-Cog-Proxy scores for each
participant in GABS.
3) The pooling stage involved taking the mean of the five estimated ADAS-Cog-Proxy
scores for each participant. These final averaged scores were labelled “T#_ADASproxy”
and merged back into the GABS database using Participant ID.
A summary of ADAS-Cog-Proxy descriptive statistics at each time point were assessed to
ensure merging was performed correctly and to further assess plausibility of the estimated
scores, and are presented in Table 16.
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Table 16 ADAS-Cog-Proxy Scores in the Gait and Brain Study
Timepoint
Baseline
6 Months
12 Months
24 Months
36 Months
48 Months

6.1.2

Minimum
2.77
3.80
2.60
0.29
2.75
5.26

Quartile 1
7.89
8.24
7.34
6.85
7.93
9.05

Median
9.34
9.61
8.78
8.43
9.62
10.64

Mean
9.74
9.75
9.24
8.61
9.77
10.95

Quartile 3
11.36
11.36
11.04
10.62
10.88
12.36

Maximum
18.41
17.24
17.89
14.03
17.30
17.08

Step 2: Select Additional Measures for the Novel Outcome
Measure

The overall goal for PI component selection was to select lowly correlated variables, with
at least one variable from each of the following three categories thought to be important
components of pre-dementia and dementia syndromes: cognition, motor function, and
motor-cognitive performance. For simplicity candidate variables were separated into
these three categories, but in reality these categories are not mutually exclusive. Including
up to six component variables with low pairwise correlations in a PI has been shown to be
advantageous in terms of content validation (covering multiple important domains) and in
terms of reducing the variability of the final PI score.9-11 Although statistically there is
little or no advantage to including more than six component variables or component
variables with pairwise correlations higher than about |rho|=0.4 in a PI, doing so does not
affect the validation of the PI nor preclude potential non-statistical advantages that may
be gained by including certain measures.9
To select candidate variables to include in the PI the following steps were followed, using
baseline GABS data. Correlation coefficients were calculated using all complete pairwise
correlations.
1. Treat the ADAS-Cog-Proxy as the “base” of the PI to cover the cognitive domain.
2. All single-task quantitative gait parameters gathered by the GAITRiteTM
electronic walkway system were considered for the motor function category of
potential PI components. Pairwise correlations were calculated between all
quantitative gait parameters and the ADAS-Cog-Proxy, Table 17:
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Table 17 Correlation Coefficients for Quantitative Gait Parameters and ADAS-CogProxy
Single-Task Gait Parameter
Gait Velocity
Stride Time
Stride Time Variability
Step Time
Stride Length
Step Length
Double Support Time
Swing Time
Stride Width
Stride Velocity
Cadence
Step Time Variability
Stride Length Variability
Step Length Variability
Double Support Time Variability
Swing Time Variability
Stride Width Variability
Stride Velocity Variability

Correlation with
ADAS-Cog-Proxy
-0.32
0.26
0.09
0.25
-0.28
-0.28
0.03
0.04
-0.06
-0.33
-0.26
0.08
0.11
0.13
0.12
0.16
-0.001
0.07

3. Nine Dual-Task Cost (DTC) assessments were selected to be included in the
functionality category of candidate PI components based on the presence of
literature supporting their importance for dementia or pre-dementia syndromes.
Details on the DTC paradigm can be found in Chapter 5. Pairwise correlations
were calculated between candidate DTC variables and the ADAS-Cog-Proxy,
Table 18:
Table 18 Correlation Coefficients for Dual-Task Cost Assessments and ADAS-CogProxy
Dual-Task Cost
(Secondary Task, Gait Parameter)
Counting Backwards by Ones, Gait Velocity
Counting Backwards by Ones, Stride Time
Counting Backwards by Ones, Stride Time Variability
Counting by Serial Sevens, Gait Velocity
Counting by Serial Sevens, Stride Time
Counting by Serial Sevens, Stride Time Variability
Naming Animals, Gait Velocity
Naming Animals, Stride Time
Naming Animals, Stride Time Variability

Correlation with
ADAS-Cog-Proxy
0.28
-0.28
-0.30
0.28
-0.22
-0.26
0.30
-0.27
-0.14
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4. Assess pairwise correlations between single task gait and DTC variables that, in
Steps 2 and 3, had |rho|<0.2 with the ADAS-Cog-Proxy, or had |rho|=0.2 to 0.4
with the ADAS-Cog-Proxy and evidence in published literature demonstrating
importance in dementia or predementia syndromes, or demonstrating significant
associations with cognition or functionality abilities thought to be important for
older adults with dementia or pre-dementia syndromes (Table 19). It was also
ensured that the direction of correlation coefficients was congruent with the
ADAS-Cog-Proxy scoring of higher indicating worse dysfunction. If a variable
was scored as higher numbers indicating worse performance, positive correlation
coefficients were favoured. If a variable was scored as higher scores indicate less
dysfunction, negative correlation coefficients were favoured.

Table 19 Correlation Coefficients for Single Task and Dual-Task Cost Gait
Variables that were Retained after Steps One to Three
GV
ST
STV
SWT
SW
DSTV
SWV
SVV
C_GV
7_GV
A_GV
A_STV

GV
1.00
-0.63
-0.28
-0.09
-0.09
-0.01
0.06
-0.45
-0.27
-0.28
-0.25
0.11

ST
-0.63
1.00
0.16
0.67
0.07
-0.05
-0.11
0.24
0.13
0.28
0.22
-0.19

STV
-0.28
0.17
1.00
0.04
-0.09
0.15
0.20
0.55
0.17
0.07
0.02
0.25

SWT
-0.09
0.67
0.04
1.00
-0.19
-0.18
-0.02
0.06
0.02
0.21
0.10
-0.18

SW
-0.09
0.07
-0.09
-0.19
1.00
0.11
-0.43
-0.2
-0.09
-0.01
0.03
-0.07

DSTV
-0.01
-0.05
0.15
-0.18
0.11
1.00
-0.05
0.36
0.17
0.10
0.07
0.02

SWV
0.06
-0.11
0.20
-0.02
-0.43
-0.05
1.00
0.09
0.09
-0.12
-0.03
0.12

SVV
-0.45
0.24
0.55
0.06
-0.02
0.36
0.09
1.00
0.21
0.13
0.15
0.08

C_GV
-0.27
0.13
0.17
0.02
-0.09
0.17
0.08
0.21
1.00
0.64
0.71
-0.28

7_GV
-0.28
0.28
0.07
0.21
-0.01
0.10
-0.12
0.13
0.64
1.00
0.82
-0.45

A_GV
-0.25
0.22
0.02
0.10
0.03
0.07
-0.03
0.15
0.71
0.82
1.00
-0.56

A_STV
0.11
-0.19
0.25
-0.18
-0.07
0.02
0.12
0.08
-0.28
-0.45
-0.56
1.00

Legend: GV=Gait Velocity, ST=Stride Time, STV=Stride Time Variability,
SWT=Swing Time, SW=Stride Width, Double Support Time Variability, Stride Width
Variability, SVV=Stride Velocity Variability, C_GV=Dual-Task Cost (DTC) for Gait
Velocity with Counting backwards by ones, 7_GV=DTC for Gait Velocity while
counting backwards by Serial Sevens, A_GV=DTC for Gait Velocity while Naming
Animals, A_STV=DTC for Stride Time Variability while Naming Animals.
5. When numerical and theoretical considerations were similar, as described in Step
4, box plots of the individual gait (Figure 10 to 12) or DTC (Figure 13 to 16)
variables were created to visually assess distribution between diagnostic
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categories of NC, SCI, and MCI. Variables showing greater variability and a
stepwise progression from NC to SCI to MCI were favoured.

Figure 10 Box plot of gait velocity by baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.

Figure 11 Box plot of gait stride time by baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.
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Figure 12 Box plot of gait stride time variability by baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.

Figure 13 Box plot of dual-task gait velocity cost when counting backwards by ones
against baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.
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Figure 14 Box plot of dual-task gait velocity cost when counting backwards by serial
sevens against baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.

Figure 15 Box plot dual-task gait velocity cost when naming animals against baseline
diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.
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Figure 16 Box plot of dual-task stride time variability cost when naming animals
against baseline diagnostic category.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.
6. When numerical, theoretical, and distributional assessments were similar,
practical considerations in terms of ease of assessment were taken into account
both for individual variables and for the PI as a whole. Gait velocity is the only
quantitative gait parameter that can be measured easily without the use of an
electronic gait mat.
7. Scatterplots of the most promising candidate variables and the ADAS-Cog-Proxy
were assessed to ensure low pairwise correlation coefficients were not in spite of a
strong non-linear relationship, Figures 17 to 19:
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Figure 17 Scatterplot of gait velocity against ADAS-Cog-Proxy scores.

Figure 18 Scatterplot of dual-task gait velocity cost with secondary task of counting
backwards by ones against ADAS-Cog-Proxy scores.
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Figure 19 Scatterplot of dual-task gait velocity cost with secondary task of counting
backwards by ones against gait velocity.

The final three variables selected for inclusion in the PI were ADAS-Cog-Proxy, gait
velocity, and DTC for gait velocity with the secondary task of counting backwards from
100 by ones. Pairwise correlation coefficients are presented below, in Table 20.

Table 20 Pairwise Correlation Coefficients between Final Pooled Index Components
ADAS-Cog-Proxy
Gait Velocity
Dual-Task Cost

6.1.3

ADAS-Cog-Proxy
1.00
-0.32
0.28

Gait Velocity
-0.32
1.00
-0.27

Dual-Task Cost
0.28
-0.27
1.00

Step 3: Combine Measures Using a Pooled Index Approach

Baseline PI scores (for Objective 2) were calculated according to the following steps9–11:
1) Multiply gait velocity by -1 so that all variables are coded as higher scores
indicating worse performance (slower=worse).
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2) Calculate the baseline mean and Standard Deviation (SD) separately for gait
velocity, DTC, and ADAS-Cog-Proxy measures.
3) Calculate standardized scores (𝑍 = (𝑋𝑖 − 𝑋̅)/𝑆𝐷) for gait velocity, DTC, and
ADAS-Cog-Proxy measures.
4) Sum together the three standardized scores and divide by three (take average).

6.2

Objective 2

A One-Way Analysis of Variance (ANOVA) was the initially planned statistical test to
assess responsiveness of the ADAS-Cog-Proxy and of the PI to group-level betweenperson differences in stage of disease progression at one point in time. Box plots and QQ
plots, included in Appendix B (Figures B.12 to B.15), were used to assess the suitability
of parametric tests. Assumptions of normality and homoscedasticity were not supported,
and there were small sample sizes for NC and SCI categories, so the non-parametric
Kruskal Wallis test was used instead of an ANOVA to assess whether the three diagnostic
categories arose from the same distribution. Non-parametric Mann-Whitney U tests were
then used to assess all pairwise comparisons between diagnostic categories. Results were
presented in Chapter 5.
Including Activities of Daily Living. An additional analysis not included in Chapter 5
includes a Lawton-Brody Instrumental Activities of Daily Living (IADL) test. Although
the GABS sample contains strictly participants with pre-dementia stages of disease
progression where by diagnostic definition ADLs must be intact,12 ADLs are a common
assessment of functionality and have previously been shown to improve responsiveness
of the ADAS-Cog 11.13 To assess whether it would be beneficial to include an ADL
measure on top of the motor, DTC, and cognitive measures included in our PI, a four
component PI was created that included the cognitive, motor function, and DTC variables
as well as the Lawton Brody IADL assessment (score reversed). Visual evaluation was
used to compare baseline box plots for the four component PI (Figure 20, below) and the
three component PI (Figure 21, below). The addition of the IADL assessment did not
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appear to provide an advantage for baseline discrimination, so the simpler PI version was
maintained.

Figure 20 Box plot of a pooled index that includes an assessment of instrumental
activities of daily living against baseline diagnostic category.
Pooled index components included: ADAS-Cog-Proxy, gait velocity, DTC gait velocity
with secondary task of counting, and instrumental activities of daily living assessments.
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild
Cognitive Impairment.

Figure 21 Box plot of pooled index against baseline diagnostic category.
Pooled index components included: ADAS-Cog-Proxy, gait velocity, and DTC gait
velocity with secondary task of counting. Legend: CTL=Normal Cognition,
SCI=Subjective Cognitive Impairment, MCI=Mild Cognitive Impairment.
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6.3

Objective 3

Standardized Response Mean (SRM) calculations were performed for the ADAS-CogProxy, the complete PI, and the standardized ADAS-Cog-Proxy combined with each
individual component of the PI (also using a PI approach) for 6, 12, 24, 36, and 48 month
follow-up periods. Larger SRM values indicate better responsiveness to measured decline
over time, and can be calculated with the following formula14:
SRM = mean(difference score) / SD(difference score)
PI difference scores (both complete and subcomponent versions) were calculated
according to the following steps:
1.

Create a variable for DTC at each timepoint.

2.

Create a variable for reversed gait velocity (multiply by -1) at each time point.
Summary statistics were calculated to check that the reversal was performed
correctly.

3.

Create subsets of data that correspond to the participants present at each
follow-up time point. This will allow standardization with respect to the
baseline distribution of participants who have been enrolled in the study long
enough to reach the desired follow-up timepoint without dropping out or being
excluded.

Steps 4 to 10 were completed for each follow up subset of data.
4.

For each variable, calculate the baseline mean for the subset of participants
present at the follow-up visit.

5.

For each variable, calculate the baseline SD for the subset of participants
present at the follow-up visit.

6.

For each variable, calculate a standardized baseline score as:
𝑍 = (𝑋𝑖,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 − 𝑋̅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )/𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

7.

Calculate baseline PI scores by taking the average of the Z-scores calculated in
Step 6.

8.

For each variable, calculate a standardized follow-up score as:
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𝑍 = (𝑋𝑖,𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 − 𝑋̅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )/𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
9.

Calculate follow-up PI scores by taking the average of the Z-scores calculated
in Step 8.

10.

To get difference scores, subtract the baseline PI score (Step 7) from the
follow-up PI score (Step 9).

All SRM results can be found in Chapter 5, Table 11.
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6.4
1.
2.
3.
4.
5.

6.
7.
8.

9.

10.
11.

12.
13.

14.
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Chapter 7

7

Discussion

The purpose of Chapter 6 is to provide an overview of the findings of this thesis, put these
findings into the context of peer-reviewed literature, discuss limitations, suggest
directions for future research, and highlight clinical implications.

7.1

Summary of Findings

The purpose of this thesis was to assess use of the present gold standard for assessing
efficacy of antidementia treatments, namely the Alzheimer’s Disease (AD) Assessment
Scale–Cognitive Subscale (ADAS-Cog 11), in pre-dementia populations, and to explore
whether adding motor function assessments to the ADAS-Cog 11 improves
responsiveness in a pre-dementia sample.
The literature review (Chapter 3) suggested that the ADAS-Cog 11 is not optimally
responsive for use in pre-dementia populations. Furthermore, its content validity is
reduced through research advancements that propose constructs not assessed by the
ADAS-Cog 11, such as executive function (EF) and motor function, that could be
understood as important aspects of disease severity. Several modification approaches
have improved the responsiveness of the ADAS-Cog 11 through altered scoring
methodology or content, but no modifications incorporating motor function were found.
This may be, at least in part, due to the apparent lack of a database that contains both the
ADAS-Cog 11 and high-quality motor function assessments. An ADAS-Cog-Proxy
measure was developed to address this challenge. The corresponding methods, including
concurrent criterion validation of the ADAS-Cog-Proxy model with the ADAS-Cog 11 in
the Alzheimer’s Disease Neuroimaging Initiative database, may be applied in similar
situations where all desired variables are not present in a single database, but one of the
key variables is present in a second database with comparable subjects. Both databases
must contain overlapping variables that are similar to the key variable. After
approximation of ADAS-Cog 11 scores in the Gait and Brain Study (GABS), a pooled
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index (PI) approach was used to combine quantitative motor assessments with ADASCog-Proxy scores. The resulting Gait and Brain Pooled Index (GAB-PI) consists of gait
velocity, dual-task gait velocity cost (DTC), and the ADAS-Cog-Proxy.
Overall the GAB-PI showed similar levels of responsiveness as the ADAS-Cog-Proxy to
baseline discrimination of pre-dementia syndromes, demonstrating that combining the
ADAS-Cog 11 with motor function assessments did not obscure its ability to detect
differences between diagnostic categories that were defined based on a primarily
cognitive conceptualization of the disease. Specifically, both the ADAS-Cog-Proxy and
GAB-PI demonstrated the ability to discriminate between normal cognition (NC) and
Mild Cognitive Impairment (MCI), and between MCI and Subjective Cognitive
Impairment (SCI), but not between NC and SCI groups. Other studies have found similar
results for the ADAS-Cog 11, and for ADAS-Cog 11 modifications.1–4
Although diagnostic categories can serve many useful purposes, they do not necessarily
represent all meaningful changes that may occur during progression, or regression, within
diagnostic categories. Analyses of responsiveness to disease progression whereby no
diagnostic classification was used, except to exclude older adults who progressed to
dementia, found that in general the GAB-PI had comparable or slightly better
responsiveness than the ADAS-Cog-Proxy. Specifically, for six and forty-eight month
follow-up periods the GAB-PI detected more decline than the ADAS-Cog-Proxy, while
for thirty-six months of follow-up the ADAS-Cog-Proxy detected greater decline. For
twelve and twenty-four month periods the ADAS-Cog-Proxy found overall improvement
while the GAB-PI found almost no change. Although not common, other studies that
included older adults with NC or MCI have found improvement over one to two years on
the ADAS-Cog 11 as well as on ADAS-Cog modifications (ADAS-Cog 12, ADAS-Cog
13, ADAS-Cog 3, ADAS-Cog 5, ADAS-Rasch, ADNI-Mem, ADAS-Tree).5,6 Treating
the ADAS-Cog-Proxy as the gold standard, and the cognitive modifications as potential
improvements thereof, this indicates that the GAB-PI may not be picking up on changes
in the correct direction. However, in one of the studies where the ADAS-Cog 11 and
modified versions found improvement over two-years for older adults with NC, the
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), which is a well-respected

153

assessment of overall disease severity,7–9 found the largest magnitude of change over
time, and it was in the direction of worsening.5 Furthermore, knowing that the progression
from NC to MCI to dementia is not linear,10 but that motor function decline may be
detectable in advance of further cognitive decline,11,12 and that motor function and
cognitive ability are both important for functionality,13–16 it is possible that the measures
detecting decline over time are presenting a more accurate detection of changes in overall
disease severity. Further validation analyses against clinical indicators of overall disease
severity may help to clarify this.
Interestingly, the PI combining only gait velocity with the ADAS-Cog-Proxy increased
responsiveness to measured decline compared to the ADAS-Cog-Proxy alone for all
follow-up periods, and demonstrated larger responsiveness than the full GAB-PI for the
two longest follow-up periods (36 and 48 months). The PI combining only DTC with the
ADAS-Cog-Proxy was never more responsive than the full GAB-PI, and for at least two
follow-up periods was less responsive than the ADAS-Cog-Proxy alone.
These findings were surprising as the DTC paradigm was designed to tap into the limited
capacity of the brain such that when one is asked to perform an attention demanding task
while walking, some of the brain capacity that would otherwise be devoted to walking
(single-task gait can use all available capacity) is reallocated to the secondary task, and
gait performance worsens.12,17–20 As neurodegeneration progresses en route to dementia,
there is less and less capacity to devote to the two tasks, and the DTC should
increase.14,21,22 Previous research on gait assessments alone has found significant
differences between single- and dual-task gait parameters within MCI and NC
populations,18,23–26 whereby the disruption is often greater for MCI than NC.17,24,26,27 The
ability of DTC to discriminate between pre-dementia syndromes is better than single-task
gait,27,28 and DTC in MCI has been associated with risk of progression to dementia.29
Hence, more consistent and advantageous results from the addition of a DTC assessment
to the ADAS-Cog-Proxy for responsiveness to disease progression was expected.
The cueing effect refers to an improvement in gait under dual-task compared to singletask conditions, and is thought to occur because the secondary task can serve as a pacer or
rhythmic auditory stimulation to aid gait.30 The cueing effect, may account for some of
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the inconsistent influence of the DTC measure on responsiveness to measured change
over time. A negative DTC, as would be seen if the cueing effect were occurring, was
present in about one third of the GABS sample at baseline for the DTC on gait velocity
when counting backwards by ones. Other gait parameters and other secondary tasks that
were considered for inclusion in the PI also demonstrated non-uniform effects of the
secondary task on gait (i.e. a mix of participants with positive and negative DTC). A
complementary explanation that may also account for some of this variability is that the
current DTC paradigm is only concerned with gait performance and does not include in
the score any indication for how well an individual performs the cognitive task. In spite of
being instructed not to try harder on one task or the other, some people may prioritize the
gait task while others prioritize the cognitive task, which could lead to different DTC
scores even if brain capacity is similar.23 Although this is more of a concern for
individual-level than group-level measurement as the majority of people do demonstrate
the expected gait worsening under dual-task conditions, revising the DTC paradigm to
lessen some of these individual differences may improve group-level responsiveness of
the GAB-PI.

7.2

Comparison with other ADAS-Cog Modifications

Scoring modification. First, the GAB-PI incorporates a statistical modification to scoring
by standardizing component variables that originally had different scoring scales.
Standardization allows these variables to be combined to produce a single final score with
lower variability than the original raw score of any single component variable. One other
ADAS-Cog 11 modification used a PI approach to combine the ADAS-Cog 11 with other
cognitive tests, assessments of mood or behaviour, and assessments of the ability to
perform activities of daily living. This PI demonstrated better responsiveness to a
treatment effect in a clinical trial for Alzheimer’s Disease than the ADAS-Cog 11 alone.31
In pre-dementia populations, three distinct approaches to scoring ADAS-Cog 13 (Section
3.3.1) data yielded different amounts of responsiveness to disease progression and
responsiveness to treatment effects in MCI populations.32 In one instance, a re-weighted
version of the ADAS-Cog 13 demonstrated greater responsiveness to disease progression
in MCI than a version that included additional assessments of EF and functionality.32
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Taken together, this demonstrates that the way outcome measure data are analysed, and
not just the content of that data, is important for outcome measure performance. The
responsiveness of the GAB-PI may reflect a combination of the measures it comprises,
and the PI approach used to combine them.
Additional cognitive assessments. In general, adding memory items to the ADAS-Cog
11, occasionally accompanied by the removal of other tasks, improved responsiveness to
disease progression and to treatment effects.3,5,6,33 Adding assessments of EF to the
ADAS-Cog 11, with or without modifying scoring methodology, and with or without
additional measures of memory, was found to improve responsiveness to disease
progression and to treatment effects in MCI populations in all but one instance.6,32–35 It is
conceivable that at least some of the responsiveness of the GAB-PI to changes in predementia syndromes is due to gait velocity and DTC picking up on EF or other cognitive
abilities. For example, gait velocity has been associated with EF,15,18,22,25 and there is
mixed evidence around the potential association of gait velocity or DTC gait velocity
with memory.18,23,25
Adding functionality assessments. It has been stated that ideal measures for MCI and
early AD should include both cognitive and functional assessments,34,35 and the results of
the literature review on ADAS-Cog 11 modifications support this. Modifications that
added items to assess functionality, alone or in combination with other cognitive tests or
alternative scoring methods, demonstrated superior responsiveness to disease progression
and to treatment effects in MCI populations than ADAS-Cog 11 modification approaches
that only modified cognitive content alone or in combination with scoring modification
techniques.32–34,36 The only exception was that the ADAS-Tree outperformed the ADASPlus-EF&FA for responsiveness to disease progression, although the ADAS-Plus EF&FA
demonstrated superior responsiveness over the ADAS-Tree to treatment effects32; this
point also serves to demonstrate the context specificity of responsiveness. The CDR-SB
alone, which includes assessments of cognition and functionality, was also found to be
more responsive to measured decline over two years in MCI and NC samples than several
ADAS 11 modifications that re-weighted scores and/or added cognitive tests but did not
include any assessment of functionality.5
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Walking is a complex task,15 and gait velocity in particular has been considered a marker
of functionality for older adults in the context of cognitive disorders specifically and
ageing in general.15,16,30,37,38 Gait velocity and DTC are expected to reflect more subtle
changes in functionality than those captured by the assessments used for previous ADASCog modifications, such as the Functional Activities Questionnaire (FAQ), which rely on
categorical response options of how well, if at all, a person can perform certain
activities.39 For example, the FAQ item assessing, through informant report, a subject’s
ability to perform “Shopping for clothes, household necessities, or groceries” may not
capture changes that are noticeable and meaningful to a patient or caregiver but are not
impactful enough to move from a categorical rating of “normal” to “has difficulty but
does by self” or to “requires assistance”. Nonetheless, during GAB-PI development it was
explored whether adding an assessment of instrumental activities of daily living (ADL) to
the PI would improve distinction between baseline diagnostic categories. This did not
appear to be the case, so the simpler three item PI was retained (see Appendix B, Section
B.2 for more information).
More generally, cognitive ability, the ability to move through one’s environment, and the
ability to perform mental and motor tasks at the same time, are all important aspects of
functionality, and may be impacted by dementia and pre-dementia neuropathology. Even
if a treatment does not alter the underlying pathology causing dementia, it can have a
substantial impact on a patient’s quality of life, as well as the burden held by caregivers,
by stabilizing or slowing decline in cognitive ability, in motor function, or in the ability to
maintain motor control while performing a cognitive task. There are several anecdotal
reports of caregivers or clinicians noticing overall improvements in a patient when taking
symptomatic treatments that are not accompanied by changes on standard tests of
cognitive ability, and pharmacological treatments for dementia that demonstrate only
modest effects on cognitive tests have been shown to delay admittance to nursing
homes.40–42 This suggests that cognitive tests alone are not capturing all important
changes in disease severity. The GAB-PI was developed by selecting one measure to
cover each of the three aspects of functionality presented above. Specifically, the ADASCog-Proxy was selected to cover cognitive ability, single-task gait to cover movement,
and dual-task gait cost to cover simultaneous cognitive and motor performance; however,
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these three categories are not mutually exclusive. In particular, gait assessments may tap
into cognitive domains, such as EF, that have been identified as important components of
pre-dementia syndromes but are not covered by the ADAS-Cog 11.12,15,18,22,23,25,43 This
introduces the idea that a single measure may serve the dual purpose of assessing both a
manifest variable (gait velocity) and a latent variable (executive function), where both the
manifest and latent variables are integral components of a disease, and changes in either
the manifest or latent variable alone, or in combination, are meaningful. This contrasts
with most cognitive assessments, including the ADAS-Cog 11, where the questions or
tasks administered as manifest variable measures (e.g. the ability to draw a circle) are of
much less importance than the latent variable that the resulting scores are intended to
assess (e.g. praxis). The potential for gait assessments, under single-task or dual-task cost
paradigms, to serve as a simultaneous measure of the fundamental bases for
functionality—latent cognitive domain(s) and manifest motor function—may reduce
inefficiencies in the measurement process and more closely represent whether treatments
are having a meaningful impact on overall disease severity. Further research is needed to
ascertain the validity of this statement, but the results of this thesis put into context with
findings from other ADAS-Cog 11 modifications, suggest that gait assessments,
supplemented with additional cognitive assessment, could play a valuable role in future
studies of pre-dementia populations.

7.3

Limitations

The results of this thesis should be interpreted as preliminary, because a statistical model
was used to approximate ADAS-Cog 11 scores in the GABS. More specific limitations to
this process include slightly different study samples used to build the ADAS-Cog-Proxy
from the GABS, and further error that may have been introduced through imputation of
missing ADAS-Cog-Proxy covariates in the GABS. Furthermore, partly due to the nature
of using data from an on-going cohort study, there were small sample sizes, especially at
the longest follow-up time points. When assessing differences between people who did
versus did not have each follow-up visit, it was found that participants with twenty-four
and forty-eight month visits had statistically significant differences in gait speed (faster)
than those who did not reach those follow-up visits. There were no statistically significant
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differences in baseline gait velocity for the other lengths of follow-up, or for any followup length in age, education, DTC, or ADAS-Cog-Proxy scores.
When assessing responsiveness to disease progression, the standardized response mean
(SRM) allows for direct comparison between the PI and the ADAS-Cog-Proxy, but the
clinical meaningfulness of SRM units is not obvious. Furthermore, although this thesis
only considered group-level responsiveness for the intended purpose of use in research
studies, if individual-level responsiveness was of interest, such as for use in a clinical
setting, a reference population would be needed to perform standardization of the PI
component variables. It may be difficult to find a suitable pool of reference individuals.
In terms of the GAB-PI itself, the units are hard to interpret, and scoring calculations are
more complex than for the ADAS-Cog 11. One major limitation is that the GAB-PI may
not be useful for people with mobility impairment that is explainable by an event or
disease other than dementia or pre-dementia syndromes (e.g. severe osteoarthritis of the
lower limbs, Parkinson’s Disease, amputation, stroke with residual motor deficits), even
if some assessment of gait could be obtained. Most studies evaluating motor function in
the context of dementia or pre-dementia syndromes, including the GABS, exclude
individuals with severe mobility restrictions, which limits the generalizability of results.
On a broader level, based on the literature review in Chapter 3, the GAB-PI will be the
thirty-second documented modified version of the ADAS-Cog 11. This thesis does not
directly address the problem that has led to the creation of so many modifications:
maintaining the ADAS-Cog 11 as the gold standard for assessing efficacy of treatments
for dementia and pre-dementia populations, despite knowing it is not optimally
responsive to important changes at the stages of disease where potential benefit of
intervention may be greatest. While modifications can be beneficial in terms of withinstudy quality, they introduce a level of inconsistency and inefficiency that renders
between-study comparisons, such as for meta-analyses, difficult; did intervention A find a
benefit while intervention B did not because intervention A is truly more effective than
intervention B, or because the ADAS-Cog 11 modification used to assess the efficacy of
intervention A is more responsive to treatment effects than the one used to assess
intervention B? Although modifications that maintain backwards compatibility with the
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ADAS-Cog 11 have the potential to produce results on a standard metric, it is often up to
the researchers of the study to produce these analyses, and the results are not necessarily
expected to be consistent. By combining the ADAS-Cog 11 (or Proxy substitute) with
quantitative gait assessments, the GAB-PI contributes to the heterogeneity of ADAS-Cog
11 modifications in a major way without a clear indication of how to reconcile results that
may be inconsistent with those found on the ADAS-Cog 11 or other modified versions.

7.4

Suggestions for Further Research

Once an appropriate database with both the ADAS-Cog 11 and gait assessments becomes
available, the PI can be re-built using the ADAS-Cog 11 instead of the ADAS-CogProxy, and construct validation analyses comparing the GAB-PI to the ADAS-Cog 11 on
responsiveness to baseline discrimination and to disease progression in a pre-dementia
sample repeated. Test-retest as well as inter-rater reliability of the GAB-PI as a whole
should be assessed, even though reliability of the individual components has previously
been evaluated.44,45 If possible, it may also be of interest to compare the GAB-PI to other
ADAS-Cog 11 modifications, especially those which incorporate assessments of
functionality, and to repeat validation and reliability analyses for older adults with mild to
severe dementia as an ideal outcome measure will be reliable, valid, and responsive to
changes across the disease spectrum from NC to severe dementia.35,43,46
The responsiveness of the GAB-PI to pharmacological and non-pharmacological
treatment effects in pre-dementia populations should also be assessed. Although an
outcome measure that is responsive to disease progression is often expected to also be
responsive to treatment effects that slow, stop, or reverse disease progression, this is not
always the case. For example, if a treatment targets one aspects of a disease that a given
measure does not assess, that measure may miss important treatment effects but still be
highly responsive to changes in natural history if it assesses other dynamic aspects of the
disease that are not affected by the treatment. In the ADAS-Cog literature review most
ADAS-Cog 11 modifications that demonstrated better responsiveness than the ADASCog 11 to disease progression in pre-dementia populations also demonstrated superior
responsiveness to treatment effects,3,5,32,33 but there was at least one notable exception to
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this trend, which was a modification focused specifically on memory impairment.5 Thus,
it will be important to assess the responsiveness of the GAB-PI to treatment effects in
addition to disease progression. Ideally this would be done in the context of a treatment of
known efficacy, but none exist for pre-dementia syndromes. Instead, the GAB-PI will be
assessed as a secondary outcome measure for the SYNchronizing Exercises, Remedies in
Gait and Cognition (SYNERGIC) clinical trial that will assess the effect of aerobic and
progressive resistance training exercises, combined with cognitive training and vitamin
D3, in older adults with MCI.47 The SYNERGIC trial is currently recruiting participants
in Ontario and British Columbia. The GAB-PI may be used to assess change over the 20week study period within each treatment group (responsiveness to group-level withinperson observed change over time), as well as between treatment groups (responsiveness
to group-level between-person differences of within-person observed change over time),
and compared to other outcome measures including the ADAS-Cog-Plus-EF&FA.
A final future direction revisits a key motivation behind this thesis, and proposes an
alternative, more data-driven approach than ADAS-Cog 11 modification to explore the
potential role of motor function assessments in detecting important changes in predementia syndromes. The three components of the GAB-PI were selected based on
theoretical, statistical, and practical considerations. Despite best efforts, these three
components may not be the combination of measures most responsive to important
changes in pre-dementia syndromes, such as those that occur between NC and MCI. A
penalized regression analysis allows the simultaneous consideration of many more
variables than can be sorted through manually.48 This analysis will be used to obtain a
model, composed of some subset of a pool of candidate variables, for discriminating
between older adults with NC or SCI and older adults with MCI in GABS. The candidate
pool of variables will contain all non-duplicate quantitative gait parameters collected by
the electronic gait mat used in the GABS, including both those that have been studied
substantially in the literature and those which have not, under single and the three dualtask conditions, as well as the DTC for each gait parameter and secondary task; balance
assessments; the ADAS-Cog-Proxy and other global cognitive tests such as the Montreal
Cognitive Assessment and domain specific cognitive tests; patient characteristics such as
age and years of education; and ADL assessments. Given limits in human discernment,
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this is far more variables than could be considered for inclusion in the GAB-PI, but an
argument could be made for the potential utility of any of them for baseline
discrimination purposes. The penalized regression analysis gradually provides the
opportunity for more and more of these candidate variables to enter the model, and then
cross validation can be used to obtain the best model, or regression equation, for baseline
discrimination.48 Further rationale for this analysis, alluded to earlier, is that the results of
this thesis cannot discern if the addition of gait velocity and DTC to the ADAS-Cog 11 is
leading to improvements in responsiveness beyond that which could be obtained by
adding more standard assessments of functionality or additional cognitive tests; gait
velocity may simply be serving as an assessment of traditional ADLs or EF rather than
improving responsiveness because motor function is an integral component of the disease
beyond that which may be captured by previously established outcome measures. Note
that this would not negate any practical advantages of using gait assessment over more
traditional outcome measures, such as brevity of assessment and language independence.
Taking this one step further, from a purely measurement perspective, the ability to detect
important changes is more important than the explanation about why these changes are
being detected. The penalized regression analysis is a data-driven method that will help to
identify whether motor function assessments (and if so, which ones) are selected for
inclusion in a model for baseline discrimination between pre-dementia syndromes, even
when the model has the option of global and domain specific cognitive tests, more
general assessments of functionality, and patient characteristics previously shown to be
relevant for pre-dementia syndromes. If motor assessments are selected this will further
support their potential utility for detecting important changes in pre-dementia syndromes,
but will not identify why this may be the case.

7.5

Clinical Implications

As clinical syndromes, dementia and pre-dementia stages of disease involve more than
cognitive impairment; a key aspect of these syndromes is the impact that cognitive
deficits have on functionality. Walking, or gait performance, is also important for the
ability to perform several basic ADLs and has been postulated as a marker of overall
functionality and a sixth vital sign to be assessed in older adults.16,49 Gait, and particularly
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dual-task gait performance, has been shown to capture subtle changes during the
cognitive decline associated with ageing and neurodegeneration, especially in MCI
populations, which are not always captured by cognitive testing.29 This thesis has shown
that adding gait assessments to the ADAS-Cog 11 may help to differentiate between
cognitively defined diagnostic groups, and detect progression in disease severity over
time. The GAB-PI is also expected to be sensitive to changes in progression due to
pharmacological and non-pharmacological treatments. To the knowledge of those who
have contributed to this thesis, this is the first attempt to incorporate motor function
assessments, which have previously been associated with progression to dementia,50,51
with the ADAS-Cog 11 which is the gold standard for testing interventions in dementia
and pre-dementia syndromes.

7.6

Conclusion

This thesis has highlighted three challenges related to outcome measurement development
and use, including those pertaining to the maintenance of a long-standing gold standard in
a rapidly developing research field, to how outcome measures may be modified for
improvement, and to the situation of performing secondary data analysis when not all
necessary outcome measures are present in a single database. These challenges were
considered in the field of dementia research. Overall this thesis suggests that the gold
standard ADAS-Cog 11 is not an ideal outcome measure for studies on pre-dementia
syndromes, and that improvements may be made by adding quantitative gait assessments
to the ADAS-Cog 11 using a PI approach.
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Appendices
Appendix A: Summary Table of ADAS-Cog 11 Modifications
Outcome
Measure
ADASCog 111

Test Items

ADASCog 1370

VaDAS72,7
3

ADAS127,17,75,76
TE4DCog6

Pooled
Index77

ADASRasch78

Scoring
Modifications

CV
NC
0.4912
0.4683
0.4684
0.4528
0.46825

CV
MCI
0.3833
0.3834
0.3817
0.3028
0.4128
0.45212
0.37519
0.38325
0.38486

CV
Dementia
0.6271
0.3942
0.3353
0.3394
0.5176
0.3907
0.3338
0.32012
0.34613
0.33919
0.34125

ADAS-Cog 11, delayed recall,
number cancellation or maze

0.4323
0.44725

0.2633
0.24912
0.26725

ADAS-Cog 11, two number
cancellation tasks, delayed
recall, maze, symbol digit
modalities, digit backwards,
animal category retrieval task

N/A

0.3333
0.43912
0.33925
0.33786
N/A

ADAS-Cog 11, delayed recall

N/A

0.3437

0.3107

Commands, 7-word immediate
recall, semantic memory (name
seasons and match month to
season), clock drawing,
category fluency, orientation
from ADAS-Cog 11, delayed
recall
Standardized ADAS-Cog 11,
GDS, DBRI frequency,
standardized MMSE, ADL, and
DBRI
ADAS-Cog 11

N/A

N/A

0.7326

Pooled Index
approach

N/A

N/A

N/A

Items weighted by
measurement
precision and based
on IRT (OPLM)
analysis.
Test items
reweighted by
random forest treebased algorithm

0.7293
0.72925

0.4663
0.46625

0.3793
0.37925

0.4433
0.44325

0.3213
0.32125

0.2313
0.23125

N/A

N/A

N/A

Word recall, naming objects and
fingers, commands,
constructional praxis, ideational
praxis, orientation, word
recognition, language,
comprehension of spoken
language, word finding
difficulty, and remembering test
instructions

ADASTree18

ADAS-Cog 11, delayed word
recall, number cancellation

cADASCog79

ADAS-Cog 11, delayed recall,
number cancellation, maze

N/A
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TDAS80

CAMCOG
-Plus81

tasks; computerized multiphasic
interactive neurocognitive
display system for
administration
Word recognition, command,
orientation, visual-spatial
perception (modified
constructional praxis), naming
fingers, object recognition
(modified naming objects),
accuracy of the order of a
process (modified ideational
praxis), money calculation,
clock time recognition (nondigital); computerized version
of items administered with
touch panel.
Up to 25 items from CAMCOG
(18 items in candidate pool),
neuropsychological tests (12
items in candidate pool),
ADAS-Cog (10 tasks in
candidate pool), and MMSE (11
items in candidate pool)

ADASCog -5
Subset82

Ideational praxis, remembering
test instructions, language,
comprehension, word finding
difficulty

ADASCog -6
Subset82

Word recall task, naming
objects and fingers, commands,
constructional praxis,
orientation, and word
recognition

Computer
algorithm to
estimate cognitive
ability. Item
difficulty estimated
with OPLM and
computerized
algorithm selects
next questions
based on previous
responses and
continuously
updates estimate of
cognitive ability
until 25 items
administered or
standard error of
measurement for
cognitive ability
corresponds to 90%
precision
Subsetting analysis.
Compare
proportion of
responders:
responder=1=did
not get worse over
time on all items.
Nonresponder=0=subje
ct got worse (prepost diff >0) on at
least one item
Subsetting analysis:
Responder=1=did
not get worse over
time on all items.
Nonresponder=0=subje

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A
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ADASbifactor3

ADAS-Cog 13

ADASCog-PlusEF3
ADASPlusEF&FA
bifactor
model3
Common
Item
Pooling20

ADAS-Cog 13, category
(vegetable) fluency

ADNI
Memory
Composite

Word Recognition, RAVLT,
delayed word recall, MMSE 3
word memory task with
distractors, logical memory test
ADAS-Cog 11

25

ADASCog
IRT83,84
ADAS-319
CC119

CC219
CFC119
CFC219
Parmacom
etric
ADASCog 1315
IRT&
Pharmaco
metric
ADASCog 1315

ct got worse (prepost diff >0)
Bi-factor model
that accounts for
residual
correlations
between word
recognition and
recall and between
the 4 tasks based
on interviewer
report
Bi-factor model

N/A

N/A

N/A

N/A

N/A

N/A

ADAS-Cog 13, category
(vegetable) fluency, TMT A&B,
DSST, 5 Pfeffer FAQ items

Bi-factor model
with methods
factor for 5 FAQ
items

N/A

N/A

N/A

Various combinations from
CAMCOG, ADAS-Cog,
MMSE, neuropsychological
tests

Common item
pooling whereby
OPLM used to
estimate test item
difficulty and
subject cognitive
ability, expressed
as T-scores
Factor score from
single factor model

N/A

N/A

N/A

N/A

N/A

N/A

IRT scoring
methodology

N/A

N/A

N/A

N/A

N/A

N/A

N/A

10.93019

0.53319

N/A

13.42919

0.53819

N/A
N/A
N/A

9.27319
7.69219
N/A

0.59219
0.60919
N/A

N/A

N/A

N/A

Word recall, delayed word
recall, orientation
ADAS-3, RAVLT Immediate,
MMSE
ADAS-3, cognitive portion
CDR-SB
CC1, FAQ
CC2, FAQ
ADAS-Cog 13

ADAS-Cog 13

Accounts for
directionality of
change

Pharmacometric
scoring
methodology
IRT and
Pharmacometric
scoring
methodology

170

iADRS85

Straightfor
ward
Sensitive
Scale86
ADASCog 3b12
ADASCog 512
ADAS13RW87

ADCOMS
88

ADAS-Cog 14, iADL OR
substitute in ADAS-Cog 13,
FAQ
[ADAS-Cog 14 = ADAS-Cog
11, maze, digit cancellation,
delayed recall]
Word recall, delayed word
recall, orientation, FAQ, CDRSB
Word recall, orientation, word
recognition
ADAS-Cog 3b, delayed word
recall, digit cancellation.
ADAS-Cog 13

Orientation, word recognition,
word finding difficulty, delayed
word recall, two MMSE items
orientation time, drawing, and
CDR-SB personal care,
community affairs, home and
hobbies, judgement and
problem solving, memory,
orientation)

[-1(ADAS-Cog14)
+ 90] + iADL

Reweight
subsections as:
memory = 0.10,
clinician-rated
tasks = 0.45,
general cognitive
tests = 0.45
Weighted linear
combination based
on partial least
squares coefficients

N/A

N/A

N/A

N/A

N/A

N/A

N/A

0.45712

0.26012

N/A

0.44212

0.20312

N/A

N/A

N/A

N/A

0.45988

N/A

Abbreviations (in order of appearance): CV=Coefficient of Variation (Standard
Deviation/Mean); NC=Normal Cognition; MCI=Mild Cognitive Impairment; ADASCog=Alzheimer’s Disease Assessment Scale-Cognitive Subscale; VaDAS=Vascular
Dementia Assessment Scale; N/A=Not Available; GDS=Geriatric Depression Scale;
DBRI=Dysfunctional Behaviour Rating Instrument; MMSE=Mini Mental State
Examination, ADLActivities of Daily Living; IRT=Item Response Theory; OPLM=One
Parameter Logistic Model; cADAS-Cog=Computerized ADAS-Cog; TDAS=Touch Panel
Type Dementia Assessment Scale ; CAMCOG=Cambridge Cognitive Examination;
EF=Executive Function; FA=Functional Assessment; TMT=Trail Making Test;
DSST=Digit Symbol Substitution Test; FAQ=Functional Assessment Questionnaire;
ADNI=Alzheimer’s Disease Neuroimaging Initiative; RAVLT=Rey Auditory Visual
Learning Test; CC=Cognitive Composite; AVLT-Immed=Auditory Visual Learning
Test–Immediate; CDR-SB=Clinical Dementia Rating Sum of Boxes; CFC=Cognitive
Functional Composite; iADRS=Integrated Alzheimer’s Disease Rating Scale;
iADL=Instrumental Activities of Daily Living; ADAS-13RW=ADAS-Cog 13 Reweighted; ADCOMS=Alzheimer’s Disease Composite Score. Note: Superscripts refer to
reference numbers at the end of Chapter 3.
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Appendix B: Supplementary Figures

Figure B.1 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 1.

Figure B.2 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 2.
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Figure B.3 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 3.

Figure B.4 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 4.
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Figure B.5 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 5.

Figure B.6 Imputation streams for baseline assessment. Mean and standard deviation
(SD) are for imputed values. Each line represents one imputation stream.
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Figure B.7 Imputation streams for six-month follow-up assessment. Mean and
standard deviation (SD) are for imputed values. Each line represents one imputation
stream.

Figure B.8 Imputation streams for twelve-month follow-up assessment. Mean and
standard deviation (SD) are for imputed values. Each line represents one imputation
stream.
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Figure B.9 Imputation streams for twenty-four-month follow-up assessment. Mean
and standard deviation (SD) are for imputed values. Each line represents one imputation
stream.

Figure B.10 Imputation streams for thirty-six-month follow-up assessment. Mean
and standard deviation (SD) are for imputed CDR-SB values. Each line represents one
imputation stream.
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Figure B.11 Imputation streams for forty-eight-month follow-up assessment. Mean
and standard deviation (SD) are for imputed CDR-SB values. Each line represents one
imputation stream.

Figure B.12 Box plot summarizing distribution of ADAS-Cog-Proxy scores in each
baseline diagnostic category (CTL=Normal Cognition, SCI=Subjective Cognitive
Impairment, MCI=Mild Cognitive Impairment).
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Figure B.13 Box plot summarizing distribution of Pooled Index scores in each
baseline diagnostic category (CTL=Normal Cognition, SCI=Subjective Cognitive
Impairment, MCI=Mild Cognitive Impairment).

Figure B.14 QQ plots to assess normality of baseline ADAS-Cog-Proxy scores.

Figure B.15 QQ plots to assess normality of baseline Pooled Index scores.
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